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ABSTRACT
Cervical cancer develops through the combined activity of the Human 
Papillomavirus (HPV) E6 and E7 oncoproteins. A defining characteristic of the 
E6 oncoproteins derived from cancer-causing HPV types is the presence of a 
PDZ binding motif (PBM) at the extreme carboxy terminus of the protein, 
which is absent from E6 proteins derived from the so-called low risk (LR) HPV 
types. This PDZ binding potential of the high risk (HR) HPV E6 oncoproteins 
is important for their ability to support the viral life cycle and to cooperate in 
the induction of malignancy. However, PDZ interactions can be negatively 
regulated by phosphorylation within the E6 PBM. In this study, I have 
investigated the differential regulation of diverse HR HPV E6 PBMs. 
Depending on the HPV type, PDZ binding activity can be regulated by 
phosphorylation with PKA or AKT. This in turn inhibits PDZ recognition 
whilst conferring direct association with 14-3-3 family members. Such 
regulation is highly conserved between E6 proteins derived from HPV-16, 
HPV-18 and HPV-58, whilst being somewhat weaker or absent from other 
types such as HPV-31, -33 and -51. Phosphorylation is important for 
maintaining the steady state levels of HPV-18 E6 and this is also can be 
affected by its association with 14-3-3. I also show that HPV-18 E6 
phosphorylation occurs primarily during the G2/M phase of the cell cycle 
whereas HPV-16 E6 phosphorylation occurs during S phase. This cell cycle- 
dependent phosphorylation in turn regulates the levels of E6 expression and 
confers enhanced interaction with multiple 14-3-3 isoforms. E6 does not
1
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degrade 14-3-3, but it alters the subcellular distribution of 14-3-3 and as a 
consequence, inhibits p53/l 4-3-3 transcriptional transctivation in an E6 PBM 
dependent manner. These studies reveal unexpected differences in the 
regulation of HPV-16 and HPV-18 E6 function and have important implications 
for how phosphorylation of E6 might be expected to play a role during the 
respective viral life cycles and tumour development.
2
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CHAPTER 1: INTRODUCTION
1.1 Cancer
An enormous amount of effort has been invested in researching and finding 
novel therapeutic drugs for cancers, however, the cancer prevalence and 
mortality due to cancers are increasing year by year. According to the 
GLOBOCAN report in 2008, the number of cancer cases reported was 12.7 
million and among these, there were 7.6 million of deaths. In the GLOBOCAN 
2012 report (Ferlay et al, 2013), the global cancer burden has increased to 14.1 
million new cancer cases and 8.2 million people died from cancer. The major 
types of cancer that lead to mortality are lung, breast, colorectal, stomach, liver, 
and cervical. The general global trend shows that, in developing countries, the 
burden of cancers related to reproduction, dietary and hormonal risk factors are 
increasing largely due to changes in lifestyle. Furthermore, whilst the incidence 
of cancer appears to be the highest in developed countries, the mortality rate is 
the highest in the less developed countries. It was predicted that the number of 
cancer cases will reach 19.3 million per year by 2025 and number of deaths will 
increase to over 13.1 million in 2030 (Ferlay et al, 2010).
Cancer is a complex disease, which can arise from all tissue types that 
eventually exhibit abnormal features, grow uncontrollably and then metastasize. 
Carcinogenesis is a multi-stage process where cells undergo physiological 
changes, including increased responsiveness to cell survival signals, and
3
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reduced responsiveness to growth inhibitory signals, evade apoptosis, gain 
ability for cells to replicate, increased angiogenesis, and eventually cells invade 
or metastasized (Hanahan & Weinberg, 2000). Cancer progression involves 
karyotypic alteration of neoplastic cells (Pitot, 1986), with several hallmarks 
such as mutations, genetic instability and the gaining of unlimited replication 
potential (Hanahan & Weinberg, 2000; Apian, 2006). During this process, there 
is a sequential accumulation of mutations that activates oncogenes and disrupts 
tumour suppressor genes. These events, in combination with multiple cycles of 
clonal selection and evolution, facilitate the process of carcinogenesis.
1.2 Human Papillomavirus (HPV) and Cervical cancer
Cancer-causing viral infections, such as Hepatitis B virus (HBV) or Hepatitis C 
(HCV) and Human papillomavirus (HPV) contribute to 20% of cancer deaths in 
low and middle income countries (http://www.who.int/cancer/en/V Cervical 
cancer is the fourth most common malignancy affecting women worldwide; 
ranked second most common cancer in developing countries and 10th in the 
developed countries (Ferlay et al, 2013). The most important causative agents 
of cervical cancer are HPVs, viruses that belong to the family Papillomaviridae, 
with more than 99% of all cervical cancers being associated with HPV infection 
(zur Hausen, 1991, 1996). Besides causing cervical cancers, HPV infection can 
also lead to other anogenital cancers, such as those of vulva, anus and penis. In 
addition, HPV infection is associated with certain head and neck cancers (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007).
4
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Based on the viral DNA sequences, there are over 200 different types of HPV, 
of which 85 genotypes are well-characterised. Among these types, the WHO 
classified at least 12 as being cancer-causing agents (WHO/IVB/07.05, 2007) 
with 3 or 4 others as potential cancer-causing agents. In general, HP Vs are 
grouped into cutaneous or mucosal types, depending on the origin of the 
infected tissues. Cutaneous types are found in the skin of hands and feet 
whereas mucosal types affect mucosal linings (Harwood et al., 1999; Gillison 
and Shah, 2003; Burd, 2003). Cutaneous types such as HPV-5 and -8 have been 
linked to the development of non-melanoma skin cancers in immunosuppressed 
individuals (Harwood et al, 1999). This is particularly apparent in patients 
suffering from Epidermodysplasia verruciformis where HPV-5 and -8 have 
been linked to the development of squamous cell carcinoma at sun exposed sites 
(Lutzner et al, 1984; Pfister, 1992; Bouwes Bavinck et al, 2001; Wallace et al, 
2012). However, the vast majority of HPV-associated cancers are caused by 
mucosal types.
Based on the degree of association with cervical cancer and on their ability to 
induce tumorigenesis in infected tissues, HP Vs are categorised as either high 
risk (HR) or low risk (LR) types. The HR HPV types are often associated with 
mucosal malignancies, these include HPV-16, -18, -31, -33, -35, -39, -45, -51, - 
52, -56, -58 and -59 (zur Hausen & de Villiers, 1994; Bouvard et al, 2009; de 
Villiers, 2013). Among the HR HPV types, HPV-16 and -18 are the most 
commonly described as cancer causing agents worldwide (Munger & Howley,
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2002; Fehrmann & Laimins, 2003; Miinger et al, 2004; Snijders et al, 2006), 
especially causing invasive cervical cancers (Smith et al, 2007; Li et al, 201 la). 
The other six most common HR HPV types are types 31, 33, 35, 45, 52 and 58 
(Clifford et al, 2003a; Smith et al, 2007). Among cervical cancers, squamous 
cell carcinomas (SCC) are the most common followed by adenocarcinomas 
(ADC) (IARC, 2007), accounting for 85% and 15% of cancers, respectively 
(Smith et al, 2007). HPV-16 is more commonly associated with SCC (55%) 
than ADC (33%), whereas HPV-18 is more commonly found in ADC (37%) 
than in SCC (13%) (Clifford et al, 2003b; Smith et al, 2007). Infection with low 
risk (LR) HPV types, such as HPV-6, -11, 42, -43 and -44 leads to benign 
genital warts (Laimins, 1993).
When the virus gains entrance to the cell, it releases its viral genomic DNA, 
which enters the nucleus of the infected cells as an episome. The subsequent 
expression of the viral genome results in microscopic changes to the cell, which 
ultimately results in macroscopic changes to tissue architecture. In the early 
stages of infection, the virus modifies the normal differentiation in the lower 
third of epithelial tissues, which results in the formation of low-grade squamous 
intraepithelial lesions (LSIL) or cervical intraepithelial neoplasia grade 1 
(CIN1). In this low grade lesion, the productive viral infection may progress 
normally or remain unchanged for several weeks to months. Lesions at this 
stage are more differentiated than later lesions and can be eliminated by the 
immune system. The average time from the initiation of HPV infection to 
detection of CIN1 has been estimated to be approximately 4 months, whilst
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development of CIN2 or 3 was detected after approximately 14 months (Winer 
et al, 2005). Although 99% of cervical cancers are associated with HR HP Vs 
(zur Hausen, 1991, 1996; Walboomers et al, 1999), the infected woman will not 
necessarily develop the disease. The majority of the infections do not result in 
cervical cancer and most infections are cleared by the host immune system 
within 1 to 2 years. Approximately 5% of the HPV infection leads to cervical 
cancers. However, because the virus does not lyse the infected cells or cause 
necrosis, this aids in maintaining a persistent infection by avoiding host 
immune responses (Stanley, 2008).
As previously mentioned, in most cases, the viral infection is likely to be 
resolved by the host immune system. If this does not happen or the host is 
immunosuppressed, the virus can remain as a persistent infection for many 
years, and such infected tissues can progress to severe dysplasia or high grade 
squamous intraepithelial lesions (HSIL) or CIN2 and CIN3. Severe dysplastic 
lesions may remain as HSIL or advance to invade below the basement 
membrane, leading to local invasion (McMurray et al., 2001). In CIN2 and 
CIN3 lesions, the proliferative phase is more extensive than in CIN1 and the 
productive stage of the viral life cycle is poorly supported (Middleton et al, 
2003). This progression to CIN3 and ultimately invasive cancer is driven by the 
expression of the viral oncoproteins, E6 and E7, which leads to the 
hyperproliferation of the lower epithelial layers (Jeon et al, 1995; Jeon & 
Lambert, 1995; von Knebel Doeberitz, 2002). These viral oncoproteins can 
induce the DNA damage response by activating ATM/ATR pathway, and
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abrogating cell cycle checkpoints. These favor viral genome amplification, but 
also result in inadequate DNA repair (Moody & Laimins, 2009; Park et al, 
2014; Wallace & Galloway, 2014). The accumulation of DNA damage and the 
resulting accompanying mutations all contribute to the disease progression (von 
Knebel Doeberitz, 2002; Pett, 2004). Furthermore, HPVs can manipulate the 
host immune response by reducing inflammatory cytokines, such as IL-1, IL-6, 
TNF-a and TGF-p in the HPV-positive keratinocytes (Arany & Tyring, 1996; 
Fichorova, 1999; Alcocer-Gonzalez et al, 2006; Stanley, 2008), as well as 
decreasing levels of interferons (Arany & Tyring, 1996; Ronco et al, 1998; Li et 
al, 1999; Rincon-Orozco et al, 2009).
In high grade lesions with persistent infection, the viral genome can become 
integrated into the host genome, resulting in upregulation of the E6 and E7 viral 
oncoproteins, and loss of expression of most of the other viral genes which 
often occurs as a result of viral integration into the host DNA (Shirasawa et al, 
1989; Schwarz et al, 1985; Jeon & Lambert, 1995). Approximately 70% of 
metastatic cells have integrated HPV sequences, indicating that DNA 
integration is likely an important step for the pathogenesis of cervical cancer 
(McMurray et al, 2001). However, episomal integration is not a prerequisite for 
CIN2 or CIN3 to progress to cervical cancer, although there are differences 
between HPV-16 and HPV-18. For cervical cancers containing HPV-16, 
approximately 30% of cases contain solely viral episomal DNA, whereas in the 
remaining 70% the viral genome is integrated (Matsukura et al, 1989; Pett, 
2004; Vinokurova et al, 2008). In contrast, in the case of HPV-18, the viral
8
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DNA is almost always integrated into the host genome in patients with HSIL 
and invasive carcinoma (Cullen et al, 1991; Pirami et al, 1997; Badaracco et al, 
2002; Fehrmann & Laimins, 2003; Woodman et al, 2007; Vinokurova et al, 
2008). It has been suggested that the common fragile sites (CFS) of the host 
chromosome, like FRA13C (13q22), FRA3B (3pl4.2), and FRA17B (17q23) 
are the preferred site for viral genome integration, with possible normal gene 
expression being disrupted (Thorland et al, 2003). Intriguingly, the site of viral 
integration might be linked to the capacity of the viral transcriptional regulator, 
E2, to interact with Brd4 (You et al, 2004; Baxter et al, 2005), which binds E2 
and the viral genome to region of interaction that is actively transcribed and is a 
potential viral integration site (Jang et al, 2014).
1.3 HPV genome and life cycle
Papillomaviruses are small, non-enveloped viruses with an icosahedral capsid 
of approximately 50 to 60 nm in diameter, containing a circular, double­
stranded DNA genome of approximately 8,000 base pairs. The genome is 
divided into three regions, the long control region (LCR), the early (E) region 
and the late (L) region and this is illustrated in Figure 1(a). The LCR is 
involved in regulating viral gene expression and replication. The E region, 
which consists of the E l, E2, E4, E5, E6 and E7 genes, encoding proteins 
required for viral gene expression and viral DNA replication. Many of these 
proteins interact with a variety of cellular target proteins, with the aim of
9
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creating an environment favourable for the viral life cycle. The L region 
encodes the viral structural proteins, LI and L2, the major and minor capsid 
proteins respectively.
The El protein is 600 to 650 amino acids in length and is the only viral protein 
possessing enzyme activity, being a DNA helicase. The E2 protein is 350 to 500 
amino acids long and plays a pivotal role in regulating the expression of the 
viral genome and also enhancing viral DNA replication by recruiting the El 
protein to the viral origin of replication. E2 also has a role in ensuring the 
correct partitioning of viral episomes to the daughter cells during cell division 
by tethering the viral episomes to the host chromosome through Brd4, as 
mentioned above. The E4 ORE (open reading frame) is located within part of 
the E2 ORF, but is translated in another reading frame, it encodes a very 
abundant protein of 90 to 250 amino acids. E5 is a transmembrane-associated 
hydrophobic protein of 75 to 100 amino acids and plays a role as a minor 
oncoprotein. E6 is a small protein of approximately 150 amino acid residues, 
containing four zinc-binding Cys-X-X-Cys (CXXC) motifs, whereas E7 is a 
small zinc-binding protein of 100 amino acids containing two CXXC motifs. 
Both E6 and E7 are major oncoproteins. Both of the LI and L2 late genes 
encode the viral capsid proteins of approximately 500 amino acid residues. All 
of these genes are coordinately expressed during the viral life cycle during the 
differentiation of the infected keratinocytes. The different phases of the life 
cycle are discussed below and is illustrated in Figure 1(b).
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1.3.1 Viral Entrance
HPV infection is initiated when the viral particles gain access to basal cells 
through micro-trauma of the epithelium (Burchell et a l, 2006), or to 
epithelial stem cells such as those in the hair follicle (Schmitt et al, 1996; 
Egawa, 2003). For HR HPVs, studies have shown that the epithelial cells 
around the squamo-columnar junction of the cervical transformation zone 
are more susceptible to HPV infection and cancer progression (Grayson et 
al, 2002; Herfs et al, 2012). As would be expected, the viral capsid proteins 
play major roles in the process of infection. The viral capsid is made up of 
360 copies of LI, assembled into 72 icosohedral capsomeres, and there are 
believed to be a mininum of 12 copies of L2 per virus (Modis et al, 2002; 
Buck et al, 2008). LI can self-assemble to form immunogenic virus-like 
particles (VLPs), even in the absence of L2 (Kimbauer et al, 1992, 1993; 
Hagensee et al, 1993), whilst L2 is incorporated below the axial lumen of 
the LI capsomeres (Buck et al, 2008). The precise mechanism by which 
virions attach to the cell surface receptor still remains to be defined. 
However, it has been shown that virions first attach to the cell surface 
heparan sulphate proteoglycan molecules (Joyce et al, 1999; Giroglou et al, 
2001; Shafti-Keramat et al, 2003). Following the interaction of the virions 
with the host cell receptors, the capsid changes its conformation, leading to 
exposure of the L2 amino terminus which is cleaved by secreted furin (Day 
et al, 2008). This aids further attachment that might involve a6-integrin as 
the secondary receptor which is necessary for efficient HPV infection 
(Evander et al, 1997; McMillan et al, 1999; Bossis et al, 2005). Following 
attachment, the virions are internalised via endocytosis (Selinka et al, 2002;
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Day et al, 2003; Bousarghin et al, 2003; Culp & Christensen, 2004). The 
internalised virions are subjected to intracellular trafficking which occurs 
through endosomal compartments via Sorting Nexin 17 (SXN17) (Bergant 
Marusic et al, 2012; Bergant & Banks, 2013). L2 interacts with SNX17 
which is involved in endosomal recycling pathways, and thereby helps in 
avoiding lysosomal degradation (Roden et al, 2001; Bergant Marusic et al, 
2012). Acidification of these compartments is important in allowing the 
subsequent viral uncoating and egression from endosomes (Kamper et al, 
2006; Day et al, 2008; Smith et al, 2008; Dabydeen & Meneses, 2009). In 
the viral life cycle, L2 is important in transporting viral DNA through the 
trans-Golgi network into the host nucleus following nuclear envelope 
breakdown (Sun et al, 1995; Florin et al, 2004; Bossis et al, 2005; Pyeon et 
al, 2009; Schneider et al, 2011). Once in the nucleus, L2 localises to PML 
bodies where initiation of viral transcription is believed to occur (Sapp & 
Bienkowska-Haba, 2009). Meanwhile, LI is degraded in lysosomes (Spoden 
et al, 2008).
1.3.2 Viral establishment
In the infected cells, the HPV genome is maintained as a nuclear plasmid, or 
episome, at a low copy number of approximately 10 to 200 copies. In this 
stage, the early viral gene products (E6, E7, El and E2) are expressed at a 
low level (Stanley et al, 1989; De Geest et al, 1993). Expression of viral 
DNA genomes is initiated from more than one promoter region, producing 
multiple viral mRNAs with several ORFs (Graham, 2010). E6 and E7 are 
expressed from a bicistronic mRNA (Stacey et al, 2000), under the influence
1 4
CHAPTER 1: INTRODUCTION
of the viral early promoter (p97 in HPV-16). Monolayer and raft culture 
indicates that API, the host transcription regulator, is crucial to stimulate the 
E6/E7 promoter activity and for the expression of both of these HPV 
oncogenes in the differentiating epithelial cells (Chong et al, 1991; Chan et 
al, 1990; Kyo et al, 1997; Liu et al, 2002). The late promoter for the viral 
genome is located within the E7 open reading frame. Upregulation of this 
promoter leads to increased expression of other viral early genes, E l, E2, E4 
and E5 (Middleton et al, 2003). The expression of the E6 and E7 
oncoproteins encourages the basal cells to proliferate into suprabasal layers 
(Jenkins, 2007), and the functions of these oncoproteins are discussed in a 
later section.
The expression of both El and E2 is important for maintaining viral 
episomal DNA (Wilson et al, 2002) which serves as template for viral 
genome amplification. E2 regulates viral DNA replication by binding to the 
viral LCR and recruiting the viral El DNA helicase to the viral origin of 
replication (Doorbar, 2006; Blakaj et al, 2009). This allows the virus to 
replicate its DNA which occurs independently of host cellular DNA 
replication during the genome establishment and amplification phases. 
Following initiation of viral DNA replication, E2 dissociates from the viral 
origin, allowing El to form a double hexameric ring bound to the viral DNA 
(Fouts et al, 1999; Enemark & Joshua-Tor, 2006), with its helicase functions 
unwinding the DNA, which then serves as template for the host cell DNA 
replication machinery. El recruits host DNA polymerase and replication 
protein A (RPA) to the viral origin to initiate viral DNA replication (Wilson
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et al, 2002). E2 is a transcriptional regulator and depending on the 
occupancy of its recognition sites within the viral URR, it can act as either 
transcriptional activator or repressor. E2 also ensures that the viral episomes 
are retained by both daughter cells during cell division by tethering the viral 
DNA to the host chromosome during mitosis, through interactions with 
cellular proteins such as Brd4 (You et al, 2004; Doorbar, 2006; McBride et 
al, 2006; Parish et al, 2006; Blakaj et al, 2009).
1.3.3 Productive stage
From the establishment stage, the viral life cycle progresses into the 
productive stage which occurs when the daughter cells derived from the 
infected basal cells start to differentiate. This allows the amplification of the 
viral genomes and their ultimate packaging into new infectious viral 
particles. A key feature at this phase of the virus life cycle is the ability of 
E7 to create a S-phase like state in the infected cells. It does this by 
deregulating the normal cell cycle by targeting cell cycle regulatory 
proteins, such as the pRB family of pocket proteins (pi 30, pRB and p i07) 
(Miinger et al, 2001; Roman, 2006). These proteins interact with E2F 
transcription factors that regulate genes required for Gl/S and G2/M 
transitions during the cell cycle (Classon & Dyson, 2001; Cam & Dynlacht, 
2003). Interaction between E7 and pRB proteins results in the degradation of 
pRB, and the subsequent release of active E2F from the E2F/pRB complex 
(Rawls et al, 1990; Gonzalez et al, 2001; Barrow-Laing et al, 2010). This, in 
turn, promotes the expression of genes required for DNA replication and 
favors S-phase entry (Rawls et al, 1990; Tommasino & Crawford, 1995;
16
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Gonzalez et al, 2001; Barrow-Laing et al, 2010). E7 further manipulates the 
cell cycle checkpoint by targeting and inactivating the cyclin-dependent 
kinase inhibitors (CDKIs) p21CIP1 (Jones et al, 1997b; Funk et al, 1997) and 
p27KIP1 (Zerfass-Thome et al, 1996). All of the above activities of E7 result 
in unscheduled DNA replication in the infected epithelial cells and, as a 
consequence, the cells mount a powerful pro-apoptotic response by 
upregulating the levels of p53. Thus, the E6 oncoprotein has evolved to 
counteract this apoptotic response by degrading p53 (Scheffner et al, 1990; 
Wemess et al, 1990; Huibregtse et al, 1991; Scheffner et al, 1993) and Bak 
(Thomas & Banks, 1998) in a proteasome-dependent manner. As the cells 
differentiate, the viral late promoter (p670 for HPV 16) which is embedded 
within the E7 open reading frame is activated, resulting in expression of E l, 
E2, E4 and E5 genes. These viral genes encode proteins important for viral 
DNA replication and amplification which is independent of host cell DNA 
replication (Middleton et al, 2003). In the suprabasal layers, El and E2 are 
expressed at higher levels, and thereby increase the viral copy number 
(Ozbun & Meyers, 1998b).
Together, E6 and E7 create an environment favorable for viral DNA 
replication and amplification, this activity is also most likely augmented by 
the E5 protein, although there are discrepancies in the literature about its 
role within the viral life-cycle, depending upon the virus type and the design 
of the particular assay systems. E5 is a pore-forming transmembrane protein 
that has been described as a viroporin protein (Conrad et al, 1993; Wetherill 
et al, 2012). Studies have shown that E5 can modulate processing of
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epidermal growth factor receptors (EGFRs), and maintains growth factor 
signalling and proliferation signals through promoting EGFR trafficking and 
dysregulation (Pirn et al, 1992; Straight et al, 1993; Crusius et al, 1998; 
Adam et al, 2000). One consequence of this is the activation of downstream 
MAP Kinase signalling (Fehrmann et al, 2003), including activation of ERK 
1/2 and p38 (Crusius et al, 1998, 2000). As the result of this, El has been 
proposed to accumulate in the nucleus. E5 also has potential anti-apoptotic 
activity through interference of FasL- and TRAIL-induced apoptosis 
(Conrad et al, 1993).
The other viral gene, E4, is primarily expressed as an E1AE4 fusion protein, 
containing 5 amino acid residues from the El N-terminus, as a result of 
mRNA alternative splicing (Chow et al, 1987b; Nasseri et al, 1987; Chow et 
al, 1987a; Doorbar et al, 1990). E1AE4 is expressed most highly in cells 
establishing high levels of viral DNA amplification, and is considered to be 
a viral late protein. This is the most abundantly expressed viral protein, and 
although the role of E4 in the viral life cycle is the subject of much debate, 
numerous studies indicate that it affects G2/M progression through 
association with Cyclin B (Davy et al, 2002; Nakahara et al, 2002; Davy et 
al, 2002; Knight et al, 2011). In addition, expression of E1AE4 in the upper 
layer of the terminally differentiating epithelial cells is believed to favor 
viral synthesis and release by perturbing the keratin network (Doorbar et al, 
1991; Wang et al, 2004; Doorbar et al, 1997; McIntosh et al, 2010).
18
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1.3.4 Viral packaging, release and re-infection
As cells continue to differentiate, the viral late genes LI and L2 are 
expressed which are important for viral packaging into infectious viral 
particles in the upper layers of infected tissue (Ozbun & Meyers, 1998a). L2 
recruits the LI protein to PML bodies, and this is thought to enhance capsid 
protein packaging (Zhou et al, 1993; Stauffer et al, 1998; Florin et al, 2002). 
Prior to entering the cycle of re-infection, the virus must escape from the 
infected skin cells and survive the harsh extracellular environment. This is 
thought to be helped by E1AE4 protein which is present in great abundance. 
This forms amyloid fibres via transglutaminase 3, and helps disrupt the 
normal comified envelope in the upper epithelial cells and possibly 
contributes to PVs survival (Wang et al. 2004; Brown et al. 2006; McIntosh 
et al. 2008). Although PVs are non-enveloped, they nonetheless are able to 
withstand extreme conditions, such as dehydration and high ambient 
temperature (Roden et al, 1997), and it has been shown that they can survive 
better when they are released from highly durable desquamated comified 
cells (Bryan & Brown, 2001).
1.4 Human Papillomaviruses Oncoproteins
The HPV E6 and E7 proteins, particularly those from the high risk types, 
can induce malignant progression by targeting various cellular proteins 
involved in the regulation of apoptosis and the cell cycle, potentially causing 
immortalization and, eventually, cellular transformation (Mantovani & 
Banks, 2001; Miinger et al, 2001). These oncoproteins target different sets
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of cellular proteins, but it is the synergistic effect of both E6 and E7 that 
enables HPVs to disrupt the cellular homeostasis of the host.
1.4.1 E7 Oncoprotein
HPV E7 is a small acidic polypeptide of approximately 100 amino acids, 
having a molecular weight of 18 to 20 kDa; E7 was the first HPV protein to 
be defined as an oncoprotein, where the immortalisation and transforming 
capacity of E7 was identified through its ability to induce foci and colony 
formation in soft agar (Kanda et al, 1988; Phelps et al, 1988; Vousden et al, 
1988; Watanabe & Yoshiike, 1988). Structurally, E7 contains 3 conserved 
regions (CR), CR1, CR2 at the N-terminus and CR3 at the C-terminus, as 
illustrated in Figure 2. It also shares a certain degree of amino acid sequence 
similarity with a noncontigous sequence of the Adenovirus (Ad) El A 
proteins (Phelps et al, 1988) within the CR2 homology domain, containing a 
conserved Leu-X-Cys-X-Glu (LXCXE) motif. HPV E7 is phosphorylated 
by Casein Kinase II (CKII) at amino acids Serine-31 (S31) and S32, which 
lie in close proximity to the LXCXE motif (Firzlaff et al, 1989; Barbosa et 
al, 1990). It is also phosphorylated at S71 by an unknown kinase in S phase 
of the cell cycle (Massimi & Banks, 2000). Within the CR3 domain, there 
are two CXXC motifs, which form a zinc-binding domain which has been 
shown to be the region where dimerization occurs (Barbosa et al, 1989; 
Clemens et al, 1995; McIntyre et al, 1993; Liu et al, 2006; Ohlenschlager et 
al, 2006). These E7 domains and interaction motifs are also shown in Figure
2 0
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2. HPV E7 is localised in the cytoplasm (Smotkin & Wettstein, 1987; Huh et 
al, 2005; Nguyen et al, 2007; Ressler et al, 2007), but also can be found in 
the nucleus (Sato et al, 1989; Greenfield et al, 1991; Smith-McCune et al, 
1999), and nucleolus when cells are in the G2 phase of the cell cycle 
(Zatsepina et al, 1997). E7 is a multi-functional protein. It has been reported 
to interact with a very large number of cellular target proteins, in many cases 
perturbing their normal cellular functions. Some of these interactions, with 
their consequences are summarised in Table 1.
E7 has a short half life of approximately 2 hrs (Smotkin & Wettstein, 1987) 
and is turned-over via a ubiquitin-mediated proteosomal mechanism 
(Reinstein et al, 2000) involving the cullin family of proteins. Cullin 
regulates the protein levels of E7 through an N-end rule, where the half life 
of a protein depends on the recognition of its N-terminal residues by E3 
ubiquitin ligase (Varshavsky, 1996; Bachmair et al, 1986). E7 interacts with 
an E3 ubiquitin ligase complex, SCF (Skp-Cullin-F-box) for its own 
ubiquitination and proteolysis (Oh et al. 2004). On the other hand, the E7 N- 
terminus associates with neddylated cullin-2 (Huh et al, 2007) in order to 
induce the effective ubiquitination and degradation of pRB (Huh et a l 
2007).
E7 interacts with retinoblastoma tumour suppressor, pRB and the related
pocket proteins, p i07 and p i30 (Lee et al, 1998; Gonzalez et al, 2001; Helt
& Galloway, 2001) through the LXCXE motif of E7, which is conserved in
El A, but is also present in HR and LR E7s (Miinger et al, 1989; Dyson et
al, 1989). Thus pRB binding is conserved across HPV types, regardless of
their capacity to cause cancer, suggesting that interaction with pRB and
2 1
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pRb CKII
LXCXE
JLJL
CR1 CR2 CR3 -  Zinc finger (dimerisation)
Figure 2. Basic structure of E7 oncoproteins. Schematic diagram shows 
E7 contains 3 domains: CR1 and CR2 core domain in its N-terminal part 
and a C-terminal CR3 or Zinc finger domain. The LXCXE motif embedded 
within the CR2 domain is the region important for pRB and related pocket 
protein targeting, and is also the region where CKII phosphorylation occurs. 
The C-terminal zinc finger of E7 is required for dimerisation.
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Table 1: Summary of cellular targets of HPV E7 and manipulation of
cellular events.
Cellular event 
manipulated
Cellular target 
protein
Effect of binding Reference
Cell cycle pRB
pl07
pl30
Cdk2-Cyclin A 
Cdk2-Cyclin E 
E2F-Cyclin A
p21CIP1
p27KIP1
Degradation; cell 
cycle checkpoint 
abrogated; Cells 
progress to S phase
Modulates cell cycle 
progression to S 
phase
Activates Cdk2 
kinase activity
Inactivates cyclin 
dependent kinase 
inhibitors
(Lee et al, 
1998;
Gonzalez et al, 
2001; Helt & 
Galloway, 
2001)
(Dyson et al, 
1992; Davies 
et al, 1993; He 
et al, 2003; 
Nguyen et al, 
2007)
(Jones et al, 
1997b; Funk et 
al, 1997)
Ubiquitination SCF (containing 
cullin-1/Skp)
Cullin-2
Proteolysis of E7
Ubiquitination and 
destabilisation of 
pRB
(Oh et al, 
2004a)
(Huh et al, 
2007)
Cell cycle, 
Centrosome 
function and 
cell growth
HDAC1 & 2 Increases
transactivation and 
stability of Cdc25A
(Brehm et al, 
1999; Nguyen 
et al, 2002a)
Cdk2 Centrosome
duplication
(Duensing et 
al, 2006)
y-tubulin Perturbs centrosome 
homeostasis
(Nguyen et al, 
2007)
TGF-pl Blocks suppression 
of c-myc 
transcription; 
promote cell growth
(Pietenpol et 
al, 1990)
Nuclear mitotic 
apparatus 
protein (NuMA)
Dynein mitotic 
spindle
delocalisation; 
prometaphase delay
(Nguyen et al, 
2008: N euven- -j ~ c> ~ - j. -----
& Munger, 
2009)
Transcription
machinery
Histone
acetyltransferase
- pCAF
- p300
Inhibits
transcriptional co­
activation
(Avvakumov et 
al, 2003; 
Bemat et al, 
2003)
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TATA-Box 
binding protein, 
TBP and TBP- 
transcription 
factor-110 
(TAF-110)
Modulate 
transcription 
initiation machinery
(Mazzarelli et 
al, 1995; 
Massimi et al, 
1996)
Transformation M phase 
phosphoprotein 
2 (MPP2)
Enhances
transcription activity 
and transformation
(Luscher- 
Firzlaff et al, 
1999)
c-Jun (Antinore et al, 
1996)
Insulin-like 
growth factor 
binding protein- 
3 (IGFBP-3)
Cellular
transformation and 
immortalisation
(Mannhardt et 
al, 2000; 
Santer et al, 
2007)
Apoptosis and 
DNA damage 
respond
ATM Activates
downstream CHK2, 
BRCA1, NBS1
(Moody & 
Laimins, 2009)
p600 Deregulates anoikis (Huh et al, 
2005; DeMasi 
et al, 2005, 
2007)
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subsequent release of E2F is a conserved feature of HPV replication. 
However, regions in the carboxy terminus of E7 have also been reported to 
influence the efficiency of E2F release, and this might be related to its 
transforming capacity. However, potentially more important is the capacity 
of HR E7 to target pRB pocket proteins (pRB, p i30 and p i07) for 
proteasome-mediated degradation. In contrast, LR types can only degrade 
p i07 (Zhang et al, 2006a), and this might be a critical difference in the 
respective capacity of these viruses to cause cancer. Under normal 
circumstances, RB represses E2F transcription activity in a cyclin/Cdk- 
dependent manner during late G1 phase, in this way, RB plays an important 
role in cell cycle regulation and differentiation. HPV E7 binds to the 
hypophosphorylated active form of RB (Imai et al, 1991), and degradation 
of RB subsequently leads to activation of the E2F transcription factor 
(Dyson, 1998). Both degradation and subsequent activation of E2F can 
override G1 arrest induced by p l6  (Mann & Jones, 1996; Giarre et al, 2001). 
Furthermore, through perturbing pRB/E2F transcription factors which act 
upstream of cyclin dependent kinase (Cdk), E7 is able to abrogate the cell 
cycle checkpoint and permit cells to progress into S phase (Demers et al, 
1994; Wazer et al, 1995; Dyson, 1998). Cdk2 forms a complex with Cyclin 
E or Cyclin A which regulates cell cycle progression into S phase (Koff et 
al, 1992; Ekholm & Reed, 2000). Studies showed that E7 associates with 
Cyclin E and Cyclin A (Dyson et al, 1992; Arroyo et al, 1993; Davies et al, 
1993), as well as with Cdk inhibitors p21 and p27 (Zerfass-Thome et al, 
1996; Funk et al, 1997; Jones et al, 1997a). These associations lead to 
activation of Cdk kinase activity and subsequently stimulate host and viral
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DNA synthesis (Favre et al, 1977; Swindle & Engler, 1998; He et al, 2003; 
Nguyen et al, 2007).
Cells expressing HPV oncoproteins present with an abnormal number of 
mitotic poles, mitotic spindle defects, errors in chromosomal segregation, 
and the resultant increased genomic instability (Lengauer et al, 1997; 
Duensing et al, 2000). A sucrose gradient analysis indicated that E7 
associates with centrosomal components such as Cdk2 and y-tubulin 
(Nguyen et al, 2007). Expression of E7 increases Cdk2 kinase activity, and 
it also induces centrosome over duplication and abnormalities (Duensing et 
al, 2006) which occurs in part through its association with the centrosomal 
regulator, y-tubulin (Nguyen et al, 2007). Besides that, in HPV E7- 
containing mitotic cells, the dynein mitotic spindle was found to be 
delocalised (Nguyen et al, 2008). This was later found to occur through 
interaction of E7 with the nuclear mitotic apparatus protein 1 (NuMA), 
which results in prometaphase delay (Nguyen & Mtinger, 2009). An indirect 
consequence of these activities of E7 over time might be to potentiate viral 
DNA integration (Kessis et al, 1996) and obviously to contribute to 
chromosomal instability during tumorigenesis.
The ability of E7 to transform primary cells (Yasumoto et al, 1986; Bedell et
al, 1989; Phelps et al, 1992) is also potentially mediated by its ability to
alter cellular apoptotic pathways, in particular anoikis. This form of
apoptosis occurs when cells lack appropriate cell-matrix attachment as a
result of the loss of cytoskeletal organisation (Frisch & Screaton, 2001).
Cells that are resistant to anoikis gain the ability to form foci and to grow in
an anchorage-independent manner (Kim et al, 2012). This is most likely
2 6
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related to the ability of E7 to interact with the retinoblastoma protein- 
associated factor p600, also known as UBR4 (Huh et al, 2005; DeMasi et al,
2005). In HPV E7-containing mammalian cells, the absence of p600 results 
in decreased anchorage-independent growth (Huh et al, 2005). In contrast, 
the interaction of E7 with p600 results in deregulation of anoikis, hence 
protecting floating cells from apoptosis (DeMasi et al, 2007).
1.4.2 E6 Oncoprotein
The HPV E6 oncoprotein is a small protein of about 150 amino acids with a 
molecular weight of approximately 18 kDa. Structural analysis showed that 
E6 is composed of a conserved scaffold with highly variable interaction 
surfaces involved in p53 targeting and nucleic acid binding (Nomine et al,
2006). The N- and C-termini are assembled in an anti-parallel manner, 
forming a tertiary structure of E6 with 6-stranded beta sheets and 6 a- 
helices, and its 2 zinc binding sites located at the opposite edge of the 
molecule (Nomine et al, 2006). The zinc binding sites of E6 are 
characterized by four CXXC motifs. HR HPV E6 is detected primarily in 
the nucleus (Grossman et al, 1989; Guccione et al, 2002; Tao et al, 2003), 
but is also found in the cell membrane (Grossman et al, 1989). Like E7, E6 
is a multi-functional protein which interacts with a large number of cellular 
proteins, allowing E6 to be involved in regulating their normal cellular 
functions. The consequences of E6 association with some of these proteins 
are summarised in Table 2.
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Table 2: Summary of HPV E6 cellular target proteins and consequence of
the interaction.
Cellular
event
manipulated
Target
proteins
Consequence of interaction Reference
p53 and p53-
related
regulation
E6AP Ubiquitination of p53 
Stabilisation of E6
(Scheffner 
et al, 1993; 
Hengsterma 
nn et al, 
2005)
p53 Degradation of p53, 
mediated by proteasome 
pathway through E6 AP
(Wemess et 
al, 1990; 
Huibregtse 
et al, 1991; 
Scheffner et 
al, 1991, 
1993)
Loss of p53-mediated 
TATA-containing promoter
(Lechner et 
al, 1992)
Abrogation of actinomycin- 
D-induced G1 growth arrest
(Foster et al, 
1994)
HPV viral genome 
maintenance
(Lorenz et 
al, 2013)
Apoptosis hADA3 Degradation; loss of p53 
acetylation and co-activator 
for p53-mediated 
transactivation, as well as 
cell senescence
(Sekaric et 
al, 2007; 
Shamanin et 
al, 2008)
Bak Degradation through E6AP (Thomas & 
Banks,
1998,
1999a)
Bcl-2 Prolonged expression (Alfandari
Bax Down-regulated by E6 et al, 1999)
TGF-P2 Downregulation of its pro- 
apoptotic function
(Nees et al, 
2000)
NF-kB Activates anti-apoptotic and 
cell transformation through 
inhibition of its negative 
regulators
-reduces levels of expression 
ofCYLD
- degrades NFX-91
- down-regulates p i05
(An et al, 
2008; Xu et 
al, 2010)
TNF-R1
FADD
Procaspase
8
Down-regulation of TNF- 
induced, caspase 3 and Fas- 
induced apoptosis
(Filippova 
et al, 2002, 
2007)
Telomerase Human Interact and increase (Oh et al,
2 8
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activity telomerase
reverse
transcriptase
(hTERT)
transcription activity
- through Myc (E-box) and 
hTERT promoter
- incorporation with NFX1- 
123
- repress p300 and Maz 
binding
- degrades NFXi-91
2001; James 
et al, 2006; 
Gewin et al, 
2004; Liu et 
al, 2009; 
Vliet-Gregg 
et al, 2013; 
Xu et al, 
2013)
Transcription hADA3 - SUMOylation and
degradation through 
E6AP; abrogates 
activation of p53
- Abrogates cell senescence
(Sekaric et 
al, 2007; 
Shamanin et 
al, 2008; 
Chand et al, 
2014)
TIP60 Destabilisation; perturbs 
p5 3-dependent transcription 
of pro-apoptotic genes
(Jha et al, 
2010)
CBP/p300 Degradation leads to 
repression of p53 and NF-kB 
responsive genes
(Patel et al, 
1999;
Zimmerman 
n et al, 
1999;
Thomas &
Chiang,
2005)
Cell signalling mTOR Activation of mTOR/AKT 
pathway by targeting mTOR 
inhibitor, TSC2
(Lu et al, 
2004a; 
Zheng et al, 
2008;
Spangle & 
Munger, 
2010)
Notch 
signalling 
and MAPK
Regulate its role in cell 
differentiation
(Talora et 
al, 2002b; 
Tan et al, 
2012;
Meyers et 
al, 2013)
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E6 binds to alpha-helix containing cellular proteins with an LXXLL motif, 
such as the E3 ubiquitin ligase E6AP (E6-associated protein, the ubiquitin- 
protein ligase E3A) (Huibregtse et al, 1991, 1993a, 1993b) through the 
E/D-L/J/F-L/V-G motif in E6AP (Elston et al, 1998). Structural analysis 
reveals that the alpha helix of E6 connects both the N- and C-terminal zinc 
binding domains at each end of the helices to form a deep pocket which 
could accommodate an LXXLL peptide (Vande Pol & Klingelhutz, 2013). 
Interaction between E6 and E6AP is crucial for E6 stability (Tomaic et al, 
2009b), and complex formation between E6-E6AP-p53 requires E6 to form 
a homodimer at its N-terminus (Zanier et al, 2012) as shown in Figure 3. 
Establishment of this complex is essential for the ability of E6 to direct p53 
degradation which occurs through E6 association with E6AP and the 
subsequent recruitment of p53 where E6AP transfers ubiquitin from its C- 
terminal thioester cysteine bond to p53 as shown in Figure 3 (Scheffner et 
al, 1993). Overexpression of E6AP further reduces the levels of p53 and 
results in an increased cell population in G2 (Talis et al, 1998). In contrast, 
ablation of E6AP mimics downregulation of E6, resulting in rescue of p53 
levels and restoration of p5 3-induced growth suppression (Hengstermann et 
al, 2005; Tomaic et al, 2009b). Even though E6 degrades the major portion 
of p53 in the cells, studies suggest that the remaining pool of p53 which is 
not degraded by E6 remains transcriptionally active (Butz et al, 1995; 
Banuelos et al, 2003; Kimple et al, 2013). In contrast, a recent study 
suggests that E6 is also able to inhibit p53-dependent transactivation upon 
genotoxic stress-induced DNA damage response (White et al, 2014). This 
could also occur through binding of E6 to CBP/p300 through its C terminal
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CHAPTER 1: INTRODUCTION
CXXC motif, thereby, inhibiting p53 transcriptional transactivation and the 
pro-apoptotic nuclear NF-kB transactivation activity which is modulated by 
p300 (Patel et al, 1999; Zimmermann et al, 1999; Thomas & Chiang, 2005). 
Besides p300, other histone acetyltransferases that have an effect on p53 
transcriptional transactivation, such as hADA3 and TIP60, are also targeted 
by E6 . In the case of hADA3, E6  inhibits its activity by proteasome- 
mediated degradation (Shamanin et al, 2008; Chand et al, 2014), which is an 
alternative way to inhibit p53 transcriptional transactivation (Kumar et al, 
2002; Sekaric et al, 2007; Shamanin et al, 2008), since hADA3 functions as 
the co-activator for p53-mediated transactivation. Likewise, E6  can 
manipulate TIP60 function, where this association leads to destabilisation of 
TIP60 and subsequently perturbs the p53-dependent transcription of pro- 
apoptotic genes (Jha et al, 2010).
Whilst E6  can degrade p53, this however depends on the manner of the 
E6/p53 association. The E6  C-terminal half of all HPV types can bind to 
p53, but HR HPV E6  binds and degrades p53 through its N-terminus (Crook 
et al, 1991). Degradation of p53 also depends on the region of p53 
associated with E6 , and this appears to be different between the HR and the 
LR types. The HR E6  binds to the core structure of p53 for degradation 
mediated by E6 AP. Degradation of p53 by HR HPV E6  allows cells to 
override actinomycin-D-induced G1 growth arrest (Foster et al, 1994) and to 
maintain the HPV viral genomes as extrachromosomal episomes (Park & 
Androphy, 2002; Lorenz et al, 2013; Brimer & Vande Pol, 2014). On the 
other hand, LR E6  binds to the C-terminal region of p53 (Li & Coffino, 
1996). Even though LR E6  can bind p53 through E6 AP, this does not result
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in p53 degradation (Brimer et al, 2007). Instead, LR HPV E6  utilises a 
different approach in modulating p53, including repression of p53 
transcription of TATA-containing promoters (Lechner et al, 1992), inhibit 
p53 transcription transactivation (Kiyono et al, 1994), retaining p53 in the 
cytosol (Sun et al, 2008) and through association with CBP/p300 even 
though the association is weaker than the HR HPV E6  (Patel et al, 1999).
Several studies suggest that for E6  proteins to exert their full oncogenic 
potential they require interactions with many other cellular pro- and anti- 
apoptotic proteins (Ishiwatari et al, 1994; Nakagawa et al, 1995). One of the 
first to be described is Bak, which is involved in induction of apoptosis upon 
a variety of stimuli, including UV irradiation. In this case, both HR and LR 
types of E6  bind and degrade Bak through E6 AP, abrogating its pro- 
apoptotic function (Thomas & Banks 1998; 1999). Intriguingly, this activity 
also appears to be significant for the cutaneous HPV types (Jackson & 
Storey, 2000; Jackson et al, 2000), suggesting that it is an important 
function for many HPV types. Expression of HR HPV 16 E6  in 
keratinocytes enables the cells to circumvent serum- and calcium-mediated 
differentiation (Sherman & Schlegel, 1996; Alfandari et al, 1999). E6 - 
mediated suppression of apoptosis in cells subject to serum-calcium switch 
occurs through manipulation of anti-apoptotic Bcl-2 and pro-apoptotic Bax. 
Normally, the levels of Bcl-2 decrease whilst the levels of Bax increase in 
serum-calcium switch cells. However, when E6  is expressed, the expression 
levels of Bcl-2 is increased whereas Bax levels is lower (Alfandari et al, 
1999). E6  also modulates the Fas and caspase pathways by reducing the 
cellular levels of Fas-associated death domain (FADD) and procaspase 8 ,
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respectively (Filippova et al, 2004, 2007). Another pro-apoptotic protein 
downregulated by E6  is the transforming growth factor-[32 (TGF-P2) and 
this also results in downregulation of the expression of TGF-P2 responsive 
genes (Nees et al, 2000).
Increased telomerase activity has always been implicated in cancer 
development. Cells with activated telomerase, an enzyme that adds 
TAAGGG repeats onto the telomeres (Feng et al, 1995), have the ability to 
continue to grow (Greider & Blackburn, 1985). Increment of the telomerase 
activity, which is normally suppressed in healthy somatic cells, is crucial for 
immortalisation (Kim et al, 1994; Artandi & DePinho, 2010). In cells 
containing HPV E6  and E7 oncoproteins, the length of the telomere is 
reduced after surviving crisis, but the length of telomere increases in late 
cell passages (Klingelhutz et al, 1994). Later studies showed that HPV E6  
alone is sufficient to activate telomerase in a mechanism independent of p53 
degradation (Klingelhutz et al, 1996) and independent of the E6 -PBM 
(Kiyono et al, 1998). Many studies have shown that E6  can increase hTERT 
activity through multiple mechanisms. This can involve direct interactions 
with the enzyme itself (Liu et al, 2009), although in most cases it appears to 
be indirect through an increase in hTERT gene expression levels. This can 
occur through E6  interaction with Myc and upregulation of E-box dependent 
transcription of hTERT (Oh et al, 2001) or through the ability of E6  to 
synergize with NFX1-123 to also increase its activity (Vliet-Gregg et al,
2013) and downregulate the hTERT repressors, like NFX1-91 (Gewin et al, 
2004), p300 (James et al, 2006) and Maz which binds to the hTERT 
promoter (Xu et al, 2013).
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Cellular signalling pathways play a central role in controlling and providing 
the link between cellular compartments. This involves activation or 
inhibition of cellular proteins, mainly regulated by enzymes like kinases and 
phosphatases. In order to be part of the cellular network, HPV E6 is 
involved in manipulating several cellular pathways, including the NF-kB- 
TNF, mammalian target of rapamycin (mTOR)-AKT, MAPK and Notch 
pathways. The mTOR-AKT, which are the key serine/threonine kinases in 
PI3K pathway, is activated by E6 (Sabatini, 2006; Spangle & Miinger, 
2010) through degradation of the mTOR inhibitor, tuberous sclerosis 
complex 2 (TSC2) in an E6AP-dependent manner (Lu et al, 2004b; Zheng et 
al, 2008). This can subsequently activates NF-kB (Basseres & Baldwin, 
2006) and inhibits the apoptotic effect of the TNF receptor family (Dolcet et 
al, 2005; Hayden & Ghosh, 2004). Other signalling pathways manipulated 
by E6s include repression of Notch and enhancement of MAPK signalling 
pathways (Talora et al, 2002a; Chakrabarti et al, 2004; Tan et al, 2012; 
Meyers et al, 2013).
1.4.3 Biological Synergy of E6 and E7 oncoproteins
Early studies initially showed that the HR HP Vs have the capacity to 
transform established rodent cells using a variety of different assay system, 
including NIH 3T3, C127 and 3Y1 (Tsunokawa et al, 1986; Yasumoto et al, 
1986; Morgan et al, 1988; Watanabe & Yoshiike, 1988) and mammalian 
fibroblasts (Watanabe et al, 1989). Further studies then demonstrated that 
HPVs could also cooperate with activated oncogenes, such as EJ-ras (Storey
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et al, 1988) and c-myc (Crook et al, 1989), to bring about full 
transformation of primary rodent cells. A consequence of the co-expression 
of HPV oncogenes and activation of ras genes is increased cell density, and 
the primary rodent cells presented with transformed morphology 
(Matlashewski et al, 1987). Dissection of the viral gene products responsible 
for these activities indicated a major role for the viral E7 oncoprotein 
(Storey et al, 1988; Phelps et al, 1988; Vousden et al, 1988), with somewhat 
weaker activities for. the E6 oncoprotein (Hawley-Nelson et al, 1989; 
Sedman et al, 1991). Most significantly, in the majority of the cases, these 
activities were specific for the E7 oncoproteins derived from cancer causing 
HPV types (Storey et al, 1988).
The most relevant cell types to be used for assessing the transforming 
capabilities are obviously the natural target cells of the virus, human 
keratinocytes. Early studies demonstrated that HR HP Vs could efficiently 
immortalise human keratinocytes, whether they were derived from either 
cervical or foreskin demonstrating that HPV had the potential to initiate 
events leading to transformation in cells derived from multiple locations 
where the viruses had been associated with the development of malignancy 
(Durst et al, 1987; Pirisi et al, 1987; Kaur & McDougall, 1988; Schlegel et 
al, 1988; Woodworth et al, 1988, 1989). It should be emphasized that these 
immortalized cells were not fully transformed. Extended passages with 
additional activated oncogenes and the deactivation of tumour suppressors, 
was required to bring about a fully transformed phenotypes (Band et al, 
1991; Hurlin et al, 1991; Wazer et al, 1995; Nakagawa et al, 1995). This 
demonstrates the requirement for other events in addition to the expression
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of E6 and E7 for the development of malignancy. These observations reflect 
the fact that HPV-induced carcinogenesis is a lengthy multi-step event.
Further analyses showed that the ability of HPV to immortalise primary 
human cells required the combined activity of both E6 and E7, and thus 
reflected the situation in vivo, where both E6 and E7 continue to be 
expressed in the HPV-induced tumours. The initial findings demonstrated 
that E7 contributes to increased cell density and transformed morphology, 
whereas E6 was responsible for the tumorigenicity (Yutsudo et al, 1988) and 
this relative role of both HPV oncoproteins is illustrated in Figure 4. 
Following this observation, the mechanistic targets of both of these 
oncoproteins became more apparent. E7 appears to be involved in the early 
stage of malignant progression, where it induces cell proliferation by 
targeting pRB and the related pocket proteins, pi 07 and p i30 (Dyson et al, 
1989; Imai et al, 1989; Miinger et al, 2004). Meanwhile, E6 targets p53 
(Scheffner et al, 1991; Huibregtse et al, 1991; Scheffner et al, 1993) and 
contributes to the progression of the malignancy (Song et al, 2000; Riley et 
al, 2003). These results showed that manipulation of these tumour 
suppressors by HPV oncoproteins is an essential step for HPV-induced 
tumour progression. Indeed, studies showed that in HPV-negative cervical 
cancer cell lines isolated from patients, p53 and pRB are mutated and the 
consequences of these mutations may resemble tne enects seen when the 
wild type tumour suppressors are targeted by the HPV oncoproteins for 
degradation (Scheffner et al, 1991). Additionally, downregulation of E6 and 
E7 by either expressing viral E2 or using siRNA can reactivate cellular
3 7
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Loss of polarity M etastasis 
Infection Proliferation Im m ortalisation and cell-contact and invasion
Figure 4: Relative contributions of HPV E6 and E7 towards the 
development of malignancy. The early stages in the development of cancer 
are largely driven by the highly proliferative activity of the E7 oncoprotein. 
The later stages of malignant progression are probably influenced heavily by 
the E6 oncoprotein and its capacity to target cellular PDZ domain- 
containing proteins (Pirn et al, 2012).
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tumour suppressive pathways and inhibit HPV-induced immortalisation 
(Alvarez-Salas et al, 1998; Goodwin & DiMaio, 2000; Yoshinouchi et al,
2003). In order to understand the biological consequence of HPV E6 and E7 
expression in vivo, the HPV genome can be introduced into either 
organotypic raft culture or into animal models.
1.4.3.1 Organotypic raft culture
Organotypic raft culture can be used to study the viral life cycle, HPV- 
induced immortalisation of keratinocytes, and the phenotypic changes that 
could occur during differentiation and stratification of the epithelium (Pirn 
& Banks, 2010). To initiate an organotypic HPV infection, the HPV genome 
is introduced into the primary keratinocytes in monolayer culture. These 
cells are then grown on a collagen matrix at the air-liquid interface, allowing 
the cells to differentiate and stratify (Meyers & Laimins, 1994; Chow & 
Broker, 1997). This differentiation supports the expression of the different 
viral gene products, ultimately resulting in the production of new viral 
particles, thereby allowing analysis of the viral life cycle, from initiation of 
infection to the synthesis of new viral particles. As mentioned earlier, E6 
and E7 are involved in manipulating multiple events and affects a huge 
number of transcripts. Indeed, microarray analysis of primary human 
keratinocytes containing HPV-18 E6/E7 from an organotypic culture 
indicates that the viral oncoproteins regulate the expression of a multiple of 
cellular genes. Upregulated transcripts include the host transcription co­
activator, pCAF; transcripts in the MAPK signalling pathways, genes
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involved in DNA replication, including cell cycle kinases Cdk2/Cyclin B 
and Cdk2/Cyclin E; as well as genes involved in the spindle and G2/M 
checkpoints. Meanwhile, downregulated transcripts include proto-oncogene 
JunB and genes involved in protein translation (Gamer-Hamrick et al, 
2004). This further highlights the involvement of E6 and E7 in 
manipulating, directly or indirectly, the expression and functions of a global 
array of cellular genes and their respective gene products.
One of the benefits of using raft culture is that the morphology of the normal 
cells as they progress to neoplasia following HPV infection can be observed. 
Normal epithelial cells show well-defined strata; as the dysplasia progresses 
following HPV infection, the thickness of the epithelial layers increases with 
disruption of tissue architecture, irregular size and shape of the individual 
cells, enlarged and irregular size of nuclei, as well as abnormal mitoses 
(Blanton et al, 1991). The LR HPV types can also alter cell differentiation in 
raft culture, although immortalisation is extremely rare, hence for studies on 
LR HPV types E6, normal immortalised keratinocytes (NIKS) are often 
used. It has also been shown that the integrity of the viral oncogenes is 
important to establish a stable viral episomal copy number (Hummel et al, 
1992; Thomas et al, 1999; Oh et al, 2004b; Delury et al, 2013).
1.4.3.2 Animal models - Transgenic mouse models
In addition to raft culture, a number of animal models are used to study the 
consequences of HPV infection, including the transgenic mouse, canine and 
cottontail rabbit models. Among these animal models, transgenic mouse
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models are widely used to study tumour development induced by E6 and E7. 
Arbeit et al. showed that expression of HPV-16 E6 and E7 induced 
hyperproliferation of neuroepithelial cells in transgenic mice as early as 1 
month old, which further progressed to neuroepithelial tumours (Arbeit et al, 
1993). When HPV E6 and E7 were expressed from the keratin 14 (K14) 
promoter, which drives expression in basal cells (Arbeit et al, 1994), 
tumours formed at multiple epidermal and squamous sites including skin 
and cervix (Arbeit et al, 1994, 1996).
Consistent with the observations using primary cells, HPV E6 (Song et al, 
1999) and E7 (Herber et al, 1996) are individually competent at inducing 
epithelial hyperplasia and tumours in animal models. Skin tumours resulting 
from E7 expression were benign and highly differentiated, whereas E6- 
induced tumours exhibit more malignant phenotypes (Song et al, 2000; 
Simonson et al, 2005). Meanwhile, in head and neck squamous cell cancer 
(HNSCC), E7 plays a more important role than E6 in causing carcinogenesis 
with increased DNA synthesis (Strati & Lambert, 2007). In the E7- 
expressing mice, E7 inactivates tumour suppressor pRB (Balsitis et al,
2006), increases proliferation and centrosome copy number, as well as 
inducing progression of multifocal microinvasive cervical cancers (Riley et 
al, 2003). However, by using mice expressing a mutant pRB incapable of
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ability to induce DNA synthesis and overcome differentiation-induced cell 
cycle arrest, indicating other activities of E7 are also important (Balsitis et 
al, 2006).
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In the case of E6, degradation of p53 is important to induce epidermal 
hyperproliferation and circumvent p53-induced apoptosis. However, p53- 
independent activities of E6 are also required (Song et al, 1999, 1998). In
T1 90T
order to investigate the role of E6AP, E6 , in which binding to E6AP is 
strongly reduced (Nguyen et al, 2002b), and E6AP-null mice were also used 
(Shai et al, 2007b, 2010). The p53 protein levels are detectable in the mutant 
E6 mice, and the mice are irresponsive to a radiation-induced block of DNA 
synthesis (Nguyen et al, 2002b). These mice also display reduced epithelial 
hyperplasia and lower rate of tumour progression (Nguyen et al, 2002b) and 
develop smaller tumours (Shai et al, 2007a) in comparison with mice 
carrying wild type E6. Interestingly, in E6AP-null mice, E6 is able to 
abrogate the DNA damage response induced by ionizing radiation (Shai et 
al, 2007b, 2010) and can induce epithelial hyperplasia (Shai et al, 2007b, 
2010). Indeed, studies indicated E6 can also induce hyperplasia through its 
C-terminal PBM. For example, mice expressing the E6APBM (A146-151) 
retain the ability to degrade p53, but exhibit a reduction in DNA synthesis in 
the suprabasal layer and display reduced tumour sizes (Song et al, 1998; 
Nguyen et al, 2003; Simonson et al, 2005; Shai et al, 2007b), indicating the 
ability of E6 to abrogate p53-mediated functions, and the involvement of 
E6's PBM in cancer progression is also depicted in Figure 4.
In vivo studies strongly suggest that long-term exposure to estrogen results 
in HPV-induced invasive cervical carcinoma. Estrogen receptors can be 
found on the cervical squamous epithelium (Gao et al, 1983; Chung et al, 
2010). Therefore, the cells are able to respond to estrogen treatment, giving 
rise to hyperplasia and a shorter G1 phase of the cell cycle (Quarmby &
4 2
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Korach, 1984; Arbeit et al, 1996). Transgenic mice expressing E6 and/or E7 
showed that estrogen contributes to persistent and continuous development 
of cervical cancer (Brake & Lambert, 2005; Chung et al, 2013, 2008a). HPV 
infection in combination with the chronic exposure to estrogen and 
activation of estrogen receptor ERa enhances the effects of cell 
hyperproliferation (Bradlow et al, 1985; Arbeit et al, 1996; Chung et al, 
2013, 2008a; Chung & Lambert, 2009; Son et al, 2014; Spurgeon et al,
2014). Inhibition of estrogen receptor using antagonists, like raloxifene and 
fulvestrant, have been proposed to have therapeutic potential for reversing 
the progression of cervical lesions to carcinoma (Chung & Lambert, 2009; 
Spurgeon et al, 2014).
1.4.4 The E6-PBM and PDZ proteins
One of the unique features of the E6 oncoprotein of the HR HPV types is its 
ability to bind proteins containing PDZ domains (Postsynaptic density 
protein 95/Disc large protein/Zonula occludens-1 or in short, 
PSD95/Dlg/ZO-l). The E6 proteins possess a PDZ binding motif (PBM), x- 
T/S-x-L/V (Songyang et al, 1997) at the C-terminus and this feature is 
absent in E6s from low risk HPV types. PDZ domains, which are 80 to 100 
amino acids in length, are often found in multiple copies within a protein 
and are the site where protein-protein interactions occur (Fanning & 
Anderson, 1999). They play significant roles in multiple cellular functions, 
including regulating cell migration and invasion, cell proliferation, 
maintaining cell polarity, cell-cell contact, apoptosis, immune cell
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recognition and cell signalling (Jacob et al, 1987; Woods & Bryant, 1991; 
Bilder, 2000, 2004; Subbaiah et al, 2011) and many of these cellular 
proteins have potential roles as tumour suppressors (Javier, 2008). E6 targets 
multiple PDZ proteins through its PBM, and these include human 
homologue of the Drosophila Disc large protein (hDlg) (Kiyono et al, 1997; 
Lee et al, 1997), the Scribble (Nakagawa & Huibregtse, 2000) and the 
membrane-associated guanylated kinase inverted (MAGI) proteins 
(Glaunsinger et al, 2000).
hDlg was the first PDZ protein to be identified as a target for HR HPV E6 
(Kiyono et al, 1997; Lee et al, 1997). hDlg is a member of the membrane- 
associated guanylate kinase (MAGUK) family of proteins. MAGUK contain 
PDZ domains, src-homology 3 (SH3) or WW domains and guanylate kinase 
(GUK) homology domains, all of which can act as modules for protein- 
protein interactions (Gonzalez-Mariscal et al, 2000; Gardoni et al, 2009). 
These proteins can be found at junctions between epithelial cells where they 
maintain the integrity of the cell junctions, the localisation of basolateral 
membrane proteins and apico-basal cell polarity (Woods & Bryant, 1991, 
1993; Woods et al, 1996). Functionally, they can act as scaffold proteins, 
binding to transmembrane proteins and bridging signals from the plasma 
membrane to the downstream effector proteins, and are implicated in diverse 
activities, including the maintainence of cell polarity and cell signalling 
(Anderson, 1996). They are also involved in nuclear-cytoplasmic shuttling 
mediated by the actin cytoskeleton (Islas et al, 2002; Jaramillo et al, 2004; 
Traweger et al, 2003), and control the kinetics of actin polymerization
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(Baumgartner et al, 2008) and depolymerisation (Shen & Turner, 2005). 
Loss or mislocalisation of the PDZ proteins that exist as complexes at the 
cell junction often results in loss of cell polarity and can contribute to 
carcinogenesis (Gateff & Schneiderman, 1974; Mechler et al, 1985; Bilder 
& Perrimon, 2000). The ability of E6 to associate with hDlg is conserved 
among the HR HPV types (Gardiol et al, 1999; Pirn et al, 2000). hDlg is 
degraded by E6 in a proteasome dependent manner (Woods et al, 1996; 
Kiyono et al, 1997; Gardiol et al, 1999; Pirn et al, 2000), thus contributing 
to a loss of cell polarity, morphological transformation and proliferation. 
However, the ability of E6 to target hDlg can be influenced both by its 
location, and its phosphorylation status (Matsumine et al, 1996; Gaudet et 
al, 2000; Narayan et al, 2009a).
MAGI-1 is important in the establishment of tight junctions, and can affect 
cell proliferation, apoptosis and cell signalling. MAGI-1 was originally 
found colocalised with ZO-1 which is an essential component of the 
epithelial tight junctions (Dobrosotskaya et al, 1997; Van Itallie & 
Anderson, 1997), and has been reported to also regulate AKT activity 
through complex formation with PTEN, an activity which is also showed by 
MAGI-2 and MAGI-3 (Wu et al, 2000b, 2000a; Kotelevets et al, 2005). 
HPV E6 recognises MAGI-1 via PDZ domain 1 (Glaunsinger et al, 2000) 
and subsequently targets it for degradation (Kranjec & Banks, 2011; Kranjec 
et al, 2014). Recent studies showed that, re-establishment of MAGI-1 
expression in HPV positive cell lines allows the tight junction proteins ZO-1 
and PAR-3 to be recruited to the cell-cell contact area (Kranjec et al, 2014).
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Like MAGI-I protein, MAGI-2 and -3 are also targeted by HR HPV E6 for 
degradation (Thomas et al, 2002). This indicates that MAGI proteins are 
important for maintaining the integrity of cellular tight junctions, and that 
these controls are perturbed by E6 binding.
Scribble is a non-MAGUK protein, but is also a potentially important target 
of HPV E6 (Nakagawa & Huibregtse, 2000). Scribble belongs to the LAP 
(leucine-rich PDZ domain) family of proteins, containing 4 PDZ domains 
and a leucine rich region which is crucial for its basolateral localisation 
(Bryant & Huwe, 2000; Santoni et al, 2002; Legouis et al, 2003). The 
Scribble polarity module, which is localised at the basolateral junction of the 
cell membranes, consists of three proteins, Scribble, hDlg and Lgl (lethal 
giant larvae). In Drosophila, this module is important for the proper 
morphogenesis of the embryonic epithelia (Bilder & Perrimon, 2000), and 
loss of Scribble results in changes of cell shape, loss of monolayer 
organisation and loss of cell-cell junctions (Bilder, 2000; Bilder & 
Perrimon, 2000; Zhan et al, 2008). E6 targets Scribble for degradation 
through a ubiquitin-mediated mechanism (Nakagawa & Huibregtse, 2000; 
Thomas et al, 2005). Both HPV-16 and -18 E6 can interact with Scribble, 
but HPV-16 E6 is the more effective (Thomas et al, 2005). This is due to 
minor differences in the amino acid sequence of the PBM between different 
E6 oncoproteins as shown in Figure 5 (a). Indeed, structure and mutational 
analyses have precisely defined the contribution of each of the amino acids 
in the PBM in the interactions with different PDZ targets (Songyang et al, 
1997; Zhang et al, 2006b, 2007; Tonikian et al, 2008). In the case of hDlg
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and Scribble, swapping the last amino acid L/V of HPV-16 and -18 E6, 
respectively reverses the preference between these substrate proteins 
(Thomas et al, 2005).
Of mammalian PVs, the other HR type that has been defined is Rhesus 
papillomavirus, RhPV. It was discovered that like humans, the Rhesus 
Macaque monkey is a natural host for a papillomavirus in which the 
infection can be transmitted sexually (Ostrow et al, 1990; Wood et al,
2004). Rhesus papillomavirus type 1 (RhPV-1) shares the closest sequence 
similarities with HPV-16 (Ostrow et al, 1991) and following RhPV-1 
infection, Rhesus Macaques develop cervical neoplasia resembling that 
caused by HR HPV (Wood et al, 2007). Intriguingly, the RhPV-1 E7 protein 
contains a PBM rather than the E6. The PBM of RhPV-1 E7, like that of HR 
Scribble, HPV E6, confers interaction with a number of PDZ-containing 
proteins, including MAGI-2 and MAGI-3 (Tomaic et al, 2009a). However, 
the amino acid sequence of the RhPV-1 E7 PBM is very different from the 
HR HPV E6 PBM, and in this case, Par-3 seems to be the major target of 
RhPV-1 E7. Par-3 belongs to the same pathway of cell polarity control as 
hDlg and Scribble, being essential in the function of tight junctions rather 
than adherens junctions (Macara, 2004; Humbert et al, 2008; Chen & 
Zhang, 2013). RhPV-1 E7 targets the cell polarity regulator, Par3 for 
degradation in a proteasome dependent manner, similar to HPV E6 (Tomaic 
et al, 2009a). These results indicate that like HPV E6, RhPV-1 E7 can also 
potentially perturb the control of cell polarity through its PBM.
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Another group of PDZ domain-containing proteins targeted by E6 are 
tyrosine phosphatases, and these include non-receptor tyosine phosphatases 
like PTPN3 and PTPN13. In the case of PTPN3, association with HR HPV 
E6 oncoproteins results in PTPN3 degradation in a proteasome-mediated 
pathway which is linked to the ability of E6 to induce cell growth even in 
the absence of growth factors (Jing et al, 2007; Topffer et al, 2007). On the 
other hand, degradation of PTPN13 by E6 oncoproteins results in the 
upregulation of survival signalling through MAP kinase (Hoover et al,
2009), and this event, in coorperation with ras expression leads to 
anchorage-independent growth (Spanos et al, 2008b). Activation of cellular 
kinases may have important implications for the HPV oncoproteins and their 
target proteins, potentially affecting their preferences in protein-protein 
recognition and localisation.
E6's PBM plays a crucial role in viral life cycle and in HPV-induced 
carcinogenesis. In the viral life cycle, the integrity of E6 and its PBM is 
crucial for the maintenance of the viral copy number in undifferentiated 
cells (Lee & Laimins, 2004; Delury et al, 2013). Kiyono and colleagues 
showed that an intact HPV-16 E6 PBM is required to induce morphological 
transformation in rat 3Y1 cells (Kiyono et ah, 1997). Meanwhile, E6 
mutants with deletions in the PBM are unable to induce hyperplasia in 
transgenic mouse models (Nguyen et al, 2003) and are also unable to 
cooperate with E7 to immortalise human tonsillar epithelial cells (Spanos et 
al, 2008b, 2008a). In human foreskin keratinocytes (HFKs), the E6's PBM 
contributes towards induction of epithelial hyperplasia in raft cultures, and
4 8
CHAPTER 1: INTRODUCTION
also aids in the retention of viral episomes over time (Lee & Laimins, 2004; 
Delury et al, 2013; Choi et al, 2014). PDZ proteins possess dual functions, 
mostly acting as tumour suppressors, however, they can also have oncogenic 
properties, depending on the context. For instance, HPV-18 E6 was found to 
form as a complex with hDlg and the RhoG-specific guanine nucleotide 
exchange factor (GEF), SGEF, through E6's PBM and this complex 
increases RhoG activity (Subbiah et a l, 2012). Intriguingly, the pool of 
hDlg that is not degraded by E6, together with SGEF, contributes to 
invasiveness in HPV-transformed cells. This probably occurs through 
upregulation of SGEF and RhoG activity (Subbaiah et al, 2012). These 
findings collectively highlight the importance of the PBM of HR HPV E6 in 
interacting with PDZ proteins, degrading these proteins and regulating 
cellular signalling pathways that favour virus survival or cell transformation.
As can be seen in Figure 5 (a), the amino acid sequence of the E6 PBMs of 
the different HR types of HPV types are similar and this domain can 
potentially be subject to post-translational modification by phosphorylation. 
It has been shown that the E6 of HR HPV can be phosphorylated by PKA, 
but not the E6s from LR types, with the phospho-acceptor on HPV-18 E6 
mapping to T156. Kinetic assays on peptides of the different HR HPV E6s 
indicated that, despite the close similarity of the of the C-terminal PBM of 
these E6s, their susceptibility to phosphoi yictuuii oy vanes ^jvunne et 
al, 2000). Studies performed by Kuhne et al. (2000) showed several 
important points. HPV-18 E6 can be strongly phosphorylated by PKA 
compared with PKB, p70S6K and p90rsk. In addition, the Michaelis 
constant, Km, of the HPV-18 and -16 E6s phosphorylated by PKA are
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similar, 6.0 and 6.6 respectively, while the Km value for HPV-33 E6 was 
3.6 (Kiihne et al, 2000). These indicate that these proteins can be 
phosphorylated efficiently and specifically by PKA. However, the phospho- 
regulation of the full length E6 proteins remained to be verified and the 
susceptibility of the HR HPV E6s to phosphorylation by other kinases 
remained largely unknown. As the phospho-acceptor residue is embedded 
within the PDZ recognition region, the effect of phosphorylation in 
interacting with PDZ proteins was also investigated. Intriguingly, 
phosphorylation of HPV-18 E6 negatively regulates its interaction with 
hDlg, hence rescuing hDlg from degradation by E6 (Kiihne et al, 2000). 
Structural analysis revealed that the interacting groove between E6 and PDZ 
proteins is too small to accommodate a phosphate molecule as shown in 
Figure 5 (b) (Zhang et al, 2007). Even though phosphorylation negatively 
regulates the interaction of E6 with PDZ-containing proteins, it was possible 
that the post-translational modification of E6 might confer interaction with 
other cellular proteins and this aspect remained largely to be investigated. 
However, proteomic analysis performed in our laboratory and by Howie et 
al. showed that 14-3-3 proteins (Howie et al, 2011), 
phosphoserine/threonine binding proteins are possible novel interacting 
partners of phospho-E6 (pE6).
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(a) PKA consensus site 
PDZ binding motif: 
HPVE6 types
18
16
33
51
58
31
RRXT/S 
XT/SXV/L 
PBM Sequence
 RLQRRRETQV*
 SSRTRRETQL*
 WRSRRRETAL*
 RLQRRNETQV*
....WRPRRRQTQV*
....WRRPRTETQV*
MAGI-
Figure 5. The E6 PDZ binding motif (PBM). (a) Close similarity of amino 
acid sequence of PBM of E6 across the different cancer-causing HR HPV 
types E6. This is the region where the potential PKA phosphorylation site 
embedded within PBM of HPV-18 E6 has been identified, (b) E6 (E l55 
residue) and PDZ proteins (GFGL motif spanning from amino acid 461 to 
464 in MAGI-1 PDZ domain 1) interaction is held by hydrogen bonding 
(dotted blue line). The hydroxyl group of T3 is only 3A (0.3 nm) away from 
aB of the MAGi-1. Adding of a phosphate group (red sphere P (V )  by PKA 
phosphorylation at T156 of E6 creates a steric hindrance that prevents E6 
from interacting with MAGI-1 (Adapted from Zhang et al,  2007).
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1.5 14-3-3 genes, protein structure and their general cellular functions
14-3-3 proteins were first discovered in 1967 from a fractionation analysis 
of soluble proteins isolated from brain (Moore & Perez, 1967). The 
nomenclature of these proteins was given according to the combination of 
their fraction number on DEAE-cellulose chromatography and their 
migration pattern on eletrophoresis (Moore & McGregor, 1965). 14-3-3 
proteins are highly conserved in most eukaryotes including mammals, 
amphibians, insects and plants (Aitken et al, 1992), and seven isoforms of 
14-3-3 have been identified in mammals, namely a/p, y, s, CJ§, t |,  t / 0  and o  
(Mackintosh, 2004), which are encoded by distinct genes located on 
different chromosomes (Aitken, 2002).
14-3-3 proteins are highly acidic, with isoelectric points of 4 to 5 and 
molecular weights of 25 to 33 kDa (Jones et al, 1995a) and they are 
ubiquitously expressed in cells. They are also extremely abundant: it was 
estimated that 14-3-3 protein made up 1% of the brain soluble protein 
(Boston et al, 1982). Although it was initially found in brain tissue, 14-3-3 
was later found to be present in almost all tissues analysed (Celis et al, 
1990). In terms of its intracellular distribution, 14-3-3 is found 
predominantly in the cytoplasm, but it is also found in plasma membranes, 
nucleus and Golgi apparatus (Celis et al, 1990; Leffers et al, 1993; Tang et 
al, 1998; Freed et al, 1994; Garcia-Guzman et al, 1999; Fanger et al, 1998).
The crystal structures of the r  and f  isoforms showed that 14-3-3 are dimeric 
proteins. Each of the monomers contains variable N-terminal and conserved 
C-terminal domains, with the 9 a-helices arranged in anti-parallel manner
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(Liu et al, 1995; Xiao et al, 1995). Figure 6 shows the arrangement of the 
14-3-3 dimer, and as can be seen, the molecule is orientated in such a way 
that it has a cup-like structure. Its outer surface is variable whilst the inner 
amphipathic concave surface is highly conserved. The dimer is formed 
through packing of helices a l (amino acid residue 3 - 15) of one monomer 
with helices a3 (around amino acid 40 - 67) and a4 (around amino acids 75 - 
107) (Liu et al, 1995; Xiao et al, 1995). The dimer interface forms a 
negatively-charged channel (Aitken, 2002; Xiao et al, 1995), and the dimer 
is held together by salt bridges (Liu et al, 1995; Yang et al, 2006). This 
fundamental structure of 14-3-3 and dimerisation are also illustrated in 
Figure 6. Due to the specificity with which the monomers can interact, each 
isoform is restricted in how it can form homo- or heterodimers with the 
other 14-3-3 isoforms (Jones et al, 1995b). When 14-3-3 binds to the ligand, 
the ligand runs in the opposite direction within the amphipathic binding 
groove of the 14-3-3 dimers (Jones et al, 1995a; Fu et al, 2000). This dimer 
formation and ligand protein binding is illustrated in Figure 7. Only specific 
combinations of 14-3-3 isoforms form dimers, and this may confer some 
kind of specificity upon 14-3-3 function. This will be discussed in a later 
section.
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-conserved, basic
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Figure 6: Basic molecular structure of 14-3-3. The 14-3-3 monomer 
contains 9 a-helices and the protein is folded in such a way that the variable 
surface is facing out (red) and the amphipathic concave surface which is 
conserved among the isoforms is facing inward (purple). The dimer 
interface results from the packing of the a-1 monomer (blue) with a3 and a4 
helices of the other (green). The 14-3-3^ homodimer is hold together at R18 
and E21 (embedded within a2 helix), as well as L85 and M88 (embedded 
within a4 helix) through salt bridges (red crosses).
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1.6 14-3-3 ligand protein recognition and consequences of the 
association
14-3-3 binds to over 100 cellular proteins and many of these interactions 
occur in a phosphorylation-dependent manner. Although 14-3-3 can also 
bind to non-phosphorylated proteins, the number of these interactions are 
fewer than those with phosphorylated proteins. From co-crystallization 
analysis of 14-3-3^ bound to different peptide ligands, it was shown that 
binding of both phosphorylated and non-phosphorylated peptides to 14-3-3 
occurs within the conserved concaved amphipathic groove (Yaffe et al, 
1997; Rittinger et al, 1999; Petosa et al, 1998). 14-3-3 can alter the 
functions or nuclear-cytoplasmic localisation of its bound ligand proteins; it 
can either protect it from, or promote its susceptibility to further post- 
translational modifications and affect its ability to interact with other cellular 
proteins (Hermeking, 2003). Binding of 14-3-3 to the ligand proteins and the 
mode of regulation by 14-3-3 are also illustrated in Figure 7.
1.6.1 Phosnhoprotein recognition
All 14-3-3 isoforms are known to be phospho-serine/threonine binding 
proteins (Muslin et al, 1996). They recognise the consensus motifs 
RSXpSXP, RXY/FXpSXP and p(S/T)X!-2-COOH and these binding motifs 
are present in many of the 14-3-3 binding proteins (Yaffe et al, 1997; 
Coblitz et al, 2006). The binding site for the phophoserine/threonine 
proteins is the basic pocket of 14-3-3 consisting of Lys-49 (K49), Arg-56 
(R56), Arg-127 (R127), and Tyr-128 (T128). Cellular proteins which are 
recognised as phosphorylated proteins by 14-3-3 include protein kinases
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(murine leukemia viral oncogene homologue - RAF1, MEK kinase, PI3 
kinase, and GrblO), growth factor receptor proteins (insulin-like growth 
factor 1 and glucocorticoid receptors), enzymes (serotonin N- 
acetyltransferase, tyrosine and tryptophane hydroxylase), structural and 
cytoskeletal proteins (vimentins, and keratins), scaffolding molecules 
(calmodulin), proteins involved in cell cycle control (Cdc25, p53, p27, and 
Weel), proteins involved in transcriptional control (histone 
acetyltransferase, and TATA box binding proteins), and proteins involved in 
apoptosis (Bad) (Yaffe et al, 1997; Aitken, 2002; Fu et al, 2000; Mhawech,
2005).
1.6.2 Unmodified protein recognition
As mentioned above, 14-3-3 can also interact with unmodified proteins
(Hermeking, 2003; Mackintosh, 2004). Examples of these include
mitochondrial targeting signal sequences (Alam et al, 1994), the platelet
glycoprotein, GPIba (Du et al, 1996), the ExoS ADP-ribosyltransferase (Fu
et al, 1993; Masters et al, 1999), inositol polyphosphate 5-phosphatase (5-
phosphatase) (Campbell et al, 1997), the pro-apoptotic protein Bax (Nomura
et al, 1999), as well as Raf-1 at its cysteine rich domain (CRD) (Michaud et
al, 1995; Clark et al, 1997). Unlike the phosphoserine/threonine binding
motif, 14-3-3 recognition of unmodified ligands seems to depend upon the
presence of multiple negatively-charged residues, such as Glutamic acid (E)
or Aspartic acid (D). For example, 14-3-3 recognises the RSxSxP-like motif
RSESEE, which is located close to the catalytic domain of 5-phosphatase
(Campbell et al, 1997). Similarly, a small 18-amino acid peptide, R18,
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which contains multiple negatively charged E residues can also bind to 14- 
3-3 and act as an antagonist (Wang et al, 1999). Interestingly, the 
interactions of 14-3-3 with non-phosphorylated ligands can occur with high 
affinity, for example the 13-mer peptide of 5-phosphatase containing the 
RSESEE motif has a Kd (dissociation constant) value of 92 nM (Campbell et 
al, 1997). In contrast, p53 peptides mono-phosphorylated at S366, S378 or 
T387 bind to 14-3-3 with a Kd of 14 - 20 pM (Rajagopalan et al, 2008), 
whilst 14-3-3^ binds to the Raf-1 peptide pS259 with a Kd of 7.5 pM 
(Molzan et al, 2010).
1.6.3 14-3-3 regulation of its target proteins
14-3-3 interactions with its target proteins can have a wide variety of effects, 
depending upon the particular context. In the case of enzymes, this may 
involve stimulation of enzymatic reaction. For instance, association of the 
14-3-3 dimer with Raf-1, increases its intrinsic serine/threonine kinase 
activity (Morrison et al, 1993; Tzivion et al, 1998). Likewise, association of 
14-3-3 with a serotonin N-acetyltransferase also enhances its enzymatic 
activity (Obsil et al, 2001).
14-3-3 can also mediate nuclear-cytoplasmic shuttling of its target proteins 
(Muslin & Xing, 2000). In most cases, 14-3-3 mediates localisation of its 
target protein to the cytoplasmic compartment. For instance, the cell cycle 
regulator, Cdc25 also associates with 14-3-3, and as a consequence, Cdc25 
is relocalised into the cytoplasm as an inactive form (Dunphy & Kumagai, 
1991; Lopez-Girona et al, 1999; Yang et al, 1999; Uchida et al, 2004c),
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keeping it away from cyclin-dependent protein kinase (Cdk) complexes 
(Chou et al, 2010). It was initially thought that the cytoplasmic 
relocalisation of 14-3-3-ligand complexes was due to the presence of a 
putative nuclear export sequence (NES) in the C-terminal region of 14-3-3 
(Lopez-Girona et al, 1999; Rittinger et al, 1999), but several studies now 
appear to disagree with this (Yang et al, 1999; Zeng & Piwnica-Worms, 
1999; Kumagai & Dunphy, 1999; Brunet et al, 2002). For example, it was 
shown that a 14-3-3 mutant which is not able to bind to its ligand 
accumulates in the nucleus (Brunet et al, 2002). This is thought to be due to 
the fact that the 14-3-3-ligand interaction results in a conformational change 
of the target protein, which in turn facilitates an alteration in cellular 
localisation, depending on the exposure of an NES or NLS on the target 
protein. Hence, 14-3-3 may serve as a chaperone protein (Brunet et al, 2002; 
Muslin & Xing, 2000). For instance, FKHRL1 when phosphorylated by 
AKT binds to 14-3-3, and this confers a structural change which exposes 2 
NESs within FKHRL1. At the same time, this association also masks the 
nuclear localisation sequence (NLS) of FKHRL1 and prevents its 
relocalisation into the nucleus, thereby, maintaining FKHRL1 in an inactive 
form in the cytoplasm (Brunet et al, 2002). Other examples of proteins 
which are sequestered by 14-3-3 into cytoplasm in their inactive form 
include histone deacetylase 4 (HDAC4) and HDAC5 (Grozinger & 
Schreiber, 2000; Ellis et al, 2003), high-mobility-group nucleosomal- 
binding protein 1 (HMGN1) (Prymakowska-Bosak et al, 2002), 
transcription co-activator in Hippo pathways, TAZ (Kanai et al, 2000), 
transcription factor DAF16 (Cahill et al, 2001) and p27 (Fujita et al, 2002).
5 9
CHAPTER 1: INTRODUCTION
14-3-3 can also serve as an adaptor protein where it bridges 2 proteins that 
do not interact directly. A classic example of this is again provided by Raf-1 
where interaction with 14-3-3 bridges the interaction with Bcr (Braselmann 
& McCormick, 1995), protein kinase C-£ (PKC-Q (Van Der Hoeven et al, 
2000) and a zinc finger protein, A20 (Vincenz & Dixit, 1996) through 14-3- 
3 dimers. 14-3-3 interactions can also alter the susceptibility of the bound 
protein to further post-translational modifications, for example, binding of 
14-3-3 to Bad (Chiang et al, 2001) and tristetraprolin (TTP) (Sun et al, 
2007; Kraemer & Clement, 2014), a zinc finger RNA binding protein, 
protecting these proteins from dephosphorylation.
1.7 Regulation of 14-3-3 by phosphorylation
The role of 14-3-3 in regulating the function of its binding partners has been
discussed. However, 14-3-3 proteins themselves are also subject to
regulation, mainly by phosphorylation, which in turn can affect 14-3-3
dimerisation. From the structural analyses, it was predicted that under
physiological conditions where the majority of 14-3-3 exists as a dimer, it
might be difficult for a kinase to gain access to the phosphorylation sites.
This is because the 14-3-3 dimers are very stable under normal conditions
(Aitken, 2002; Shen et al, 2003). However, numerous studies have shown
that 14-3-3 can be phosphorylated at residues S58, S59, S64, S I85 and S233
by several different kinases. For example, S58 can be phosphorylated by
PKA, AKT or mitogen-activated protein kinase (MAPK)-activated protein
kinase 2 (MAPKAPK2). It was initially shown that under in vitro
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conditions, 45% of 14-3-3^ is phosphorylated by AKT at S58, a site 
embedded within the dimerisation interface and this phosphorylation does 
not affect 14-3-3 dimerisation (Powell et al, 2002). Later studies 
contradicted this with the observation that PKA phosphorylation of 14-3-3 
at S58 affects its dimerisation and affects its functional interaction with p53 
(Gu et al, 2006). Like PKA, phosphorylation of 14-3-3 at S58 by MAPK- 
activated protein kinase 2, MAPKAPK2, also inhibits the dimerisation of 
14-3-3 and its subsequent interaction with Raf-1 (Powell et al, 2003).
14-3-3 proteins are also subject to phosphorylation by Casein kinase I (CKI) 
at T233 in 14-3-3C and S233 in 14-3-3t. This residue is also implicated in 
14-3-3 target recognition. In the case of Raf-1 recognition, phosphorylation 
of 14-3-3 at this site inhibits the interaction, and thereby has important 
implications for the Raf-1 signal transduction pathway (Dubois et al, 1997b, 
1997a). Other kinases shown to regulate 14-3-3 include protein kinase C 
(PKC) and sphingosine-dependent protein kinase (SDK1) with different 
PKC isoforms phosphorylating different 14-3-3 isoforms. For instance, 
PKC-£ can phosphorylate 14-3-37? and r (Van Der Hoeven et al, 2000), 
whilst 14-3-3y can be phosphorylated by PKCa, p, y, 0 and 5 isoforms 
(Autieri & Carbone, 1999). SDK1 can phosphorylate 14-3-3rj, p and but 
not the o and x isoforms (Megidish et al, 1998). Taken together, these 
studies show that phospho-regulation of 14-3-3 is highly complex, and 
varies considerably between the different isoforms. However, in all cases, it 
has important implications for 14-3-3 regulation and function.
6 1
CHAPTER 1: INTRODUCTION
1.8 The 14-3-3 Heterodimer
14-3-3 can exist as either homo- or heterodimers. Although not all isoforms 
can heterodimerise with each other and there is a clear preference for 
specific 14-3-3 isoforms in each heterodimer (Jones et al, 1995a). The 
preferential combinations are listed in Table 3. It is important to note that, 
once formed, the heterodimers are stable and binding partners are not readily 
exchanged (Jones et al, 1995a).
Studies using overexpression of different 14-3-3 isoforms revealed distinct 
preferences for particular monomer combinations that are largely 
independent of the cellular conditions. It was found that 14-3-3y can exist as 
a homodimer but also formed heterodimers, mainly with 14-3-38 (Chaudhri 
et al, 2003). Other studies found that, besides dimerising with 8, 14-3-3y 
also weakly dimerised with the C, and p isoforms (Jones et al, 1995a). In 
addition, x can dimerise with the £ isoform, whilst a  isoform preferentially 
exists as a homodimer (Wilker et al, 2005; Chaudhri et al, 2003). As noted 
above, the ability of 14-3-3 to dimerise is a critical aspect of 14-3-3 
function, and this is revealed most strongly when it performs a bridging role, 
as for example with Raf-1 and Bcr. This bridging involves 3 14-3-3 
isoforms, p, x and 14-3-3 p and x associate with Bcr while the C, and P 
interact with Raf (Braselmann & McCormick, 1995) as illustrated in Figure 
7, and this brings Raf and Bcr into close proximity.
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Table 3: Summary of the 14-3-3 isoform interactions with other 14-3-3 
isoforms to form homo- or heterodimers. Symbols: V indicates that the 
monomers can dimerise, x indicates that the monomers does not bind to 
each other, whilst ? means that no information is available._______________
Isoforms y d a 7 £ n t / 0 p/a
y  8 V X V V 9 V V
o X V V V 9 9 9
7 V 9 V V V V V
£ V 9 V V/x V V V
n 9 9 V V V 9 9
t / 0 V 9 V V 9 V 9
p/a V 9 V V 9 V V
1.9 14-3-3 regulates the Ras-Raf-MAPK pathway
The activation of Raf-1 is regulated by 14-3-3 (Fu et al, 1994; Freed et al,
1994). Structurally, Raf-1 is divided into anN-terminal Ras binding domain 
(RBD), CRD and a C-terminal kinase domain. 14-3-3 can bind to the 
phospho-acceptor residues of Raf-1 at S233, S259 and S621 in the C- 
terminal kinase domain (Morrison et al, 1993; Muslin et al, 1996; Rommel 
et al, 1997; Molzan & Ottmann, 2012). The mutation S259A and S621A, 
which cannot be phosphorylated, abolish the interaction of Raf-1 with 14-3- 
3, indicating that this association occurs in a phosphorylation-dependent 
manner (Michaud et al, 1995). When both S259 and S621 of Raf-1 are 
phosphorylated, 14-3-3 will bind to the N-terminus of Raf-1 and this 
introduces a conformational change in Raf-1 (Dumaz & Marais, 2003). 
Association of 14-3-3 with Raf-1 can have 2 possible consequences: binding 
of 14-3-3 to Raf-1 at S233 and S259 inhibits Raf-1 activity by retaining Raf- 
1 in the cytoplasm; in contrast, binding of 14-3-3 to S621 increases Raf-1
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kinase activity. When the cells are unstimulated, Raf-1 is phosphorylated at 
S233 and S259, creating a 14-3-3 binding motif (Rommel et al, 1997; 
Dubois et al, 1997b; Dumaz & Marais, 2003). 14-3-3 keeps Raf-1 in the 
cytosol in an inactive form, away from Ras and preventing recruitment of 
Raf-1 to the plasma membrane (Rommel et al, 1997; Dumaz & Marais, 
2003). Therefore, 14-3-3 plays a critical role in suppressing Raf-1 
activation. However, upon stimulation, Ras associates with Raf-1, 
displacing 14-3-3 from interaction with Raf-1 (Li et al, 1995; Michaud et al, 
1995; Rommel et al, 1996, 1997; Light et al, 2002). Studies suggested that 
this displacement might indicate that 14-3-3 is not required for Raf-1 kinase 
activity (Li et al, 1995; Michaud et al, 1995; McPherson et al, 1999; Roy et 
al, 1998; Light et al, 2002). However, other studies disagreed with this 
notion. It was shown that when the cells is stimulated, 14-3-3 can bind to 
Raf-1 at S621, which is located in the C-terminal kinase domain of Raf-1, 
and this association appears to be required for activation of Raf-1 (Dent et 
al, 1995; Dhillon et al, 2009; Tzivion et al, 1998; Fischer et al, 2009). 14-3- 
3 association at S621 confers a conformational change of Raf-1 and prevents 
it from dephosphorylation (Dent et al, 1995; Thorson et al, 1998) and the 
activated Raf-1, either by Ras or 14-3-3 association at S621, is recruited to 
the plasma membrane (Marais et al, 1995; Stokoe et al, 1994). This 
activation also requires the oncogenic B-Raf, one of the Raf family 
members, to form heterodimers with Raf-1 mediated by 14-3-3 (Wan et al, 
2004; Garnett et al, 2005; Rushworth et al, 2006; Ritt et al, 2010). Different 
14-3-3 isoforms may play different roles in Raf-1 activity. The expression of 
14-3-3y results in increased Raf-1 activity (Radhakrishnan & Martinez,
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2010) and subsequently leads to phosphorylation of kinases involved in the 
MAPK signalling pathway (Aitken, 2002; Downward, 2003; Galabova- 
Kovacs et al, 2006; Seger & Krebs, 1995). In contrast, 14-3-3a inhibits 
these activities (Radhakrishnan & Martinez, 2010). The kinase that 
phosphorylates the kinase domain of Raf-1 is PKC and this creates a 14-3-3 
association with Raf-1 (Kolch et al, 1993), and this subsequently leads to 
activation of survival MAPK signalling cascade, as well as PI3K (Takihara 
et al, 2000; Radhakrishnan & Martinez, 2010). In this way, PKC plays a 
positive role in activating a member of the MAPK pathway, like MEK 
(Blumer et al, 1994). All these studies indicate that 14-3-3 plays a critical 
role in mediating the Raf-1 signalling pathway in cell growth, regardless of 
whether it is active or inactive and this is summarised in Figure 8.
1.10 14-3-3 in DNA damage-induced cell cycle checkpoints
During interphase, 14-3-3 exists predominantly in the cytoplasm, and it 
enters the nucleus during the mitosis, particularly in the perichromosomal 
region (Su et al, 2001), thus suggesting a role in cell cycle regulation. This 
regulation occurs through the association of 14-3-3 with components of the 
cell cycle checkpoint control pathways, including Cdc25 (Cdc25A, B and 
C), p53, cyclin-dependent kinase (Cdk) inhibitor p27 and tuberous sclerosis 
complex (TSC) proteins (Hermeking & Benzinger, 2006). In general, when 
the cell does not have the cell cycle checkpoint activation, these proteins are 
kept in an inactive form in the cytoplasm by 14-3-3. In the case of Cdc25, it
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Figure 8: The role of 14-3-3 in Ras-Raf-MAPK signalling pathway. 14-
3-3 dimer (in blue and green) associates with Raf-1 in a phosphorylation- 
dependent manner and regulates Raf-1 function in different cellular 
compartments. In cytosol, 14-3-3 associates with the N-terminal Ras binding 
domain (RBD) of phosphorylated Raf-1 and keeps it in an inactive form. 
Upon receiving cell growth stimuli by epidermal growth factor (EGF), Raf-1 
is recruited to the plasma membrane and associates with GTP-Ras. 
Phosphorylation of the C-terminal kinase domain of Raf-1 by PKC confers 
association with 14-3-3 and thereby enhances its kinase activity to activate 
its downstream MEK and ERK pathways. This in turn activates the 
downstream transcriptional activities which are crucial for cell division.
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is phosphorylated at S216, S263 and S247 (Peng et al, 1997; Esmenjaud- 
Mailhat et al, 2007; Chan et al, 2011) and this confers binding to 14-3-3. As 
a result, Cdc25 is sequestered by 14-3-3 in the cytoplasm and remains 
inactive. When the cells enter mitosis, Cdc25 is dephosphorylated by protein 
phosphatase 2A (PP2A) (Margolis et al, 2006; Forester et al, 2007), and 
Cdc25 becomes active; it can then enter the nucleus to dephosphorylate and 
activate Cdkl/Cyclin B complex, which is the key regulator of the onset of 
mitosis (Lammer et al, 1998; Hoffmann et al, 1993; Gautier et al, 1991). 
Activation of Cdkl then triggers cell cycle to progress to mitosis (Russell, 
1998).
When cells encounter cell cycle checkpoint activation as a result of DNA 
damage, Cdc25 is phosphorylated by TAK or Chkl at S216 (Peng et al, 
1998; Liu et al, 2000; Chaturvedi et al, 1999; Sanchez et al, 1997; Peng et 
al, 1997) to generate a 14-3-3 binding motif. As a result, Cdc25 is 
sequestered in the cytoplasm by 14-3-3, and therefore remains inactive, as it 
is not able to dephosphorylate the Cdkl/Cyclin B complex, and the cell 
cycle progression into mitosis is halted (Hermeking & Benzinger, 2006). 
The involvement of 14-3-3 in regulating cell cycle progression in interphase, 
DNA damage-initiated G2 arrest, and mitotic entry is shown in Figure 9.
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Figure 9. The role of 14-3-3 in regulating Cdc25 and Cdks during cell 
cycle. During interphase or DNA damage induction, Cdc25, Cdks (Cdk2 in 
Gl/S and Cdkl in G2/M phases) and p53 are subject to phosphorylation by 
several kinases including Chkl or Chk2 and this creates a 14-3-3 binding 
motif. 14-3-3 (light blue and green) association leads to recruitment of 
Cdc25 and Cdks into the cytosol, thereby maintaining them in an inactive 
state. Association of p53 with 14-3-3 enhances p53 DNA binding ability and 
thereby enhances p21 transcriptional activation. p21, can in turn, block 
activation of Cdks. This is important to allow cells to undergo DNA repair 
before entering mitosis. When mitosis is initiated, dephosphorylation of 
Cdc25 and dissociation from 14-3-3 allows Cdc25 to dephosphorylate Cdks 
in the nucleus and hence allows cells to enter mitosis.
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1.10.1 14-3-3 during the Gl/S phase of the cell cycle upon DNA damage
When the cells receive DNA damage stimuli, the ATM/ATR pathway is 
activated. ATM and ATR are kinases belonging to the PI3K family and their 
activation is required for G2 arrest (Cliby et al, 1998; Rudolph & Latt, 
1989). ATM/ATR activates downstream Chkl/Chk2 kinase, and mitogen- 
activated kinase p38 activation (Nyberg et al, 2002; Bao et al, 2001; Bulavin 
et al, 2001; Forrest & Gabrielli, 2001; Giles et al, 2003). In Gl/S phase, 
Chkl is phosphorylated at S296 and is located diffusely in the nucleoplasm, 
and it interacts with 14-3-3y (Kasahara et al, 2010). Association between 
Chkl and Cdc25A is bridged by 14-3-3y (Kasahara et al, 2010) and this 
association results in phosphorylation of Cdc25A by Chkl at S76 (Sanchez 
et al, 1997; Jin et al, 2003). Phosphorylation of Cdc25A also confers 
association with 14-3-3, which subsequently sequester Cdc25A in the 
cytoplasm (Chen et al, 2003), leading to the degradation of Cdc25A (Jin et 
al, 2003; Kang et al, 2008) in a proteasome-dependent manner (Kasahara et 
al, 2010). As a consequence, Cdc25A cannot associate with Cdk2 (Peng et 
al, 1997). On the other hand, 14-3-3a also has a role in this phase of the 
checkpoint, where it associates directly with the Cdk2 and Cdk4, and 
thereby prevents cell cycle entry by inhibiting cyclin-Cdk activity (Laronga 
et al, 2000). All of these studies showed that different 14-3-3 isoforms may 
play distinct roles in regulating cell cycle through targeting different 
components of the cell cycle.
14-3-3 has also been reported to have a role in regulating cell cycle through 
p27. p27 associates with importin-a, which is a protein involved in
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transporting proteins across the nuclear envelope into the nucleus (Goldfarb 
et al, 2004). Since Cdks are nuclear proteins, localisation of p27 in the 
nucleus is crucial for it to inhibit Cdks (Slingerland & Pagano, 2000; Cheng 
et al, 1999) and induce G1 arrest. Like other proteins, 14-3-3 associates with 
p27 depending on its phospho-status at T157, T179, T197 and T198. AKT 
can phosphorylate p27 at T157 and T198, with phosphorylation at T157 
conferring interaction with 14-3-3 p, e, y, £ and 0, whilst phosphorylation of 
p27 at T198 confers interaction with 14-3-3 s, r| and x, but not P and £ (Shin 
et al. 2002; Kossatz et al. 2006; Viglietto et al. 2002; Fujita et al. 2002; 
Sekimoto et al. 2004; Short et al. 2010). This association between 14-3-3 
and p27 perturbs p27 interaction with importin-a, since the importin-a 
interaction site overlaps with 14-3-3 site at T157 (Sekimoto et al, 2004). In 
this way, 14-3-3 keeps p27 away from importin-a and it remains in the 
cytosol (Sekimoto et al, 2004).
1.10.2 14-3-3 in G2/M of cell cycle upon DNA damage stimuli 
At the G2/M transition in the cell cycle, 14-3-3 proteins are also involved to 
ensure that the cell undergoes proper checkpoint regulation before entering 
mitosis. At this phase of the cell cycle, Cdc25B and Cdc25C, which act 
upstream of the Cdkl/Cyclin B complex (Boutros et al, 2007; Hoffmann et 
al, 1993; Baldin et al, 1997; Lammer et al, 1998), as well as p53, are 
regulated by 14-3-3. Following DNA damage response, Chkl/Chk2 is 
activated, leading to phosphorylation of Cdc25B (Forrest & Gabrielli, 2001; 
Giles et al, 2003; Uchida et al, 2004a; Astuti et al, 2010) and Cdc25C (Peng
7 0
CHAPTER 1: INTRODUCTION
et al, 1997; Esmenjaud-Mailhat et al, 2007; Chan et al, 2011), which then 
confers interaction with 14-3-3, sequestrating Cdc25 into the cytosol, 
leaving Cdkl/Cyclin B complex in an inactive state (Uchida et al, 2004b; 
Dalai et al, 2004; Esmenjaud-Mailhat et al, 2007).
p53 can be phosphorylated at multiple sites following DNA damage. 
Phosphorylation of p53 by ATM/ATR kinases at its N-terminus confers 
interaction with 14-3-3a or x (Saito et al, 2002; Seong & Ha, 2012), which 
protects it from Mdm2-mediated degradation and nuclear export, thereby 
increasing p53 stability and transcriptional activity (Craig et al, 1999; Teufel 
et al, 2009; Yang et al, 2003; Rajagopalan et al, 2010). Chkl/Chk2 also can 
phosphorylate p53 (Ou et al, 2005) at S315, S366, S376, S378, and T387, 
which are located within the region containing putative NES signals at its C- 
terminus (Shaulsky et al, 1990). Interestingly, phosphorylation of p53 
around this region has an impact on p53 activity, particularly its DNA 
binding ability (Hupp et al, 1992; Halazonetis et al, 1993; Waterman et al, 
1995). Phosphorylation on S315 stimulates p53 transactivation and tumour 
suppressive function (Slee et al, 2010; Blaydes et al, 2001), but whether 
phosphorylation of this residue confers interaction with 14-3-3 is yet to be 
known. When both S376 and S378 are phosphorylated under non-irradiated 
condition, p53 does not associate with 14-3-3 (Waterman et al, 1998). 
However, following exposure to DNA damage, S376 of p53 is 
dephosphorylated, while S378 and T387 are phosphorylated by Chkl/2, and 
this creates a consensus binding site for 14-3-3y, £, 0 and a  proteins and 
allows association with p53. This in turn increases the affinity of p53
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binding to DNA and subsequent activation of p53 responsive promoters 
(Agarwal et al, 1995; Waterman et al, 1998). Following this p53 activation, 
the expression of its downstream target p21 is increased (Agarwal et al,
1995), leading to inhibition of nuclear Cdk kinase activity and thus causing 
a cell cycle arrest (Harper et al, 1995; Hermeking et al, 1997; Rahman et al, 
2014; James et al, 2014).
1.11 14-3-3 and cancer
Considering the number of critical cellular control pathways that can be 
regulated by different 14-3-3 isoforms, it is not surprising that perturbation 
in their levels of expression have been implicated in the development of 
many human cancers. Among the different 14-3-3 isoforms, 14-3-3c which 
is also known as human epithelial marker-1 (HEM-1) or stratifin has been 
implicated directly in cancer development. As described before, it is closely 
linked to the regulation of p53 tumour suppressive function and stability, 
and 14-3-3 a  levels are downregulated by promoter methylation in multiple 
malignancies (Iwata et al, 2000; Suzuki et al, 2000; Moreira et al, 2004; 
Yatabe et al, 2002; Logsdon et al, 2003; Ferguson et al, 2000), although not 
in cervical cancers (Holm et al, 2009; Sano et al, 2004). Whilst 14-3-3o 
seems to exert a tumour suppressive role, the other 14-3-3 isoforms have 
potentially pro-oncogenic activities. For example, many isoforms can 
interact in a phosphorylation-dependent manner with ETS variant 1 (ETV1). 
This is a DNA-binding transcription factor which regulates matrix- 
metalloproteinase-1 and -7 (MMP1 and MMP7) expression. Interaction with
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14-3-3 increases ETV1 transcription activation of these MMPs, and thereby 
contributes to cancer invasion (Oh et al, 2013). Likewise, downregulation of 
14-3-3^ and 14-3-3a using small interfering RNA and overexpression 
showed that 14-3-3a  is required for TGF-pi-mediated growth inhibition 
whereas 14-3-3^ negatively modulates such growth inhibitory responses 
(Hong et al, 2010). In addition, 14-3-3^ maps to human chromosome 8q23 
which happens to be a region frequently amplified in metastatic cancers 
(Ghadimi et al, 2003; Tada et al, 2000). Indeed, the levels of 14-3-3£ are 
increased in different tumours including pancreatic (Shen et al, 2004), 
stomach (Jang et al, 2004), oral squamous cell carcinoma (Arora et al, 2005; 
Matta et al, 2007), lung (Fan et al, 2007) and breast cancers (Green & 
Streuli, 2004). Upregulation of 14-3-3^ has been implicated in epithelial-to- 
mesenchymal transition (Keshamouni et al, 2006; Huang et al, 2013), 
indicating its significant role in tumourigenesis and metastasis. Recent 
proteomic studies suggested that 14-3-3£ could play a role in linking and 
manipulating multiple cellular events in cervical cancers (Higareda-Almaraz 
et al, 2013). Overexpression of £ contributes to anchorage independent 
growth, whilst downregulation of £ reduces tumour growth (Neal et al, 
2009). In mammary epithelial cells, overexpression of £ increases AKT 
activity, which in turn, phosphorylates Mdm2 and translocates Mdm2 into 
the nucleus, leading to p53 degradation (Danes et al, 2008). 14-3-3£ also 
forms a complex with pl-integrin, which subsequently mediates integrin- 
induced Rac-1 activation, thus initiating motility-inducing pathways and 
increased cell migration (O’Toole et al, 2011). Moreover, a recent study 
shows that in non-small cell lung cancer, 14-3-3£ forms a complex with heat
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shock protein 27 (Hsp27), and the overexpression of this complex 
contributes to cell invasion and metastasis, which is also correlated with 
poor prognosis (Zhao et al, 2014).
Other 14-3-3 isoforms may also play important roles in carcinogenesis. 
Recent studies suggested that besides 14-3-3 s and p isoforms are also 
contributing to proliferation, survival, migration, metastasis of cancer cells 
(Bai et al, 2014; Okayama et al, 2014) and also contribute to chemotherapy 
resistancy (Hodgkinson et al, 2012b, 2012a). Due to the increasing data 
indicating roles for 14-3-3 in carcinogenesis, they have been suggested as 
cancer biomarkers (Neal & Yu, 2010; Hodgkinson et al, 2012b; Padden et 
al, 2014). As mentioned earlier, although 14-3-3 predominantly localises in 
the cytoplasm, it is also expressed in the nucleus, and this cytoplasmic- 
nuclear localisation may be used as a biomarker for prognosis of cancer. For 
example, the nuclear pool of e may serve as a tumour suppressor, as 
decreased nuclear expression of s correlates with poor prognosis of 
colorectal cancer patients (Wang et al, 2012), whilst upregulation of 14-3-3s 
in the cytoplasm leads to downregulation of E-cadherin and subsequently 
contributes to epithelial-mesenchymal transition (Liu et al, 2013).
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All of the above indicates that the different 14-3-3 isoforms have different 
potentials to contribute towards human cancer progression in different 
anatomical settings. To date, there is limited information on the role of E6 
post-translational modification in regulating E6 interactions with proteins 
other than PDZ domain-containing substrates, and there is no information on 
whether phospho-E6 might associate with other classes of cellular proteins. 
Considering the above discussion, 14-3-3 proteins are prime candidates. 
Since 14-3-3 regulates many cellular processes, and can be considered to be 
a group of "hub" proteins, E6 interaction with them might offer the virus a 
way to manipulate multiple cellular regulating pathways, these include 
affecting cell cycle regulation, DNA damage response, p53 transcriptional 
transactivation, apoptosis and carcinogenesis. Therefore the aim of this 
study is to investigate the propensities of different HR HPV E6 oncoproteins 
to be regulated by different kinases and to understand the functional relevant 
of such post-translational modification for E6 function.
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2.1 Cell culture and transfection
HeLa, HEK293, HaCaT and H I299 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum, penicillin-streptomycin (100 U/ml), and glutamine (300 pg/ml). 
Cells were cultured in an incubator at 37°C with 5% CO2 .
HeLa cells were transfected with siRNA against the designated genes using 
Lipofectamine RNAiMax transfection reagent (Invitrogen). HEK293 cells 
were transfected using calcium phosphate precipitation (Wigler et al, 1979), 
whilst transient transfection of HaCaT and HI 299 cells was performed using 
polyethylenimine (PEI) (Boussif et al, 1995).
2.2 Plasmids.
In order to generate glutathione ^-transferase (GST) fusion proteins, HPV- 
11, HPV-16, HPV-18 E6 and HPV-31 E6 proteins, hDlg and Scribble were 
cloned and expressed in pGEX2T as described previously (Thomas et al, 
1996a; Gardiol et al, 1999; Pirn et al, 2000; Nagasaka et al, 2010). The GST 
HPV-31 and -58 E6 fusion proteins were generated by subcloning PCR 
amplified pcDNA:HPV-31E6 and -58E6, respectively, into compatible 
BamR I and EcoR I restriction sites of pGEX2T. The pGEX2T:HPV-18 E6 
mutants R153A, T156E, T156D, S82A and S82A/T156E, as well as - 
31E6delPDZ and 31E6 T145AdelPDZ fusion proteins were produced using
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the Gene Tailor Mutagenesis kit (Invitrogen). The pcDNA:HA- HPV-18E6 
R153A was generated by subcloning pGEX2T:HPV-18E6 R153A into 
compatible BamR I and EcoR I restriction site of pcDNA. The GST HPV- 
33E6 was done by direct subcloning from pcDNA:HPV-33E6 into 
compatible BarriH. I and EcoR I restriction sites of pGEX2T. The GST-HPV 
51 E6 was generated by mutational alteration of the HPV-18E6 PBM to 
match the PBM of HPV-51, and the PCR amplified product was then 
subcloned into compatible BamR I and EcoR I restriction sites of pGEX2T. 
Primer sequences used are:
Type of E6 Primer sequences
18 R153A (F): (F) 5’- AACGACTCCAACGAGCGAGAGAA 
ACAC AAGTA-3 ’,
(R )5’-TCGTTGGAGTAGTTCCTGTCGTGC-3\
T156D (F): 5’-CTCCAACGACGCAGAGAAGACCAA 
GTATAAG-3’
(R): 5’-TTCTCTGCGTCGTTGGAGTCGTTCC-3’
T156E (F): 5 ’ -C A ACG ACGC AG AG AAG A AC A AGT AT 
AAGAATTC-3’
(R): 5’-TTCTCTGCGTCGTTGGAGTCGTTCC-3’
S82A (F): 5' - AGAG A ATT A AG AC ATT AT GC AG ACT 
CTGTGTA - 3'
(R): 5' - ATAATGTCTTAATTTCTAATTCTA 
GAA-3'
33 (F): 5'- AGGG ATCC AT GTTT C AAG AC ACT G 
AGG - 3'
(R): 5' - CCG A ATT CT C A AC AGT GC AGTTT CT 
CTAC - 3'
18:51 (F): 5' - TTTGGATCCATGGCGCGCTTTGAGG 
ATCCA - 3'
(R): 5' - GAATTCTACTTGCGTTTCATTGCG - 3'
58 (F): 5' - AT GGATCC AT GTT CC AGG ACGC A 
GAG - 3'
(R): 5' - CGGAATTCTTACACTTGTGTTTGT 
CTGC - 3'
31 delPDZ (F): 5' - CCGGATCATGTTCATCAAAAATC - 3'
(R): 5' - CCGA ATT CTT A AGT ACGAGGT - 3'
T145AdelPDZ (F): 5' - CCGGATCATGTTCATCAAAAATC - 3'
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(R): 5' - CCG A ATT CTT AT GC ACG AGT C - 3'
S82A (F): 5' - CG AT GGT AT AG AT AT GC AGT GT AT G 
GAACAAC - 3'
(R): 5' - GTTGTTCCATACACTGCATATCTATA 
CCATCG - 3'
Resulting plasmids were all verified by DNA sequencing (Eurofins MWG 
Operons). These HPV-18 and -31 E6 mutants are all depicted schematically 
in Figure 11. The pCA:HA-HPV-18E6 R153A was obtained by subcloning 
the HPV-18 E6 R153A excised from pGEX2T:HPV-18E6 R153A using 
BamH I and Xba I, the DNA was then ligated into the pCA vector digested 
with the compatible restriction enzymes (Tomaic et al, 2009a). All the 
expression constructs were transformed into E. coli strain DH5-a.
The pGWT.HA-tagged hDlg and pGWT.HA-tagged MAGI-1 expression 
plasmids have been described previously (Gardiol et al, 1999; Glaunsinger 
et al, 2000). The pSCM:Flag-14-3-3£ and a  expression plasmids were 
kindly provided by Prof. Haian Fu; pGWI:HA- HPV-18 and -16E6 were 
kindly provided by Ron Javier; the Flag-p53 expression plasmid was kindly 
provided by Georgine Faulkner.
2.3 GST fusion protein production and purification.
GST and GST-tagged fusion proteins (GST-18 E6, -16 E6, -11 E6, -31 E6, - 
18E6 R153A, -18 E6 T156E, -18 E6 T156D, -18 E6 S82A and -18 E6 
S82A/T156E) were expressed and purified as described previously (Thomas 
et al, 1996b). In brief, the clones harbouring the appropriate expression 
plasmids, transformed into E. coli strain DH5-a were grown in 40ml of
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Luria Broth (LB) culture media containing 75mg/ml Ampicillin overnight at 
37°C. The bacterial cultures were then transferred into 400ml of LB culture 
media containing 75mg/ml Ampicillin and incubated at 37°C for 1 hour (hr). 
Recombinant protein expression was then induced by addition of isopropyl- 
P-D-thiogalactopyranoside (IPTG, Sigma) to a final concentration of 1 nM 
and incubated for a further 3 hrs. For low producing clones, such as 
pGEX:HPV-31 E6 and its mutants, pGEX:HPV-33E6 and pGEX:HPV- 
18:51E6, the induction was carried out at room temperature (RT) overnight. 
After centrifugation at 4225x g for 5 minutes, the bacterial pellets were 
lysed with 10ml of IX PBS containing 1% Triton X-100, and sonicated 
twice for 30 seconds (sec). The lysates were then centrifuged again at 7648x 
g for 10 minutes. The supernatants were collected and incubated with 
glutathione-conjugated agarose resin on a rotating wheel overnight at 4°C. 
The resins were centrifuged briefly at 1075x g for 3 minutes and the 
supernatant was discarded. The resins were then washed thrice with IX PBS 
containing 0.3% Triton X-100. The resins were then mixed with glycerol to 
10% v/v and kept at -20°C for long term storage.
2.4 In  vitro  phosphorylation.
For each phosphorylation 2 to 5 jig of GST fusion proteins were washed with 
IX phosphate-buffered saline (PBS) containing 0.1% Triton X-100, 
followed by washing twice with the respective kinase buffers. The buffers 
used are as follows:
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Kinase Content of kinase buffer
PKA 25 mM Tris HC1, pH 7.5, lOmM MgCl2  and 70mM 
NaCl
p21 -Activated 
kinase (PAK)
50mM Hepes, pH 7.4, 12.5mM NaCl, 1.5mM MgCl2, 
0.5% Tween 20, 1.5mM MnCl2
AKT 25 mM Tris HC1, pH 7.5, lOmM MgCl2 and 5mM DTT
CamK II Kinase was diluted in IX NEBuffer (New England 
BioLabs) for Protein Kinases (PK) supplemented with 
200pM ATP, 1.2pM calmodulin and 2mM CaCl2.
In vitro phosphorylation of the fusion proteins was carried out using 20pl 
kinase buffer containing 2.5 pCi 32y-ATP and 25 Units (U) of cAMP- 
Dependent Protein Kinase, Catalytic Subunit (Promega), or 250U activated 
CamK II (NEB), or 0.2jig of AKT1 and 4pi of Reaction Buffer A from 
AKT1 Kinase enzyme system (Promega) 30°C for 45 minutes. When 
assessing susceptibility to a specific kinase, the whole reaction mix was 
analysed directly by SDS-PAGE and autoradiography.
2.5 In  vitro  phosphorylation and binding assays.
Purified GST fusion proteins (pre- and post-phosphorylation with cold ATP) 
were incubated with in vitro translated and radiolabelled 14-3-3^, hDlg and 
MAGI-1 for 1 hr at room temperature. Proteins were translated in vitro 
using a Promega TNT kit and radiolabeled with [ S]cysteine or 
[35S]methionine (Perkin Elmer). Equal amounts of in vitro translated 
proteins were added to GST fusion proteins bound to glutathione agarose 
(Sigma) and incubated for 1 hr at RT on a rotating wheel. After washing
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thrice with IX PBS containing 0.1% Triton X-100, the bound proteins were 
subjected to SDS-PAGE and analysed by autoradiography.
For direct binding assays, I used purified recombinant His-tagged 14-3-3 
isoforms: 14-3-3^, rj, y (from Abeam), £, p (from Enzolife), a  and x (from 
Geneway). The purified GST fusion proteins (pre- and post-phosphorylation 
with cold ATP) were incubated with lOng each of the purified recombinant 
14-3-3 isoforms at 4°C for 1 hr. Complexed proteins were then washed 
thrice with PBS 0.1% Triton X-100. Bound proteins were subjected to SDS- 
PAGE and western blotting for detection of His-tagged 14-3-3.
2.6 In  vivo  phosphorylation and co-immunoprecipitation.
HEK293 cells (7 x 1 0  cells) were seeded onto 10cm dishes and transfected 
with lOpg of HA-tagged HPV-16 E6, -18 E6, -18 E6 T156E, -18 E6 R153A 
and -18 E6 APBM respectively, using calcium phosphate precipitation. Five 
hours post-transfection, cells were treated with IOjiM Forskolin (Fsk) 
(Calbiochem) for 24 hrs, or with lOOnM H89 and lOpM MK2206 for 2 hrs 
in serum-free media. Cells were collected and lysed using high salt E l A 
buffer (500mM NaCl, 0.1% NP40 and 50mM Hepes pH 7.0) in the presence 
of protease inhibitors and phosphatase inhibitors followed by gentle 
syringing and incubation on ice for 20 minutes. Cell lysate was then 
centrifuged at 16,100x g for 10 minutes. The extracted lysates were either 
pretreated with 2000U of X phosphatase (NEB) at 30°C for 15 minutes or 
incubated directly with 30pl of monoclonal anti-HA conjugated agarose
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beads (Sigma) at 4°C for 3 hrs. Samples were washed thrice with high salt 
El A buffer and then subjected to western blot analysis.
To determine the interacting partners of HPV-18 and -16 E6 at different 
phases of the cell cycle, HA-tagged 18 and -16 E6 were transfected into 293 
cells using calcium phosphate precipitation. After 24 hrs, the cells were 
synchronised using Aphidicolin or Nocodazole as described. Prior to 
extraction, cells were treated with 50pM of the proteasome inhibitor CBZ 
(Sigma) for 3 hrs. The cells were then extracted using high salt El A buffer 
and co-IP was performed as described above.
2.7 Downregulation of endogenous 14-3-3 ,^ HPV-18 E6/E7 and cell 
fractionation analysis.
Approximately 1.2 x 105 HeLa cells were seeded onto 60 mm2 dishes. To 
study the effect of 14-3-3 on HPV-18 E6 stability, HeLa cells were 
transiently transfected with siRNA against 14-3-3^ (Human YWHAZ ON- 
TARGET plus SMARTpool, Dharmacon) using Lipofectamine RNAiMax 
transfection reagent (Invitrogen). HPV 18 E6 and E7 were ablated by 
transfecting siRNA against HPV 18 E6/E7 (Dharmacon) using RNAi Max 
(Invitrogen). In all cases, siRNA against luciferase was used as a negative 
control.
For cell fractionation, approximately 2.4 x 105 of HaCaT cells were seeded 
onto 60 mm dishes and were transiently transfected with plasmids
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expressing HA-18 E6 and HA-18E6 APBM using PEL Cells were collected 
by trypsinisation 72 hrs post transfection. Samples were then subjected to 
cell fractionation analysis, where samples were divided into cytoplasmic and 
nuclear fractions using the NE-PER fractionation kit (Pierce) as described in 
the manufacturer's protocol. Protein extracts were quantified by Bradford 
Assay and analysed by western blotting.
2.8 Half-life experiments.
At 24 hrs post-transfection, cells were treated with cycloheximide (50pg/ml 
in dimethyl sulfoxide [DMSO]) to block protein synthesis at different time 
points. DMSO alone-treated cells were used as the control. Cells were then 
lysed with high salt El A buffer and samples were analysed by western 
blotting for E6, and the intensity of the bands on the X-ray film was 
quantified using the ImageJ program. The standard deviation was calculated 
from at least three independent assays.
2.9 Mass spectrometry analysis
The GST-31 E6 fusion protein was phosphorylated in vitro by PKA as 
described above. The protein was then washed twice with IX PBS 
containing 0.1% Triton X-100, and followed by washing using PKA buffer. 
The sample was then subjected to mass spectrometry by Dr. Michael Myers 
as follows:
83
CHAPTER 2: MATERIALS AN D  M ETHODS
For sample preparation, the proteins were eluted from the beads using 50ng 
of sequencing grade trypsin (Promega) in 20mM diammonium phosphate 
pH 8.0 for 6 hrs at 37°C. The supernatant was then removed from the beads. 
The cysteine residues were reduced and alkylated by boiling for 2 minutes in 
the presence of lOmM Tris (2-carboxyethyl) phosphine (Pierce, Milan, 
Italy) followed by incubating with 20mM acetaminophen (Sigma) for 1 hr at 
37°C. The reactions were stopped by adding 0.1% of acetic acid. The 
mixture was desalted using C l8 Ziptips (Millipore, Milan, Italy) and 
lyophilised.
The desalted samples were then injected onto the nanobore column in buffer 
A (10% methanol/0.1% formic acid). The column were constructed using 
Picofrit columns (NewObjective, Woburn, MA, USA) packed with 15 cm of
1.8 mm Zorbax XDB C l8 particles using a homemade high-pressure 
column loader and the column was developed with a discontinuous gradient 
and sprayed directly into the orifice of an LTQ ion trap mass spectrometer 
(Thermo Electron, San Jose, CA, USA). A cycle of one full scan (400 - 1700 
m/z) followed by eight data-dependent MS/MS scans at 25% normalized 
collision energy was performed throughout the LC separation. RAW files 
from the LTQ were converted to mzXML files by READW (version 1.6) 
and searched against the Ensembl human protein database and the NCBInr 
Viral database using the Global Proteasome Machine interfaced to the X- 
Tandem algorithm (version 2006.06.01.2)
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2.10 In  vivo degradation assays
For in vivo degradation assay, HEK293 cells were transiently transfected 
with plasmids expressing Flag-tagged 14-3-3^ in the presence or absence of 
HA-tagged HPV-18 E6, at a ratio of 3:1. As transfection efficiency controls, 
the cells were also co-transfected with LacZ vector control. As a positive 
control, the cells were also transfected with plasmid expressing HA-tagged 
hDlg, in the presence or absence of HA-tagged HPV-18 E6 plasmids. After 
24 hrs, the cells were treated with H89 or Fsk as described before. The 
samples were analysed by SDS-PAGE and the levels of proteins were 
ascertained by western blotting.
2.11 Cell synchronisation and FACS analysis
HEK293 cells were transiently transfected with plasmids expressing HA- 
tagged HPV-18 or -16 E6 as described above. After 24 hrs, the cells were 
treated with 5pg/ml of Aphidicolin (Sigma) for another 24 hrs to 
synchronise cells in Gl/S phase. Synchronised Gl/S phase cells were also 
released from Aphidicolin treatment for 5 hrs to obtain a population of cells 
in S phase. To synchronise cells in the G2/M phase of the cell cycle, cells 
were treated with 125pg/ml of Nocodazole for 18 hrs. The cells were 
extracted using high salt El A buffer and HA-tagged E6 proteins were 
immunoprecipitated as described above.
r
HeLa cells (3.5 x 10 cells) were seeded on 60mm dishes. After 24 hrs, 
cells were treated with 5pg/ml of Aphidicolin (Sigma) for another 24 hrs to
CHAPTER 2: M ATERIALS A N D  METHODS
synchronise cells in Gl/S phase. Synchronised Gl/S phase cells were also 
released from Aphidicolin treatment for 5 hrs to obtain a population of cells 
in S phase. To synchronise cells in the G2/M phase of the cell cycle, cells 
were treated with 125pg/ml of Nocodazole for 18 hrs.
Alternatively, the cells were treated with 2.5mM thymidine for 16 hrs. The 
cells were washed twice with IX PBS and replenished with fresh culture 
media. After 9 hrs, thymidine was added to further synchronise the cells for 
additional 16 hrs. The cells were then collected at 0 hrs (Gl/S), 5 hrs (S 
phase) and 9 hrs (G2/M). Cells in the different cell cycle phases were 
extracted and analysed for E6 expression, with the cell cycle phases verified 
using propidium iodide staining and FACS analysis using a FACScalibur 
Cell Sorter (Becton Dickinson).
2.12 Co-immimoprecipitation of p53 and luciferase reporter assays
H I299 cells ( 7 x 1 0  cells) were seeded onto 10cm dishes and transfected 
with lOpg of plasmids expressing HA-tagged HPV-18 and -18 E6 APBM, 
respectively, using calcium phosphate precipitation, and 5 hrs post­
transfection the cells were either left untreated or treated with Nocodazole as 
described above for 18 hrs. Three hours prior to harvesting, cells were 
treated with CBZ as described above. Cells were collected and lysed with 
high salt E1A buffer. The samples were subjected to co- 
immunoprecipitation, as described above, using anti-Flag conjugated 
agarose beads (Sigma). HeLa cells (7 x 105 cells) were also seeded onto
8 6
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10cm2 dishes and cells were either transiently transfected with siRNA 
against HPV-18 E6/E7, or were treated with CBZ, or Nocodazole as before, 
or left untreated. The cells were collected and extracted using high salt E l A 
buffer. The cell lysate was then incubated with monoclonal anti-p53 (DO-1) 
antibody at 4°C overnight at a dilution of 1:200. The lysate was then further 
incubated with Sepharose A beads to immunoprecitate endogenous p53 and 
the bound proteins. The samples were then subjected to SDS-PAGE and 
western blotting.
To analyse p5 3-mediated p21 promoter transcription activity, luciferase 
reporter assays were performed by transiently transfecting p21-Luciferase 
reporter plasmid with pCMV-Renilla plasmid alone as negative control, and 
with plasmid expressing Flag-tagged p53 as positive control, or co­
transfected with plasmids expressing HA-tagged HPV-18E6, and its mutants 
APBM and R153A into H I299 cells using PEI. After 24 hrs, the cells were 
either left untreated or treated for 3 hrs with CBZ. The cells were then 
collected and luciferase assays were performed using the Dual-Luciferase 
Reporter System (Promega), as recommended by the manufacturer's 
protocol. In brief, the cells were lysed using IX Passive lysis buffer 
(Promega) for 15 minutes at RT. Lysate was then centrifuged briefly and 5 pi 
of the supernatant was then added to 20pl of Luciferase assay reagent. 20pl 
of Stop and Glow reagent was then added and the p21 promoter 
transcriptional activity was measured using TD-20/20 Luminometer (Turner 
Designs).
8 7
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2.13 Antibodies and western blotting.
Immunoprecipitation samples or total cell extracts were obtained by lysing 
the cells directly in 2X SDS-PAGE sample buffer. Western blotting and 
processing was then done as described previously (Massimi et al, 2008). 
Briefly, nitrocellulose was blocked in 5% milk in IX PBS/0.5% Tween20 
(PBST) for 1 hr at 37°C. Primary antibodies were diluted (1:1000) in IX 
PBST and were incubated at RT for 1 hr with gentle rocking. After washing 
thrice with IX PBST, the blot was incubated for 1 hr at RT with the 
appropriate secondary antibodies conjugated horseradish peroxidase (HRP, 
Dako), diluted (1:2000) in IX PBST/5% milk. After extensive washing with 
IX PBST, the blot was developed using the ECL detection system (GE 
Healthcare) according to the manufacturer's protocol. Any modifications to 
this protocol are detailed below with the description of the antibody 
concerned.
The following antibodies were used according to the protocol outlined above: 
mouse anti-6X His (BD), mouse anti-HA (Roche), mouse anti-p84 (Abeam), 
mouse anti-ubiquitin protein ligase 3A (E6AP) (BD Bioscience), rabbit anti- 
a-actinin, mouse anti-p53 DO-1, rabbit anti-1 4 - 3 -3 s, y and 0/t, goat anti- 
14-3-3a and mouse anti-14-3-3p, mouse anti-SAP97 and mouse anti-a- 
tubulin (all from Santa Cruz) and appropriate secondary antibodies 
conjugated to horseradish peroxidase (HRP; Dako).
Mouse monoclonal antibody against HPV-18 E6 (1:1,000; MAb399), 
directed against the HPV-18 E6 N-terminus, was generated and generously 
provided by the ArborVita Corporation. Western blots using this antibody
8 8
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were performed as above, with the following modifications: the blocking 
buffer was IX Tris-buffered saline (TBS)/0.1% Tween20 (IX TBST) with 5% 
milk and 5% BSA; MAb399 was used at a dilution of 1:1000 for 2 hrs at RT. 
The anti-phospho-E6 (a-pE6) specific antibody (custom-made by 
Eurogentec) was generated using H2N-RQERLQRRRET(P0 3 H2 )QV- 
COOH peptide in rabbits and was used in western blots with the following 
modifications: the blocking buffer was IX TBST with 3% BSA; a-pE6 was 
used at a dilution of 1:500 for overnight at 4°C. The blots were washed with 
IX TBST.
8 9
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3.1 High risk HPV E6 oncoproteins are common substrates of PKA.
Previous studies have shown that HPV-18 E6 and carboxy terminal peptides 
derived from several other HR HPV E6 oncoproteins are substrates of PKA 
(Kuhne et al, 2000). As mentioned before, the PBM is conserved among the 
HR HPV E6 proteins although, as can be seen from Figure 10, there is a 
degree of sequence variation between the different HR HPV E6 proteins. I 
was therefore first interested in determining whether these different E6 
proteins were all similar substrates of PKA. To investigate this, the relative 
susceptibilities of HR HPV-16, -18 and -31 E6 to phosphorylation by PKA 
were investigated. The LR-11 E6, which lacks a PKA consensus phospho- 
acceptor site, was also included to serve as a negative control. The different 
E6 proteins were expressed as GST fusion proteins and purified. These were 
then incubated with purified PKA and radiolabeled ATP; after 20 minutes 
the levels of phosphorylation were ascertained by SDS-PAGE and 
autoradiography. The results obtained in Figure 11(A) demonstrate that 
HPV-16, HPV-18 and HPV-31 E6 are all substrates of PKA, whilst HPV-11 
E6 is not, in agreement with previous studies (Kuhne et al, 2000). However, 
these results also demonstrate that among these, HPV-18 E6 is the strongest 
substrate, followed by HPV-16 E6, with HPV-31 E6 being a much weaker 
PKA substrate.
It has been shown previously that the major phospho-acceptor site on HPV- 
18 E6 is the Thrl56 (Kuhne et al, 2000), however phospho-site predictions,
9 0
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AKT consensus site 
PKA consensus site 
14-3-3 consensus 
PDZ binding motif
18 E6 
18E6T156E 
18E6T156D 
18E6 R153A
18E6 S82A 
18E6 S82A/T156E 
16 
33 
51 
58 
31
31 del PDZ 
31 T145 Adel PDZ
RXRXXS/T
RXXT/S
RRXS/T
XS/TXV
82 156
... .RHYSDS............................. RRRETQV*
.. ..RHYSDS............................. RRREEQV*
... .RHYSDS............................. RRREDQV*
....R H Y SD S..........................R4RETQV*
... .RHY.4DS........................... .RRRETQV*
....RHY.4DS...,......................RRREEQV*
GRCMSCCRSSRTRRETQL* 
 RCAACWRSRRRETAL*
 RTRQRMET QV*
.... R C  AVC WRPRRRQT QV*
   .RCIVCWRRPRTETQV*
 RCIVCWRRPRT*
 RCIV CWRRPRA*
Figure 10. Amino acid sequence of the HR HPV E6 PDZ binding motif 
(PBM). The alignments show the PBMs of HPV-18, -16,-31,-33,-51 and - 
58. Also shown are the different mutant derivatives, HPV-18 E6 T156E, 
T156D and R153A, together with the HPV-18 E6 S82A mutation and the 
S82A/T156E double mutant. The HPV-31 E6 mutations delPDZ and 
T145AdelPDZ are also shown. For comparison, the consensus recognition 
sequence for AKT (Obata et al, 2000), PKA (Pearson & Kemp, 1991), 14-3- 
3 ( M u s l i n  p t n l  1 QQfi'i anH  t h e  P D Z  h in H in a  m o t i f  t S n n a v a n a  P t  n l  1 Q 9 7 ) a r e
-  V------------------------------— ' ■ > ------------   J --------------    O -------------------  V ----------- C V -------- D  * " " 5  /
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as shown in Appendix, suggest that S82 might also be recognized by PKA. 
To verify whether Thrl56 is indeed the major site of PKA phosphorylation 
of HPV-18 E6, a series of HPV-18 E6 mutants were generated. These 
included 2 phospho-mimic mutants, T156D and T156E, and the R153A 
mutation which destroys the PKA consensus recognition site. Mutations 
were also introduced at the predicted phospho-acceptor site, both singly with 
S82A and the double mutation of S82A/T156E. All of these mutations are 
also depicted in Figure 10. In order to assess whether these mutants could be 
phosphorylated by PKA, they were again expressed as GST fusion proteins, 
purified and incubated with PKA and radiolabelled P-yATP. The results 
demonstrated that T156 is the only PKA phospho-acceptor site on HPV-18 
E6 (Figure 1 IB and C), with mutations at this residue and at R153, which is 
essential element of the PKA recognition sequence, destroying PKA 
phosphorylation of the E6 protein, whilst mutation of S82A (Figure 11C) 
has no major impact upon the susceptibility of E6 to phosphorylation by 
PKA.
The above results demonstrated quite surprising differences in the 
susceptibility of HPV-18, HPV-16 and HPV-31 E6 proteins to 
phosphorylation by PKA, despite their all having very similar carboxy 
terminal residues. Therefore, there is a possibility that other kinases might 
potentially phosphoryiate the different E6 oncoproteins. To investigate this 
possibility, phosphorylation was performed using kinase predicted p21- 
activated Kinase (PAK) (personal communication with Dr. Sally Roberts) 
and those scored highly in the phospho-site prediction software (Obenauer et 
al, 2003): Ca2+/Calmodulin kinase II (CamKII) and Protein kinase B (PKB)
9 3
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or AKT (shown in Appendix). The susceptibility of HPV-18 E6 to PKA 
phosphorylation was used as a control, and this was compared with Scribble, 
a protein known to be phosphorylated by multiple kinases (Li et al, 201 lb; 
Nagasaka et al, 2010; Yoshihara et al, 2011; Skouloudaki et al, 2009). The 
results again showed a high levels of HPV-18 E6 phosphorylation by PKA 
(Figure 12A), with little or no phosphorylation by CamK II (Figure 12B). 
There is very weak phosphorylation of E6 by PAK, which is not T 156- 
dependent (Figure 12C). However, there is a significant level of 
phosphorylation by AKT (Figure 12D) and the level of phosphorylation of 
HPV-18 E6 T156E by AKT is reduced (Figure 12C), indicating that AKT 
phosphorylation also occurs within the PBM. To further determine whether 
this was mediated by recognition of the carboxy terminal consensus site 
(Figure 10), the assay was also repeated using the R153A mutant and, as can 
be seen from Figure 12D, this also abolishes phosphorylation by AKT. 
Having found that AKT was the kinase most likely to phosphorylate E6 in 
addition to PKA, HPV-16 and -31 E6 were then analysed for their 
susceptibility to be phosphorylated by AKT. The results in Figure 12E 
demonstrate that HPV-16 E6 is the better substrate for AKT, with HPV-31 
E6 being phosphorylated more weakly, at a level similar to that seen with 
HPV-18 E6. Taken together these results demonstrate that HR HPV E6 
proteins can be substrates for either PKA or AKT, albeit with different 
efficiencies depending upon the HPV types. In the case of HPV-18 E6, the 
phospho-acceptor site for both AKT and PKA is T156, and both kinases 
recognise the same consensus site as defined by the R153 residue.
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3.2 Phosphorylation of the E6 PBM is conserved across multiple HPV 
types.
Having shown significant variation in the degree to which different HR 
HPV E6 proteins are phosphorylated, I next wanted to extend the analysis to 
additional HPV types. To do this, HPV-33, -18:51 and -58 E6 proteins were 
expressed as GST fusion proteins, with HPV-16, -18 and -31 E6 GST fusion 
proteins for comparison. These HPV types were chosen as they were subtly 
different within their last 6 amino acids in their C-terminal from HPV-16, - 
18 and -31 E6 (Refer to Figure 10). HPV-18:51 E6 GST fusion protein used 
in this study was generated by mutating C-terminal PBM of HPV-18 E6 to 
mimic that of HPV-51 E6. The purified proteins were incubated with 
purified PKA or AKT, together with radiolabeled ATP. The levels of E6 
phosphorylation were then ascertained by SDS-PAGE and autoradiography. 
The results in Figure 13A demonstrate that HPV-18 E6 is the strongest 
substrate for phosphorylation by PKA, being closely followed by HPV-58 
E6. HPV-33, -18:51 and -31 E6 are all somewhat weaker substrates for 
PKA. In the case of AKT, HPV-16 E6 and -58 E6 are the strongest 
substrates. HPV-31 then follows, with HPV-33 and -18:51 being poor 
substrates for AKT (Figure 13B). These results demonstrate that, whilst all 
the high-risk HPV E6 proteins analysed can be phosphorylated by PKA 
and/or AKT, and perhaps other kinases which remain to be identified, there 
are major differences in the efficiency with which this occurs.
Analysis of the HPV-31 E6 carboxy terminal sequence (Figure 10) indicates 
the existence of two potential phospho-acceptor sites (Threonine residues)
9 6
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Figure 13. High risk HPV E6 oncoproteins are phosphorylated by PKA 
or AKT. A. The purified GST fusion proteins of HPV-18, -33, -18:51, -58 
and -31 E6, either untreated (-) or incubated with PKA (+) and 32P-yATP as 
indicated. Proteins were analysed by SDS-PAGE and autoradiography. B. 
HPV-16, -33, -18:51, -58 and -31 E6 GST fusion proteins, either untreated 
(-) or treated with AKT (+) and P-yATP as indicated. In each case the 
upper panels show the autoradiograms and the lower panels show the 
Coomassie stained gels. Arrows indicate the relevant GST proteins.
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within this region: one within the PBM (T147) and one located just 
upstream (T145). Since HPV-31 has been used extensively as a model virus 
for analysing the HPV life cycle and its role in the development of 
malignancy (Frattini et al, 1996; Moody & Laimins, 2009), I was interested 
in investigating whether HPV-31 E6 was indeed phosphorylated within the 
PBM. To identify which of these potential sites was phosphorylated, two 
mutations within the HPV-31 E6 carboxy terminus (see Figure 10) were 
generated. The purified GST fusion proteins were then subjected to 
phosphorylation with PKA and AKT and the results obtained are shown in 
Figure 14. As can be seen, removal of the PBM and mutation of T145A in 
HPV-31 E6 has no effect on the levels of PKA phosphorylation (Figure 
14A). In the case of AKT, removal of the PDZ domain almost completely 
abolished phosphorylation by AKT, and mutation of T145A has no further 
effect (Figure 14B). This indicates that HPV-31 E6 is phosphorylated by 
AKT at T147 within the the PBM. In order to identify the PKA phospho- 
acceptor site, mass spectrometry of the PKA phosphorylated HPV-31 E6 
was performed. The result in Figure 14C reveals that the phospho-acceptor 
site used by PKA is S82, indicating that the potential consequences of PKA 
phosphorylation of HPV-31 will be very different from those seen with 
other high risk HPV E6 oncoproteins.
In order to develop tools to be able to assess the phospho-status of HPV E6 
in vivo, an anti-phospho-E6 specific (a-pE6) antibody was generated which 
could specifically recognise phosphorylated forms of HPV-18 E6. This was 
done through Eurogentec, where rabbits were immunised with a 13-mer C- 
terminal phospho-peptide of HPV-18 E6 (as shown in Figure 15 A). In order
9 8
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CHAPTER 3: RESULTS
to characterise the antibody, western blots were done using GST-16 and -18 
E6 pre- and post-phosphorylation with PKA. The result in Figure 15B 
shows that the a-pE6 antibody can recognise PKA phosphorylated HPV-16 
and -18 E6 and, to a lesser extent, the HPV-18 E6 T156E phospho-mimic 
mutant. As can be seen in Figure 15B, T156E was recognised by the a-pE6 
antibody in the absence of phosphorylation, but the levels of detection do 
not change significantly following incubation with PKA. This suggests that 
the phospho-mimic charge mutation on HPV-18 E6 does behave as such, at 
least with respect to recognition by the a-pE6 antibody. I then extended the 
same analysis to determine whether this a-pE6 antibody can cross-react with 
other HPV E6s. The result in Figure 15C shows that the a-pE6 antibody can 
recognise HPV-58 E6 phosphorylated by PKA. In contrast, PKA 
phosphorylated HPV-31 E6 is not detected by this antibody (Figure 15C), 
consistent with the HPV-31 E6 PKA phospho-acceptor site lying outside the 
PBM. In contrast, it is clear that wild type HPV-31 E6 phosphorylated by 
AKT is recognized by the a-pE6 antibody, whereas the two carboxy 
terminal mutants of E6 are not (Figure 15D). These results demonstrate that 
the a-pE6 antibody raised against HPV-18 E6 can detect multiple HR HPV 
E6 proteins when these are phosphorylated within the PBM. Furthermore, 
these results confirm that HPV-18, -16 and -58 E6 are phosphorylated by 
PKA and AKT within the PBM, whilst HPV-31 E6 can be phosphorylated 
by both AKT and PKA, although the phospho-acceptor sites are not the 
same, and only AKT phosphorylates HPV-31 within the PBM.
1 0 2
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3.3 HPV E6 is phosphorylated by AKT and PKA in vivo.
The above results demonstrated that the high risk HPV E6 proteins are 
potential substrates for PKA, although there is little evidence directly 
demonstrating E6 phosphorylation within its carboxy terminal region in 
vivo. To investigate this, HEK293 cells were transfected with HA-tagged 
HPV-16 E6, HPV-18 E6, HPV-18 E6 T156E and HPV-18 E6 R153A 
expression constructs and incubated in the presence or absence of forskolin 
(Fsk) in order to stimulate endogenous PKA activity. After 24 hrs the cells 
were harvested and immunoprecipitations were performed using anti-HA 
antibody-conjugated agarose beads. The immunoprecipitates were then 
analysed by western blotting using the anti-HA and a-pE6 antibodies to 
detect total and phospho-E6, respectively. The results in Figure 16A, B and 
C demonstrate a number of interesting features. Firstly, in the absence of 
Fsk, HPV-18 E6 appears to be only weakly phosphorylated (Figure 16A, B 
and C), whilst there is a slightly higher level of phosphorylation of HPV-16 
E6 (Figure 16A). However, incubation of the cells with Fsk results in a more 
dramatic increase in the levels of both HPV-18 as compared to HPV-16 E6 
phosphorylation as shown in Figure 16A. In contrast, the HPV-18 E6 T156E 
mutant shows weak reactivity with the a-pE6 antibody, consistent with the 
mutation only acting as a partial phospho-mimic (Figure 16B). The PKA 
mutant, R153A was not readily recognised by a-pE6 antibody either in the 
absence or presence of Fsk stimulation (Figure 16C), confirming that this 
mutation also abolished phosphorylation of the HPV-18 E6 PBM in vivo. 
These results demonstrate that transiently transfected HPV-16 and HPV-18 
E6 are highly phosphorylated in vivo following stimulation of PKA. In the
1 0 3
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Noil-treated
a-pE6 —5
i-HA '
Figure 16. HR HPV E6 is phosphorylated in vivo. A. HEK293 cells were 
transfected with empty vector or the HA-tagged HPV-18 or -16 E6 
expression plasmids as indicated in the presence (+) or absence (-) of 
forskolin (Fsk). After 24 hrs, the cells were harvested and subjected to 
immunoprecipitation using anti-HA-conjugated agarose beads. The presence 
of E6 was then detected by western blotting using either the anti-phospho- 
E6 specific (a-pE6) antibody to detect phosphorylated E6 (upper panels) or 
the anti-HA antibody to detect total levels of E6 protein (lower panels). B. A 
similar analysis of HA-tagged HPV-18 E6 or -18 E6 T156E phosphomimic 
mutant was transiently expressed in HEK293 cells as described in Panel A, 
the cells were either untreated (-) or incubated with Fsk (+) as indicated. C. 
A similar analysis of HA-tagged HPV-18 E6 or HPV-18 E6 R153A PKA 
mutant was transiently expressed in HEK293 cells as described in Panel A. 
The cells were either left non-treated or incubated with Fsk (+Fsk) as 
indicated.
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absence of PKA stimulation the levels of E6 phosphorylation are weak, 
although minor differences in the levels of phosphorylation exist between 
the two E6 proteins.
To investigate which kinases were phosphorylating E6 in vivo, 293 cells 
were transfected with HA-tagged HPV-16 and HPV-18 E6 expression 
plasmids, and after 24hrs the cells were treated with H89 for 2 hrs to inhibit 
PKA, MK2206 for 2 hrs to inhibit AKT, or Fsk (overnight treatment) to 
stimulate PKA activity. The cells were extracted and immunoprecipitated 
using monoclonal anti-HA-conjugated agarose beads. The total and 
phospho-E6 was detected by western blotting using anti-HA and a-pE6 
antibodies respectively. As can be seen from Figure 17, HPV-18 E6 (Figure 
17A) was very weakly phosphorylated in asynchronous culture when 
compared with HPV-16 E6 (Figure 17B). Inhibition of either AKT or PKA 
results in a marked decrease in the levels of phosphorylated HPV-16 E6 
(Figure 17B), whilst there is a very weak reduction in the levels of phospho- 
HPV-18 E6 (Figure 17A), although this is difficult to gauge given the low 
levels of phosphorylation. In addition, stimulation of PKA activity with Fsk 
induces a dramatic increase in the levels of phospho-HPV-18 E6 (Figure 
17A), but only a modest increase in the levels of phospho-HPV-16 E6 
(Figure 17B) consistent with the results in Figure 16A. These results 
suggested that in transiently transfected asynchronousiy growing cells Eo 
can be a substrate for both AKT and PKA, but that HPV-16 E6 is 
phosphorylated to significantly higher levels than HPV-18 E6 under these 
conditions. However, when PKA activity is elevated, then HPV-18 E6 
becomes more heavily phosphorylated and this is consistent with the
1 0 5
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observation of differential phosphorylation of HPV-18 and -16 E6 by PKA 
and AKT in vitro.
I then wanted to ascertain if endogenously expressed E6 is phosphorylated 
in a similar manner. To do this, HeLa cells were stimulated with Fsk and 
then analysed by western blotting to determine whether endogenous 
phospho-E6 can be detected. The results in Figure 17C show low levels of 
phospho-E6 in unstimulated HeLa cells, but that Fsk treatment induces a 
dramatic increase in the levels of E6 phosphorylation. The identity of the E6 
protein was also verified by performing siRNA E6/E7 ablation of E6 
expression. This result shows that the a-pE6 antibody can recognise the 
endogenous phospho-E6 in HeLa cells. In order to identify the kinases that 
phosphorylate HPV-18 E6, HeLa cells were treated with Fsk, H89 or 
MK2206 and phospho-E6 was detected by SDS-PAGE and western blotting. 
The result in Figure 17D shows that HPV-18 E6 is phosphorylated at a low 
level in untreated cells and heavily phosphorylated upon Fsk stimulation. 
Phosphorylation of HPV-18 E6 was also greatly decreased upon H89 or 
MK2206 treatment, suggesting that HPV-18 E6 is subject to 
phosphorylation by both PKA and AKT in HeLa cells. It was also noticed 
that H89 and MK2206 treatment reduces the levels of p53 in HeLa cells, 
with a dramatic reduction observed with the use of MK2206. This could be 
due to the inhibition of kinases that normally phosphorylate p53, as previous 
studies have shown that phosphorylation of p53 helps maintain its stability 
(Meek, 1994; Ashcroft et al, 1999).
1 0 7
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3.4 Phosphorylation of E6 negatively regulates interaction with hDlg 
and MAGI-1.
Previous studies showed that PKA phosphorylation of HPV-18 E6 
negatively regulates its interaction with hDlg (Kuhne et al, 2000), whilst 
phosphorylation of PBMs is generally assumed to inhibit PDZ recognition 
(Zhang et al, 2007). It was therefore interesting to ascertain whether the 
other high-risk HPV E6 oncoproteins were subject to a similar pattern of 
regulation. To do this, a series of in vitro pull-down assays were performed 
using phosphorylated GST-E6s and in vitro translated radiolabelled MAGI- 
1 and hDlg. The results obtained are shown in Figure 18 and demonstrate a 
number of interesting features. Although there are variations in the degree to 
which the different E6 proteins bind MAGI-1 and hDlg, with HPV-18 and 
HPV-58 E6 being the strongest, the phosphorylation of HPV-18, -33, -18:51 
and -58 E6 all decreased their ability to interact with MAGI-1 (Figure 18A) 
and hDlg, except for HPV-18:51 E6 (Figure 18C). Similarly, HPV-16 E6 
showed a strong association with hDlg in the absence of phosphorylation, 
however, a reduction of hDlg recognition by HPV-16 E6 was observed 
when HPV-16 E6 was phosphorylated by PKA (Figure 18C). Meanwhile, 
HPV-31 E6 appears to differ: its interaction with MAGI-1 and hDlg is 
comparable to that of HPV-18 E6, but PKA phosphorylation has no effect 
on the interaction (Figure 18B and D). This is consistent with the above 
results showing that HPV-31 E6 is phosphorylated by PKA outside the PBM 
(Figure 14A and 15C). In both cases the PBM mutation confirmed that 
HPV-31 E6 PDZ interactions are mediated through classic PBM recognition 
(Figure 18B and D). These results demonstrate that although the PDZ
1 0 8
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recognition of most HPV E6 oncoproteins is negatively regulated by PKA, 
this does not hold true for HPV-31 E6.
Since the different HPV E6s display differential patterns of phosphorylation 
by PKA or AKT, I then wanted to understand whether AKT 
phosphorylation has a similar effect on the interaction between E6 and PDZ 
proteins. In order to answer this, a similar in vitro phosphorylation of GST- 
E6 fusion proteins using active AKT was performed, and the effects on 
interactions with hDlg was analysed. The results shown in Figure 18E 
reflect the capacity of the different E6 proteins to be phosphorylated by 
AKT within their PBMs. Thus, HPV-18 and -33 E6 are weak substrates of 
AKT (as shown in Figure 12E and 13B), and likewise, AKT 
phosphorylation has no effect on their ability to interact with hDlg. In 
contrast, HPV-16 and HPV-58 E6 are very good substrates of AKT (as 
shown in Figure 13B) and this is reflected in the effects on hDlg 
recognition, where phosphorylation greatly reduces the interaction with the 
two E6 proteins. As noted above, HPV-31 E6 is phosphorylated by AKT on 
the T embedded within the PBM (Figure 14B and 15D) and, not 
surprisingly, phosphorylation of HPV-31 E6 by AKT also results in a strong 
inhibition of HPV-31 E6 interaction with hDlg. Taken together, these results 
demonstrate that the capacity of different HPV E6 oncoproteins to be 
phosphorylated by different cellular kinases varies considerably amongst the 
different HR HPV E6 oncoproteins, but the consequences of such 
phosphorylation events within the E6 PBM are always the same, resulting in 
an inhibition of E6 PBM-PDZ interactions.
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3.5 Phospho-E6 interacts with 14-3-3£.
Whilst phosphorylation of HPV E6 inhibits its recognition of PDZ proteins, 
it is not known if this post-translational modification favors E6 recognition 
of other cellular proteins. As mentioned before, mass spectrometry analysis 
performed in our laboratory (personal communication Dr. Vjekoslav 
Tomaic) and performed by Howie et al. (2011), indicated that 14-3-3 
proteins are potential targets of E6 (Howie et al, 2011), and these are 
particularly attractive candidates due to their phosphoserine/threonine 
binding properties. In the mass spectrometry analysis, 14-3-3£ was identified 
as the one of the E6 target proteins. To investigate potential interactions 
between 14-3-3 and HPV-18 E6, purified GST-18 E6 fusion proteins were 
subjected to PKA phosphorylation using non-radiolabelled ATP. Interaction 
assays were then performed with in vitro translated radiolabelled 14-3-3 
As controls, parallel assays were also performed with in vitro translated 
hDlg and MAGI-1. The results obtained are shown in Figure 19A, and 
reveal a number of interesting features. In the absence of phosphorylation, 
14-3-3£ did not interact with HPV-18 E6, whilst there is strong association 
of HPV-18 E6 with both hDlg and MAGI-1. However, following 
phosphorylation of HPV-18 E6 there is a dramatic decrease in the capacity 
of E6 to recognise both hDlg and MAGI-1 and a corresponding increase in 
the capacity of E6 to interact with 14-3-3^. These results demonstrate that 
the PBM/PKA module is potentially dual functional, depending upon the 
phospho-status of the T156 residue, and this confers either recognition of 
PDZ proteins or, alternatively, recognition of 14-3-3^.
1 1 2
CHAPTER 3: RESULTS
40l>>ndu'
,f*so |
* 9 /?j'Tsrj
J .S O  | +
*
i
1
1
i a
i f f
•
1
1
i  i
i  s 
1
<
^ V '3 f-*2 o <s>~ w o
OQ ( J
.S w  o
°o,
0O f j
9 :i;/*y-
'J .S :
J-S'rj
{
{
{
m  t—«cA O
i
1■'T-A
* / 1
+  ’ | I i
■ + 1 l  i
1 • t 1 i
■f* • i i  1
• + 1 1 t
, ■ 1 1
+ 1
• + 1
n
w o
h>. Vo,C*SV
Xc.Ay,
\ p + 
<SV)
%
+
% >
■*/)9zi<?/•«As0
Yc, I■''O I
M  tvp *3 I I
r^ i v, £-h
2 - i s  S
113
CHAPTER 3: RESULTS
od < !
§ sX)
<d
c
fa+
CD
VH X
CD Q _ ,
* s
CO X
. 2  £
§  «  
a  .2
fa 3
§ B
*55 2 
*3 Oh
H J
C/5 X
o  a
73 - 2  
CD -11
3  ( D  
.2 3
73 CD#£T>
' g
2  w
V i
o
/M? CD
X  55 Si
g  . aC3 CO £uJ ^
g> 3  8
O E§ *- H73GV i
0
1
73
G
G  
73 fa£  H 
- 2
H 2G CCS
V i O o  
Cm
2 °  G «d
o  
g
<d
CD c/3
X  
H
' g
fa)
O  2  
<  fal
C/3
Q  . _
OT 2 &
S* ?  «S  c  ^C/3 O ■*“*
G ' m G
'G <3<D ^  i-> -m
o  aP ccj
CD 
73
73 73 
G G
ccS c3
fa) 2 
O  - 2
<  a
Ph O  1 G G
G 
O
. 2  'faC/3
G
GO
Q
CO
CD w  
CD G 
G £  (JD ^  
f t  v_r>
a  f?  
g  cA
CD _L
X  ^
G 'Tp 
H  G 
G 
O 
X)
+
73
<D-mCD
CDi->CD
73
§
I
I d
V i
P
X
fa
X
©
CD
jt g 
|  £
a 2G 3
2  a> 
X
fl •-5  P
<D _
£  - 5
GO CD
G X
>  <  
3  &a fa
(D X
CDVh .
CD P ^  +-* ^ G CD1/3 X
G 73
• §  . 9
O  1/5
3 ,  £
CD
O 73  
5-* G Gh *g
G
_o
"3
73 G
G G Sj G
O CD 
X  X
bD ^  
G X  
•G <D
*§5 M
>  X3
O
X3
1/3
o
X3
G,
O-»->
73
CD
73 e  m 
§  2  
G  ^
-S  X3 'O '■£
g  3
•B -
G _^p
fc* ^
O f?
G  i
§  S  
A  
G
73
§
O
X)
O
a
c3
6 c > £  
c H
G
C/3
o
XJG
X3czi
%
CD 
>  
cn 
G 
<D +-> 
X <D
00
G
-^3 73
CD CD 
00 CD
CD CD 
9  X3
c+h
O
' g
Cfl
Vh
o
GO
<D CD
«  Q
.5
t-H
V-T i
fO w
■ O2 < 3  S
5  u
>  3
0
i±u
. CJ
73 <d
1  *
• |  g
.2 ^
CD
SG
Vh 
CD
£  
5
(D5-t
W3 2D
ccS
2
o
O
C+H
o
ccS
(D
V 3
C/3
^ Go S
Ph O 
O O
G  U
X> CD 
<7 ^
< 7  C/3
4  ^1 o1-rH »"G D W
3  1 3  
'ot G
5 
£  
o
5h
73
OD
73
CD
«  2CD Xl
S
1-t
CD
X3
a
' o
73
ccS
G
G
D
£
O
•G ^
vo s:
>  a
&  I d
*2G
ov 3
^  'G 
D G
^  ?-i
3  X5
M  S
f a  £
C/3
G
Ph
H
<
' o
CD
C+H
C/3
G
D-*-»
Oi-i
G
•2 ^  
73 E~•
OD
S
G, Vh
U .2 
£  §  
O erf
OD
I f^  G 
O G
73  
OD ^  
CD G 
CD ’g
^  u
C/3 r f  
rs• i—i O
<D s
"G .’s  o  5»H ^
c  - s
.2 ja
£3 •"£
cH 5
H  73  
CO «
O  c3 
'P  • §
r f  CD 
ccS G 
CD
73
G
73
G
CD H  
O XI GO 
OD H  O
?H
OD
G
.G 1
CD
X
H
•
U
C/3
CDCD OD
S  2 ^^  G O
G
^  G
5—i
G
OD <D
G
§ *  X
5  H
OD
3
'go
.2
G
CD
X
§*
bb
o  • ^
73
G
1-4
0
1
CD W3
cS 05
^  CD 
G
G ,2  CD 70
OD
OD
&
bO 
G
X
C/3
G G 
.2 £ 
3  OD 
^  ' >
G
CD-4-»
X 
OD
bD 
G
O
73
.2
C/3
o
a
<
a
1
C/3
,G  
’OD-t-j
2  
G
G 
#o
*00 
«2 
o  H
CDbD
CD
X
CO
O
4->
§
G vo
o  w  
U  °o
g fa
X 1 X_P2 ^  C/3 I
Jh
CD
X
O
X
1/3
>fa
ffi
G
ODVh
c2XCD
S  73
G
CD
O
OD
X
H
CD
ODVi
CD
£
CD 
C/3 
CD
2 ^
• § H
2 p  ^fa H
' g  ^
t s  2
l o  o  
2G <H_|
&  o
A  CD 
T ! GD vi
G OD
P  3G  X
a  ^R  cnP h i
Ph cn
3  4
& i
2) g  
• 2  a
73 ^
G O
5h X
- 2  C/3
g §>Xfl-T3 CO
g  <  
w  d
O  C/3
Ph G 
CO f2 CJ 
Q  —
w a g
bD
.2
*C/3
G
73OD
X  G 
£  fa
o  a  5h .G
fa  73
y  CD
2  x_ > G ■
O 5h
OD ^  OX P cn
a  'p «73 Vi 73
1 1 4
CHAPTER 3: RESULTS
Having found that HPV-18 E6 could interact with 14-3-3^, I extended the 
studies to determine whether HPV-16 and HPV-31 E6 could also recognise 
14-3-3^ in a phosphorylation-dependent manner. To do this, these purified 
GST-16 and -31 E6 fusion proteins were subjected to phosphorylation by 
PKA using non-radiolabelled ATP, and binding assays performed with in 
vitro translated radiolabelled 14-3-3^. The results in Figure 19B again 
showed a strong interaction between phospho-HPV-18 E6 and 14-3-3£. A 
similar phospho-dependent interaction between HPV-16 E6 and 14-3-3^ was 
also apparent, but HPV-31 E6, which is phosphorylated by PKA outside the 
PBM, fails to interact with 14-3-3 As expected, no interaction was 
observed between HPV-11 E6 and 14-3-3^, consistent with the absence of a 
PBM/PKA module on the carboxy terminus of HPV-11 E6. These results 
demonstrate that the association between E6 and 14-3-3^ is a reflection of 
the degree to which the particular E6 oncoprotein can be phosphorylated by 
PKA in the PBM.
Having shown that phospho-E6 can interact with 14-3-3, I next wanted to 
investigate the other sequence requirements within the PBM for this 
interaction to take place. To do this, a panel of HPV-18 E6 mutants (Figure 
10) were used. These include the phospho-mimics, T156D and T156E, the 
potential PKA phospho-acceptor site mutant S82A, the double mutant 
containing both S82A and the T156E mutation (S82A/T156E), and the PKA 
consensus recognition mutant R153A. The purified fusion proteins were 
phosphorylated with PKA and in vitro interaction assays were performed by 
incubating these fusion proteins with in vitro translated radiolabelled 14-3- 
3  ^ as described above. The results in Figure 19C and D again demonstrate
1 1 5
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that phosphorylation of HPV-18 E6 is essential for the interaction with 14-3- 
3£, since no association is seen with the R153A mutant. Furthermore, these 
results also demonstrate little or no influence of the S82 residue upon the 
ability of E6 to recognize 14-3-3^. Surprisingly, the two phospho-mimics 
also failed to interact with 14-3-3 This result demonstrates that recognition 
of 14-3-3^ by HPV-18E6 is strictly dependent upon phosphorylation of 
T156 and a simple replacement with an acidic residue is not sufficient to 
confer interaction.
3.6 The interaction between phospho-E6 and 14-3-3  ^is direct.
To ensure that the interaction between E6 and 14-3-3^ was direct, and not 
mediated through an intermediate protein, the interaction assays were 
repeated using commercially available purified 14-3-3^. Following PKA 
phosphorylation of the purified GST-E6 fusion proteins, these were 
incubated with the purified His-tagged 14-3-3 and after extensive washing 
the bound 14-3-3^ was detected by western blotting using anti-His antibody. 
The results obtained are shown in Figure 20A (i), with the quantitations in 
Figure 20A(ii), and these confirm the phospho-specific association between 
HPV-16 and HPV-18 E6 and 14-3-3^, with little or no interaction occuring 
between HPV-31 and HPV-11 E6 and 14-3-3 again corresponding to their 
respective susceptibility to phosphorylation by PKA within the PBM.
Since the above results indicate that HPV-16 E6 and HPV-31 E6 can also be 
phosphorylated by AKT, the direct binding assays were repeated to 
investigate whether AKT phosphorylation of these E6 proteins could
1 1 6
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likewise stimulate interaction with 14-3-3?. The results of this analysis in 
Figure 20B(i) and 20B(ii) demonstrate that AKT phosphorylation of HPV- 
16 E6 by AKT does indeed promote interaction with the purified 14-3-3?. 
Most interestingly, phosphorylation of HPV-31 E6 by AKT, which in 
contrast to PKA phosphorylation occurs within the PBM, also confers 
interaction with 14-3-3?. This result demonstrates that the capacity of high 
risk E6 oncoproteins to interact with 14-3-3? is highly conserved across 
different HPV types, and that differences are mainly determined by whether 
phosphorylation occurs in the PBM or not.
3.7 HPV E6s interact with multiple 14-3-3 proteins in a 
phosphorylation-dependent manner.
As mentioned earlier, there are 7 mammalian 14-3-3 isoforms which often 
exist as homo- or heterodimers (Jones et al, 1995a). The ? isoforms interact 
strongly with HPV E6s and whether the other 14-3-3 isoforms can also 
interact with E6 in a similar manner is unknown. In order to understand this, 
similar direct binding assays were carried out with all of the other purified 
His-tagged 14-3-3 isoforms. The results showed that phosphorylation of 
HPV-18 and -16 E6 by PKA confers an increased interaction with 14-3-3y 
[Figure 20C (i) and (ii)], s [Figure 20D(i) and (ii)], rj [Figure 20E(i) and (ii)] 
and x [Figure 20F(i) and (ii)] isoforms, and a marginal increase was 
observed for the P isoform [Figure 20H(i) and (ii)]. A strong interaction 
between 14-3-3a and HPV-18E6 was observed, as shown in Figure 20G(i) 
and (ii), however, the interaction between a  and HPV-16E6 is somewhat
1 1 7
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Figure 20. Interaction between HPV E6 and 14-3-3 proteins is direct.
The indicated purified GST fusion proteins were either untreated (-) or 
subjected to phosphorylation with PKA (+) in the presence of cold ATP. 
These were then incubated with purified His-tagged 14-3-3 isoforms:  ^ [A 
(i)], y [C 0)1. E [D (i)l, <1 [E(i>], x [F(i)J, o [G(i)J and fi [H(i». B. The 
indicated purified GST fusion proteins were also either untreated (-) or 
incubated with AKT (+) in the presence of cold ATP and were then 
incubated with purified His-tagged 14-3-3^. After extensive washing the 
bound protein was detected by western blotting using anti-His antibody 
(upper panel). The lower panels show the Ponceau stain of the nitrocellulose 
membranes. The quantitations from at least three independent assays for the 
individual isoforms are shown in the respective Panel (ii).
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weaker. Interestingly, there is no interaction between most of the 14-3-3 
isoforms and LR HPV-11 E6, except for 14-3-30 [Figure 20H(i) and (ii)].
Since it was shown that different HPV E6 oncoproteins were subject to 
different degrees of phosphorylation, I was also interested in investigating 
the potential pattern of associations between these E6 oncoproteins and 14- 
3-3. In order to do this the different GST-E6 fusion proteins were purified 
and phosphorylated using either AKT or PKA. The E6 proteins were then 
incubated with commercially available, affinity purified His-tagged 14-3-38 
and, following extensive washing, bound 14-3-3 was detected by western 
blotting. The results in Figure 21A demonstrate that HPV-18, -16 and -58 
E6 proteins, which are good substrates of PKA, are also able to interact 
strongly with 14-3-3s when phosphorylated by PKA. Likewise, HPV-16, - 
58 and -31 E6 proteins which are good substrates of AKT, also interact 
strongly with 14-3-3s (Figure 21B) when phosphorylated by AKT. 
Meanwhile, HPV-18:51 E6, which is a poor substrate for both PKA and 
AKT, did not bind to 14-3-3e (Figure 21A and B). Taken together these 
results demonstrate that the E6 PBMs of multiple HPV types are dual 
functional, and, depending upon the phosphorylation status, can confer 
interaction with either PDZ domain-containing proteins or members of the 
14-3-3 family of proteins.
Next, I was interested in investigating the ability of HPV-18 E6 to interact 
with different 14-3-3 isoforms in vivo. To assess this, HEK293 cells were 
transfected with HA-tagged HPV-18 E6 and samples were extracted after 24 
hrs and immunoprecipitated with anti-HA conjugated agarose beads. Co-
1 2 1
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immunoprecipitated 14-3-3 was then detected by western blotting. The 
results, in Figure 22 A, show significant levels of interaction between HPV- 
18 E6 and 14-3-3^, 8 and 0, and a much weaker association with 14-3-3y, 
while no interaction was detected with o and P isoforms. Fsk was included 
in the assay to determine whether this would increase the degree of 
association between E6 and the different 14-3-3 isoforms. Surprisingly, Fsk 
treatment appears to strongly inhibit the interaction between 14-3-3 and E6 
(Figure 22A and B). The most likely explanation is that the very high levels 
of active PKA also phosphorylate 14-3-3, which, in turn, is known to inhibit 
the ability of 14-3-3 to recognize its substrates (Gu et al, 2006), and 
therefore results in a loss of interaction with E6.
To investigate further whether the interaction between E6 and 14-3-3 is 
phosphorylation-dependent, the cell extracts were incubated with X 
phosphatase or cells were exposed to treatment with H89 which is a PKA 
inhibitor, prior to performing the co-immunoprecipitation. The results in 
Figure 22B and C again demonstrate a clear co-immunoprecipitation of 14- 
3-38 with HPV-18 E6, but this interaction is abolished following treatment 
of the cells with H89, and treatment of the cell extract with X phosphatase. 
Taken together these results demonstrate that HPV-18 E6 can interact with 
multiple 14-3-3 isoforms, and that this interaction is phosphorylation- 
dependent.
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CHAPTER 3: RESULTS
3.8 HPV-18 E6 does not degrade 14-3-3
HPV-18 E6 targets many cellular proteins for degradation and it was of 
obvious interest to investigate whether E6 could affect the levels of 14-3-3 
protein. In order to assess this in the cells, HEK 293 cells were transiently 
transfected with Flag-tagged 14-3-3^ and HA-tagged HPV-18 E6, with HA- 
tagged hDlg included as control. After 24 hrs, the cells were either left 
untreated or treated with H89 or Fsk. As can be seen in Figure 23, HPV-18 
E6 degrades hDlg most efficiently when the cells were treated with H89, 
where the majority of E6 is not phosphorylated. However, Fsk treatment 
which increases phosphorylation of E6 inhibits hDlg degradation. This is in 
agreement with the previous reports showing that HPV-18 E6 association 
with hDlg is dependent upon the E6 phospho-status of E6 (Kuhne et al, 
2000). In contrast, there is no change in the levels of 14-3-3^ regardless of 
the presence of HPV-18 E6 or the H89 and Fsk treatments. Taken together, 
these results indicate that 14-3-3^ is not a degradation target of HPV-18 E6.
3.9 HPV-18 E6 is phosphorylated in a cell cycle-dependent manner.
The above results indicate that HPV-18 E6 can be phosphorylated by PKA, 
but that in asynchronously growing cells the levels of E6 phosphorylation 
are very low. This suggests that E6 phosphorylation might alter with the 
phase of the cell cycle. To investigate this, a series of in vitro 
phosphorylation assays on GST-18 E6 was performed, using cell extracts 
from cells that were harvested at different phases of the cell cycle. To verify 
that the phosphorylation was occurring within the E6 PBM, the GST-18 E6
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T156E mutant, which cannot be phosphorylated by either PKA or AKT, was 
also included. Following incubation of the fusion proteins with the cell 
extracts and radiolabelled ATP, the fusion proteins were separated by SDS- 
PAGE, and labelled protein was monitored by autoradiography. The results 
in Figure 24A show that E6 is phosphorylated by cell extracts obtained from 
cells in G2/M, whereas low levels of phosphorylation are seen using extracts 
from Gl/S or S phase cells.
In order to confirm this result, I then proceeded to investigate the pattern of 
E6 phosphorylation in vivo. HEK293 cells were transiently transfected with 
HA-tagged HPV-18 and -16 E6 and the cells were synchronized in Gl/S, S 
and G2/M phases of the cell cycle. These cells were then extracted and total 
E6 immunoprecipitated using anti-HA conjugated agarose beads. Bound 
phospho-E6 was then detected by western blotting. As can be seen from 
Figure 24B, the highest levels of HPV-18 E6 phosphorylation occur in the 
G2/M phase of the cell cycle (Figure 24B), while HPV-16 E6 is most 
heavily phosphorylated during S phase, although it is phosphorylated 
throughout the cell cycle (Figure 24C). To monitor the phosphorylation 
pattern of endogenous E6, HeLa cells were synchronized and total cell 
extracts then subjected to western blot analysis using either anti-E6 
monoclonal antibody to detect total E6 or the a-pE6 antibody. The cell cycle 
profile was verified by FACS analysis which is shown in Figure 25A (ii) 
and B (ii). As can be seen from Figure 25A, Cdc25C is phosphorylated 
during G2/M phase, which is in agreement with the previous studies (Peng 
et al, 1997). Consistent with the transient expression assay, the majority of
1 2 7
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Figure 24. Cell cycle dependent phosphorylation of HPV-18 E6. A.
Purified HPV-18 E6 and HPV-18 E6 T156E GST fusion proteins and GST 
alone were incubated with cell lysates from cells synchronised at different 
phases of the cell cycle (Gl/S, S and G2/M), together with 32P-yATP as 
indicated. Proteins were subjected to SDS-PAGE and autoradiography. The 
upper panel shows the autoradiogram and the lower panel shows the 
Coomassie stain of the gel. Arrows indicate the relevant GST proteins. B 
and C. HEK293 cells were either transiently mock transfected (NC) or 
transfected with the indicated HA-tagged HPV-18 E6 (Panel B) or HA- 
tagged HPV-16 E6 (Panel C) expression plasmid. After 24 hrs the cells were 
synchronised at different cell cycle phases as indicated, or left asynchronous 
(Asyn). The cells were harvested and subjected to immunoprecipitation 
using anti-HA conjugated agarose beads. The presence of E6 was then 
detected by western blotting using either the anti-phospho-E6 specific 
antibody (upper panels) to detect phosphorylated E6 or the anti-HA antibody 
to detect total E6.
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Figure 25. Phospho-regulation and turn-over of HPV-18 E6 occurs in a 
cell cycle dependent manner in HeLa cells. A(i) and B(ii). HeLa cells 
were synchronised using Aphidicolin (Gl/S) or 5 hrs release from 
Aphidicolin (S), or 18 hrs of Nocodazole (G2/M), or left asynchronous 
(Asy) (Panel A). Alternatively, the cells were subjected to double thymidine 
block, and cells were collected at 0 hrs (Gl/S), 5 hrs (S), or 9 hrs (G2/M) 
post release from double thymidine treatment (Panel B). These cells were 
harvested and the levels of E6 ascertained by western blotting using anti- 
phospho-E6 (a-pE6) specific antibody and total E6 detected using anti- 
HPV-18 E6 monoclonal antibody. The upper panel shows the a-actinin 
loading control. Also included are Cdc25C, 14-3-3^ and s. Cdc25C(p) 
represents phosphorylated form of the Cdc25C during the G2/M phase of 
the cell cycle. A(ii) and B(ii). FACS analysis of asynchronous (Asyn) or 
synchronised HeLa cells at different cell cycle phases as indicated.
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HPV-18 E6 phosphorylation also takes place during the G2/M phase of the 
cell cycle. The level of total E6 protein is low in the Gl/S and S phase of the 
cell cycle. The levels of 14-3-3 proteins were also studied to understand if 
their steady state levels can be affected by phospho-E6 across the cell cycle. 
The results in Figure 25A(i) showed no significant change to the levels of 
14-3-3 proteins across the cell cycle. This again indicates that phospho-E6 
does not affect the steady state levels of 14-3-3 proteins. To exclude any 
possibility that these pattern of expression might be due to Aphidicolin and 
Nocodazole treatments, I repeated the analysis using a double thymidine 
block. HeLa cells were treated with thymidine for 16 hrs, then released from 
thymidine for 9 hrs and the cells were then re-treated with thymidine for 16 
hrs. Following this, the cells were harvested at 0 hrs (Gl/S), 5 hrs (S) and 9 
hrs (G2/M). The samples were then analysed by western blotting to detect 
the levels of phospho-E6, total E6 and p53 proteins. As can be seen from 
Figure 25B, the highest levels of phospho-E6 were detected in G2/M phase 
(Figure 25B), although there is little change in the levels of total E6 in the 
different cell cycle phases.
3.10 Phosphorylation regulates E6 stability
Previous studies had shown that the E6 PBM might contribute towards 
maintaining E6 stability (Nicolaides et a/, 2011), although the precise 
mechanism is still unclear, with both PDZ and 14-3-3 association being 
implicated. In order to investigate this, cells were transfected with HA- 
tagged HPV-18 E6 and the cells were either left untreated or treated with
1 3 0
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Fsk. After 24 hrs, the cells then incubated with cycloheximide to block 
protein synthesis, and levels of E6 protein were assessed by harvesting cells 
at different time-points. HA-18 E6 was immunoprecipitated using anti-HA- 
conjugated agarose beads and the levels of total and phospho-E6 were 
ascertained by western blotting. As can be seen from Figure 26A and the 
quantitation shown in Figure 26B, phospho-E6 levels in the non-Fsk treated 
cells were low, but the half life is extended in comparison with that of the 
total E6 and E6*, which appears to have a half life of around 30 minutes 
under these conditions. In contrast, when the cells are stimulated with Fsk, 
the levels of phospho-E6 increased dramatically. In addition, the turnover of 
this phospho-E6 remains relatively unchanged, with a half-life of around 90 
minutes. However, there is a concomitant extension in the half-life of the 
total E6 and E6*, similar to that seen with the phospho-E6. This 
demonstrates that phosphorylation of HPV-18 E6 results in a significant 
increase in the stability of the E6 oncoprotein.
To investigate whether 14-3-3 might play any role in maintaining the steady 
state levels of E6, siRNA depletion of 14-3-3^ was performed in HeLa cells. 
After 72 hrs, the total extract of these samples was analysed by western 
blotting. As can be seen from Figure 27A, downregulation of 14-3-3^ also 
resulted in a modest decrease in the levels of HPV-18 E6, as shown by the 
quantification in Figure 27B. From the in vitro (Figure 19 and 20) and in 
vivo (Figure 22) binding assays, it is known that the £ and 0 isoforms bind 
strongly to HPV-18 E6. Downregulation of multiple 14-3-3 isoforms might 
have a more detrimental effect on the levels of HPV-18 E6. Taken together,
1 3 1
9H
SI-V
H
 
93 
81-VH
 
^
CHAPTER 3: RESULTS
I I I
I I
I  I  
I I
,P
'•!
1 1  t
w
a,
33
CD -v-<
CD 
- OD 
0-1
c /3
S3
cd
Vi
Vio
u
-= J! 
a £
I t l U l l O E - B  0 )  9 3  J O  O I U 'M
=33
o
O VH
CD
X
4 33t-
(N
Viou
<
o
M
C/3
Vi
cS
X
O
oucuS3
CD
C/3
■ i
Vio
+
x
Cd
00
I
>
Pm
SS
xo
.4 )
CS
X
o
4=
- o
s
v
X
4/
eo
o
x
a
x
n
o
S-
3OX)
c
(3
0 0
.5
"w
=3
S3
O
£
33ou-5—>cu
<u
X >
3
C/3
3 3
S3
cd
3 3
<Di- i
C/3
CD
>
5— i
cd
43
<D
<3
£
CD
CD
c
CD
C/3
CD5-ia.
<u
4 3
3 3
CD
' S
o
- 5
. c
C/3
cd
C /3
3 3
£
C/3
- £
I B
S3o
3 3
#o
C/3
cd
S3
<D5 i
£
a,x
<u
x
W
OO
Si
£
R
EC
u
<u
3 3
>
CU
ee
3 3  
OD 
OX) 
OX) 
cd +-• i<
EC
x  o 
PP & 
£• o
3 s  °
3  
O h 
S3
3  ^
"Bh x
o  W
2 2 Oh ^  
O  
S3 
33
£
o
5S
o  
u  cu
O h ^
O h
C /3o
43
C/3
O
£o
4 3
C/3
n  O
x  <
S *X
•8 2  1—> ”c3
5 i C
S  cd 
r£3 VO
• s  W
4-1o
>  
_au
"cd
OX)
_ o
" w  
3
OX)
S3
<U
o
<U 
4 3
H
3 3
<U -*-> 
cd cu 
CD 3 3
j o
X
S3
V i
CU 1—< 
C /3
<u
£
X!
3 3
CU
*  J  & <
X
S3
0>
X
X
O
<U
Vi
O-
<u
X
H
X <u 
CU 
Xo
x  . 53  £ 
cd o 
X  O
I  <
.£  X
§
<U
X
O
VO X  
PP w
3 3
<u
cd ^3 
(U
X  O
C /3 C/3
O 33
3 3
C
cd
X
PPi
O
X
O h
C/3
O
X
O h
X
O
cu
>
JU
<u
X > 
<U
OX) ^  
S3 3 3
£o
X
C/3
cd
3 3
S3
cd
S3 S3 
cu cu
S C/3CU
‘ sP t  
(U
O h g
x  1
a
<u-c->
CU
3 3
X
3 3
O
X
h—> cd
S3 X
- 2  *- 
3  °C  H  
<D r~  
O h  W  
<U
3 3  X
S3- n  [ i ,
cu x  
(U o
•X £
c/3 <U
cd <uJZ C —* cu
-V-; C/3
cd cu
V i 
O h  
V i 
Oe gc+1
S3
O
cd
<U <3
a
<U o  
X
O h
CU 
CU_  oX  cu
£  cd
gy 0 O ' x
«  .£
o
X
s o
H—*cucu o
S3o
O W 
—■ cd 0
o  S f l  c s
cd O hcu
«1 3 3S  au
Vi
cu
O h
S'
cd <U 
X  X  
O h ^
o 5  
£ o
O h Oo
S3 
3S
X
Xo
X
o
cd
£
£ 
• tH
CU
X
cd
X
W
. cdis +-' o oX
132
CHAPTER 3: RESULTS
A
o'r*"-,
a-Actinin
14-3-3:
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14-3-3l and HPV-18 E6 level in HeLa cells
■H PV-18 E6
-  14-3-3C
siluc si 14-3-3:
Figure 27. 14-3-3? contributes towards maintaining HPV-18 E6 steady 
state levels. A. HeLa cells were transfected with control siRNA (siLuc) and 
siRNA against 14-3-3? (si 14-3-30. After 72hrs the cells were harvested and 
the level of E6 was ascertained by western blotting using anti-HPV-18 E6 
monoclonal antibody. Also shown are the levels of 14-3-3? and the loading 
control a-actinin. B. The quantitation from at least three independent 
experiments showing the 14-3-3? knockdown and the effects upon E6 levels.
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these studies indicate that both phosphorylation and 14-3-3 interactions can 
be expected to play a role in the regulation of E6 stability.
3.11 HPV E6 recognition of 14-3-3 family members and PDZ substrates 
occurs during distinct phases of the cell cycle.
The above results demonstrate that phosphorylation of E6 can affect E6 
turnover and its capacity to interact both with 14-3-3 family members and 
PDZ domain-containing substrates. Since phosphorylation of E6 varies 
throughout the cell cycle, I next wanted to determine if this affects E6 
substrate recognition. To do this, HEK293 cells were transfected with HA- 
tagged HPV-16 E6, HPV-18 E6 and HPV-18 E6 APBM expression 
plasmids and the cells were synchronized in Gl/S, S and G2/M. Three hours 
prior to harvesting, cells were treated with CBZ and HA-HPV 18 E6 was 
immunoprecipitated with anti-HA conjugated agarose beads. Bound 
complexes were then analysed by western blotting and the results are shown 
in Figure 28A (HPV-18 E6) and Figure 28B (HPV-16 E6). As a control, co- 
immunoprecipitation of E6AP was monitored, and as can be seen this 
appears to be in complex with HPV-16 E6 and HPV-18 E6 throughout the 
cell cycle and, as expected, the HPV-18 E6 APBM mutant also retains 
ability to interact with E6AP. The levels of E6 increase slightly as the cells 
progress into S and G2/M, and there was a clear increase in the levels of 
HPV-18 E6 phosphorylation during G2/M, and, as expected, this increase in 
phosphorylation was not detected with the E6 APBM mutant. Association 
between HPV-18 E6 and 14-3-3e, £ and 0 isoforms also shows a clear cell
1 3 4
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Figure 28. HPV-18 and HPV-16 E6 interact with 14-3-3 in a cell cycle 
and PBM-dependent manner. HEK293 cells were mock transfected (NC) 
or transiently transfected with HA-tagged HPV-18 E6, HA-tagged HPV-18 
E6APBM (Panel A) or HA-tagged HPV-16 E6 (Panel B) and cells were 
either grown asynchronously (Asyn) or harvested during Gl/S, S or G2/M 
as indicated. Cells were then extracted and immunoprecipitated using anti- 
HA conjugated agarose beads and co-immunoprecipitating proteins were 
analysed by western blotting. The right hand panels show the protein inputs 
used in each of the assays. Note the increase in 14-3-3 associated with HPV- 
18 E6 in G2/M and the increase in 14-3-3 associated with HPV-16 E6 in S 
phase.
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cycle regulation, with a strong increase in the interactions in G2/M phase 
cells. Interestingly, hDlg and Scribble also showed a very similar pattern of 
co-immunoprecipitation, with a significant increase in the amount of hDlg 
and Scribble complexed with HPV-18 E6 as the cells enter G2/M. Not 
surprisingly, all associations of E6 with hDlg and 14-3-3 proteins are lost 
upon mutation of the E6 PBM, confirming the specificity of these 
interactions.
In the case of HPV-16 E6 (Figure 28B), the interactions are somewhat 
different and reflect differences in the patterns of HPV-16 E6 and HPV-18 
E6 phosphorylation. Indeed, in the cell cycle analysis, the bulk of HPV-16 
E6 phosphorylation occurs during S phase, although there was still a 
significant amount of phosphorylated HPV-16 E6 detected in G2/M. In 
concordance with this it is also clear that the majority of 14-3-3 interactions 
with HPV-16 E6 also occur during S phase, when HPV-16 E6 is most 
heavily phosphorylated. In this case HPV-16 E6 appears to interact 
preferentially with the 14-3-3^ and 0 isoforms, but not with the s isoform. 
Furthermore, 14-3-3 interactions are also still apparent during G2/M, which 
is consistent with there still being readily detectable levels of E6 
phosphorylation. Intriguingly, a very strong association of HPV-16 E6 with 
hDlg was detected during G2/M phase, whilst a strong association of HPV- 
16 E6 with Scribble was also detected during S phase and this was 
somewhat weaker during G2/M phase of the cell cycle. All these results 
indicate the differential phospho-regulation of HPV E6 and their preference 
in protein targeting during different phases of cell cycle.
1 3 6
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3.12 HPV-18 E6 alters 14-3-3 subcellular distribution.
A major function of 14-3-3 is to regulate the subcellular distribution of its 
numerous binding partners (Muslin & Xing, 2000; Aitken, 2006). Therefore, 
association of E6 with 14-3-3 may potentially have an effect on the 
subcellular distribution of 14-3-3. Since the association between E6 and 14- 
3-3 occurs primarily during G2/M, I focused on any changes during this 
phase of the cell cycle. HeLa cells were transfected with siRNA luciferase 
as a control or siRNA E6/E7. After 48 hrs Nocodazole was added to induce 
a G2/M population of cells, where E6 is expected to be most heavily 
phosphorylated. After a further 18 hrs the cells were harvested and extracts 
separated into nuclear and cytoplasmic fractions. The patterns of 14-3-3, 
hDlg and p53 expression was then ascertained by western blotting and the 
results obtained are shown in Figure 29A. As can be seen, there is a 
dramatic rescue in the levels of p53 in the nuclear fraction following 
ablation of HPV-18 E6/E7 expression. Likewise, hDlg levels were 
particularly low during G2/M, consistent with the results in Figure 28, and 
there is a corresponding large increase in hDlg levels in both the 
cytoplasmic and nuclear fractions upon ablation of HPV E6/E7 expression. 
In the case of 14-3-3, all three 14-3-3 isoforms analysed show a 
predominantly cytoplasmic distribution, with very low levels of 14-3-3 
detected within the nucleus. However, following ablation of E6/E7 
expression, the levels of these 14-3-3 isoforms within the nuclear fraction 
were increased (Figure 29A). In order to determine whether these effects 
were related to the ability of E6 to interact with 14-3-3, HaCaT cells were 
transfected with wild type HPV-18 E6 and the HPV-18E6 APBM mutant.
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After 24hrs, Nocodazole was added and after a further 18 hrs the cells were 
harvested and separated into cytoplasmic and nuclear fractions. The results 
obtained are shown in Figure 29B and demonstrate that overexpressed wild 
type HPV-18 E6 can reduce the levels of nuclear forms of 14-3-3s, 0 and £ 
that are seen following exposure to Nocodazole and this is in part dependent 
upon an intact PBM.
3.13 HPV-18 E6 inactivates p53 function depending upon 14-3-3.
Although p53 is degraded by HPV E6, there are nonetheless readily 
detectable levels of p53 in HeLa cells, which is inactive. The mechanism of 
this p53 inactivation is unclear but 14-3-3 has a role in regulating p53 DNA 
binding capability and transactivation activity in the nucleus (Waterman et 
al, 1998; Rajagopalan et al, 2010). Furthermore, recent studies have 
indicated that loss of E6-PBM function can be compensated in part by the 
loss of p53, suggesting that some of E6's PBM related activities might 
involve perturbation of p53 function (Brimer & Vande Pol, 2014). I 
therefore reasoned that E6 might perturb the 14-3-3/p53 interaction in a 
PBM-dependent manner. In order to investigate this, I first performed p53- 
14-3-3 co-immunoprecipitation assays from extracts of p53-null H I299 cells 
following transfection of Flag-tagged p53 with either wild-type HPV-18 E6 
or with the E6 APBM mutant in the presence and absence of Nocodazole. 
The results obtained in Figure 30A indicate a strong increase in complex 
formation between 14-3-3 and p53 upon Nocodazole treatment, even in the 
presence of E6. A similar analysis was also performed in HeLa cells, and as
1 3 9
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Figure 30. p53 interacts with 14-3-3 during the G2/M phase of cell cycle.
A. H I299 cells were either transfected with Flag-tagged p53 alone, or co­
transfected with HA-tagged HPV-18 E6 or APBM mutant. After 24 hrs, 
cells were either untreated (-) or treated (+) with Nocodazole for further 18 
hrs and 3 hrs prior to harvesting cells were also treated with proteasome 
inhibitor CBZ. Cells were then extracted and immunoprecipitated using anti- 
Flag conjugated agarose beads and co-immunoprecipitating proteins were 
analysed by western blotting. The right hand panels show the protein inputs 
used in each of the assays. B. HeLa cells were either non-treated (NC) or 
treated with Nocodazole for 18 hrs, CBZ for 3 hrs or transfected with siRNA 
against HPV-18 E6/E7 (siE6/E7) as indicated. As control, H I299 cells were 
either mock transfected (Mock) or transfected with Flag-tagged p53. Cells 
were extracted and p53 wase immunoprecipitated using DOl anti-p53 
monoclonal antibody and protein A sepharose beads. The bound proteins 
were ascertained by western blotting. The right hand panels show the protein 
inputs used in each of the assays.
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can be seen from Figure 30B, there is again a significant degree of 
association between p53 and 14-3-3. Indeed, removal of E6/E7 expression 
does not appear to increase the p53-14-3-3 interaction. These results suggest 
that in the presence of E6, p53 interaction with 14-3-3 can still occur. The 
next question was whether p53 was functionally active in these complexes, 
and in particular whether the E6 PBM function had a role in this aspect. To 
investigate this, I analysed the p53 activation of the p21 promoter in the 
presence and absence of HPV-18 E6 wild-type, APBM and PKA mutants. 
Assays were also performed in the absence or presence of CBZ to prevent 
the E6-induced degradation of p53. The results obtained are shown in Figure 
31 and demonstrate a robust activation of the p21 promoter by p53, which in 
turn is abolished by both wild type and mutant E6 proteins to a significant 
levels, consistent with their ability to target p53 for degradation. However, 
in the presence of CBZ, wild-type E6 can still efficiently inhibit p53 
transcriptional activity, but there is no significant change to the levels of p21 
promoter activity in the presence of both E6 mutants. In addition, in the 
presence of CBZ, both of the E6 mutants had a significant effect in 
increasing the p21 promoter activity. These results demonstrate that 
phosphorylation of the HPV-18 E6 PBM, and hence association with 14-3- 
3, most likely contribute to the ability of E6 to inhibit p53 transcriptional 
activity, independent of its ability to target p53 for degradation.
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CHAPTER 4: DISCUSSION
4.1 Differential phosphorylation of HR HPV type E6s.
The presence of a PBM on the carboxy terminus of cancer-causing E6 
oncoproteins is an essential element in the ability of these proteins to 
support the viral life cycle (Lee & Laimins, 2004; Nicolaides et al, 2011; 
Delury et al, 2013), to contribute towards cell transformation (Kiyono et al, 
1997) and to the induction of malignancy (Simonson et al, 2005; Nguyen et 
al, 2003). This is partly owing to the ability of the PBM to recognise PDZ- 
containing proteins, such as hDlg, Scribble and MAGI-1, allowing E6 to 
target them for degradation in a proteasome-dependent manner. As a result 
of this, the normal functions and distribution of these proteins are disturbed, 
and one potential consequence is perturbation of cell polarity. It was 
discovered some time ago that E6 PBM peptides from the HR HPV types 
can be phosphorylated by PKA with similar kinetics (Kiihne et al, 2000). 
However, in my analyses on full length E6 proteins, I found that 
phosphorylation by PKA is dissimilar between the E6 oncoproteins of 
different HPV types. HPV-18 and -58 E6 are the best substrates, followed 
by HPV-16 E6, HPV-31 E6 is a weaker substrate. These differences might 
reflect differences in how the HR HPV E6 proteins are regulated by kinases. 
The other potential candidate kinases predicted for the HPV-18 E6 could be 
PAK, CamK II and AKT. From my analysis, I found that HPV-18 E6 was a 
very weak substrate for PAK and CamK II, and this probably did not 
involve the PBM. HPV-18 E6 was also weakly phosphorylated by AKT, but
1 4 3
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this did involve the PBM. The analysis was then extended to study other 
HPV E6 oncoproteins. AKT can phosphorylate HPV-16 and -58 E6 
strongly, and HPV-31 E6 to a lesser extent. The results also showed that 
HPV-33 and -51 E6 are very poor substrates for both PKA and AKT even 
though these proteins contain PBM. Interestingly, HPV-51 E6 contains an 
amino acid "N" instead of "R", located within the kinase recognition motif, 
whilst HPV-33 E6 contains amino acid "A" instead of "Q" within its PBM 
(as shown in Figure 10). These may have an effect on their susceptibility to 
PKA or AKT phosphorylation, whilst for HPV-58 E6, the amino acid "Q" 
instead of f'E" within its PBM does not affect the phosphorylation. However, 
it is worth noting that HPV-51 E6 used in this study was actually HPV-18 
E6, with its C-terminal PBM mutated to mimic the PBM of HPV-51 E6. 
Therefore, the susceptibility of the full length HPV-51 E6 to PKA and AKT 
phosphorylation needs to be further verified. It is also worth mentioning that 
the differential phosphorylation observed among these different types of 
bacterially purified HPV E6 GST fusion proteins are not due to artifacts, for 
example, arising from poor protein folding or solubility, as these proteins are 
able to interact with PDZ domain-containing proteins.
The differential recognition of these different E6s by the different kinases 
can probably be explained by the fact that kinase-substrate recognition 
depends on several factors, including the structure of the catalytic cleft that 
accommodates its substrate, the 4 amino acids on either the N-terminus or 
C-terminus of the phospho-acceptor site and the docking motifs on the 
substrate that can be recognised by the interacting domain on the kinase 
(Ubersax & Ferrell, 2007). In addition, the different susceptibilities of HPV
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E6 proteins to different kinases that I have shown in this study, as opposed 
to the previous study using short peptides (Kuhne et al, 2000) is most likely 
explained by the differences in how the kinase catalytic domain can 
accomodate the phospho-acceptor site of the unstructured 10 amino acid E6 
peptides in comparison with the recognition of the full length E6 proteins, 
which are approximately 40 times bigger than the peptide.
Having defined that HPV-18 E6 is an excellent substrate for PKA 
phosphorylation, analyses were done to verify that the principal phospho- 
acceptor site was T156 within the PBM. By introducing a number of point 
substitutions in HPV-18 E6, including T156D and T156E, mutation of the 
kinase consensus motif R153A, as well as S82A, which has been predicted 
to be another potential phospho-acceptor site, it became clear that T156 is 
indeed the major phospho-acceptor site for HPV-18 E6. To extend these 
studies to other HPV E6s, the anti-phospho-E6 specific (a-pE6) antibody 
was used. As can be seen from the amino acid sequence alignment, this 
antibody could potentially cross-react with a number of E6 oncoproteins that 
are phosphorylated within their PBM. It was found that both HPV-16 and - 
58 E6 are also phosphorylated by PKA and AKT at their PBM, at T156 and 
T147, respectively, which are equivalent to T156 of HPV-18 E6. In the case 
of HPV-31 E6, it has two potential phospho-acceptor sites within the last 6 
amino acids of its carboxy terminus, this protein is a substrate for both AKT 
and PKA, but AKT would appear to phosphorylate the downstream T147 
within the PBM, whilst PKA phosphorylates HPV-31 E6 at position S82, 
well away from the PBM. This suggests that HPV-31 E6 may be regulated
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very differently from the other HPV E6 oncoproteins analysed, including the 
PDZ recognition.
From the results obtained, it is quite clear that there are significant variations 
in the manner in which the different E6 oncoproteins are regulated by 
different kinases. This raises important questions, firstly about the relevance 
of these modifications for the normal viral life cycle. In asynchronously 
growing monolayer culture, HPV-16 E6 is phosphorylated to higher levels 
than HPV-18 E6. This could be the result of higher levels of AKT in the 
cells, or it might indicate that HPV-16 E6 can be phosphorylated by other 
kinases. There are 4 potential phospho-serine/threonine kinase 
phosphorylation sites (T140, S145, S149 and S150) located in near vicinity 
of the C-terminal PBM of HPV-16 E6 (Refer to Appendix), and these sites 
could serve as "priming sites", in which phosphorylation at these sites might 
favour the accessibility of AKT to T156. However, this possibility remains 
to be verified. In the context of a differentiating epithelium, AKT levels are 
higher in the basal cells and suprabasal layer (Menges et al, 2006; Segrelles 
et al, 2007). This would suggest that HPV-16 E6 is phosphorylated more 
extensively throughout its life cycle. Previous studies showed that HPV 
E1AE4 can be phosphorylated by PKA (Bryan et al, 2000; Wang et al, 
2009), and PKA activity appears to be high at the upper intestinal epithelial 
layers (El-Yazbi et al, 2006). This may indicate that HPV-18 E6 
phosphorylation may potentially occur in the upper epithelial layers, 
however, this remains to be verified. Even though both HPV-18 and -16 
appear to have similar life cycles, they may behave differently in raft culture 
models, and this could be a reflection of the higher prevalence of HPV-16
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than HPV-18 in vivo. As for HPV-31 E6, it displays a quite different 
susceptibility to phospho-regulation from HPV-18 and -16 E6. Whether 
these different potentials in phosphorylation have an impact on this virus's 
fitness remains to be determined. But these differences should be taken into 
consideration when applying data obtained from the study of one HPV type 
to the life cycle of another HPV type.
In the case of tumour involvement, HPV-16, -18 and -58 have generally 
higher association with invasive cervical carcinoma, followed by HPV-33, - 
31 and -51 (Li et al, 2011a). Among these HPV types, HPV-16 and -18 
remain the leading causative agents for cervical cancers, and are followed by 
HPV-58 which has been reported to be of increasing clinical importance, 
especially in Eastern Asia (Li et al, 2011a; Chan, 2012; Aromseree et al, 
2014). Susceptibility to phosphorylation may be a means for the virus to 
survive in the epithelial cells derived from different tissues. For instance, 
HPV-16, HPV-58 and HPV-31, which belong to the genus Alpha-9, 
associate more commonly with squamous cell carcinoma (SCC) than with 
adenocarcinoma (ADC), whilst HPV-18, which belongs to genus Alpha-7, is 
commonly found in ADC (Clifford et al, 2003b; Smith et al, 2007; Li et al, 
2011a). SCC is found at the ectocervix and arises from squamous cells 
which are continously sloughed off and replaced, whilst ADC arises from 
glandular cells at the endocervix. There are different gene profiles in the 
squamous and glandular normal cervical cells, and these include genes 
encoding epidermal growth factor receptor (EGFR), PI3K and K-ras. The 
expression of these genes is also different when these normal cells become 
transformed to SCC and ADC, respectively. For instance, the EGFR gene is
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expressed in the basal and parabasal layers of the ectocervical normal 
epithelial cells, whilst expression of this gene is not detected in glandular 
cells (Kupryjanczyk, 1990). The gene encoding PI3K is expressed at a low 
levels in normal cervical epithelial cells (Yao et al, 2008). Activation of 
EGFR can subsequently lead to activation of PI3K, and this is important for 
cell cycle progression, growth and proliferation (Prenzel et al, 2001). The 
gene encoding EGFR is often found mutated and overexpressed in SCC 
(Wright et al, 2013; Maiti et al, 2013), whilst the PI3K catalytic domain is 
more frequently mutated in SCC than in ADC (Wright et al, 2013). These 
mutations result in the upregulation of survival kinases, including AKT, 
MAPK and ERK signalling pathways (Davis et al, 2014). Normally, K-ras 
expression is kept at a low level in cervical cells (Agnantis et al, 1988; 
Sagae et al, 1989), where it is important in cell cycle regulation, apoptosis 
and Raf-1 signalling (Jancik et al, 2010). K-ras can be activated by point 
mutations, and high level of K-ras expression has been implicated in many 
cancers, including lung, ovarian (Slebos et al, 1991; Jancik et al, 2010; Yoo 
et al, 2012; Alomari et al, 2014) and also in ADC (Wright et al, 2013; 
Matsubara et al, 2014). K-Ras mutation can lead to an increase the 
abundancy of 3?, 5f-cyclic adenosine monophosphate (cAMP) which 
subsequently activates PKA (Konishi-Imamura et al, 1987; Franks et al, 
1987; Konishi-Imamura et al, 1988), as well as activating the MAPK and 
PI3K pathways (Affolter et al, 2013; Chang et al, 2014). Therefore, it is 
intriguing to speculate that differences in the signalling pathways in the two 
different cervical tissues might contribute towards the preference for 
specific viral types in each location. Obviously, the involvement of E6 in
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regulating these pathways might contribute towards this, although future 
studies will be required to investigating this further.
It is also interesting to speculate about the other HR HPV types, such as 
HPV-35, -39, -45, -52, -56 and -59. Besides PKA and AKT, other kinases, 
such as tyrosine kinases (Lck and Src kinases) and Cdc-2-like kinase, Clk2, 
which are also serine/threonine kinases, might be involved in 
phosphorylating other HR HPV types E6s as predicted and these are shown 
in the Appendix. The differential susceptibility to phosphorylation across 
the different HPV E6s could be reflected in the consequences upon E6 
recognition of PDZ-containing proteins and 14-3-3. Indeed, this was found 
to be very similar across the different E6 oncoproteins, with phosphorylation 
of the PBM, even if only weak, nonetheless leading to a reduction in PDZ 
binding potential. All these differential phospho-regulation reactions of 
HPV E6 proteins and their correlation to PDZ or 14-3-3 recognition, with 
the possible biological implications are depicted in Figure 32.
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4.2 Consequence of E6 phosphorylation
4.2.1 Phospho-status of E6 determines PDZ and 14-3-3 recognition
It has been known for some time that phosphorylation of HPV-18 E6 could 
inhibit PDZ binding activities (Kuhne et al, 2000; Zhang et al, 2007), but there 
was no data on whether other HR HPV E6 proteins would behave in a similar 
manner. In a series of comparative assays, it was found that phosphorylation 
within the E6-PBM inhibited PDZ interactions irrespective of the kinase or 
HPV type. Intriguingly, by analysing the amino acid sequence of HPV-31 E6,1 
found that there are two potential phospho-acceptor sites within the last six 
amino acids of its carboxy terminus. This protein is a substrate for both AKT 
and PKA, but AKT would appear to phosphorylate T147 within the PBM, 
whilst PKA phosphorylates HPV-31 E6 at position S82, which is well away 
from the PBM. This suggests that HPV-31 E6 will be regulated very differently 
from the other HPV E6 oncoproteins analysed, including its PDZ recognition. 
Thus, in the presence of PKA activity, PDZ recognition by HPV-31 E6 will be 
unaffected, since the PBM will be left unmodified. It is interesting to notice 
that in comparison with HPV-16, -51 and -58 E6, HPV-31 E6 contains an 
Arginine (R) residue at -2 from S82 and this can fit into a PKA recognition 
motif. From crystal structure studies by Nomine et al, it was shown that the S82 
residue is exposed and is located within the interdomain which connects both of 
the zinc finger domains of E6 (Ristriani et al, 2002; Nomine et al, 2006), the 
region through which E6 associates with p53, E6AP and CBP/p300. This 
indicates that S82 can be accessed by PKA and that phosphorylation may confer
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a conformational change on E6, subsequently affecting its ability to recognise 
these proteins. However, this possibility remains to be investigated and 
understanding this aspect is important, as it may have an impact on the 
pathogenicity of HPV-31, as well as other HPV types that could potentially be 
regulated in a similar manner.
This study shows clearly that phosphorylation of E6 also confers the ability to 
interact with a new class of cellular targets, 14-3-3 proteins, which have been 
defined as phosphoserine/threonine binding proteins (Muslin et al, 1996). This 
indicates that phospho-regulation of E6 will be critical in controlling the precise 
function of this important region of the E6 oncoprotein. A series of studies were 
performed to compare the relative efficiencies, and subsequent consequences, 
of the phosphorylation of HPV E6 oncoproteins derived from a panel of 
different cancer-causing HPV types. Most importantly, it was found that most 
of the HR, but not LR, HPV E6 proteins analysed showed phoshorylation- 
dependent interactions with different 14-3-3 family members. The strength of 
interaction was a direct reflection of the efficiency with which the different E6 
oncoprotein PBMs were phosphorylated by the different kinases. It was also 
interesting to note that whilst there were some subtle differences in how 
strongly the different HPV E6 proteins recognised different 14-3-3 family 
members, the general trend indicated that £, s and y are the most commonly 
bound. However, an exception applies to the 14-3-3(3, which associates with 
both LR and HR HPV E6 independently of phosphorylation. Interestingly, even 
though HPV-31 E6 can be phosphorylated by PKA at S82, phosphorylation at
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this site does not confer 14-3-3 interaction, showing that except for 14-3-3p, the 
14-3-3 proteins interact with E6s at their PBMs, which in the case of HPV-31 
E6, is largely dependent on AKT phosphorylation. All of these assays were 
done in vitro, obviously, the in vivo situation can be more complex. However, 
co-immunoprecipitation with HPV-18 and -16 E6 in fact revealed similar 
patterns of interaction, with the 14-3-3^ and 0 isoforms being predominant, 
whilst s associates well with HPV-18 E6 but less so with HPV-16 E6. 
Consistently, in vivo assays also showed that the association is also dependent 
upon the phospho-status of E6 and the integrity of the E6-PBM.
I also investigated whether the potential interactions of HR HPV-33, -51 and - 
58 E6 with 14-3-3s reflect their respective susceptibility to phosphorylation. I 
found that HPV-18 E6 mimicing HPV-51 E6 protein, appear to be a poor 
substrate for both PKA and AKT, and does not interact with 14-3-3 s. As for 
HPV-58 E6, PKA and AKT phosphorylation confers a strong 14-3-3s 
association. This observations further highlights the finding that different HR 
HPV types E6s may have distinct preferences for targeting different subsets of 
cellular proteins. For instance, it is well-known that HPV-16 E6 preferentially 
targets Scribble whilst HPV-18 E6 preferentially targets hDlg (Thomas et al,
2005), although both of these proteins belong to the same Scribble polarity 
module (Humbert et al, 2008). On top of this is the differential regulation by 
kinases which also has an important influence on their choice of target proteins.
In order to establish whether the interaction between 14-3-3 and E6 could be 
enhanced, Fsk, a synthetic PKA activator was added to the cells. Fsk can induce
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at least a 3-fold increase in PKA activity (Ekholm et al, 1997; Ahn et al, 2007; 
Cyphert et al, 2014), by activating cAMP through adenylyl cyclase (Seamon et 
al, 1981; Takeda et al, 1983). In theory, Fsk stimulation should increase PKA- 
phosphorylation of E6 and, hence, increase interaction with 14-3-3. However, 
the opposite outcome was observed where Fsk stimulation reduced the E6 
interaction with 14-3-3. This is most likely explained by the fact that very high 
levels of PKA activity will also result in 14-3-3 phosphorylation, which 
subsequently inhibits the dimerisation and binding activities of 14-3-3 (Gu et al,
2006), as illustrated in Figure 33. Therefore, the use of synthetic activators or 
inhibitors in this analysis is not appropriate in studying the biological 
consequences of the E6-14-3-3 association. Even though these synthetic kinase 
activators or inhibitors have been widely used to study the kinase activity in 
cells, the drawbacks are their lack of specificity in activating or inhibiting the 
downstream signalling cascades. Besides activating PKA, Fsk-induced 
activation of cAMP can also activate AKT and ERK (Filippa et al, 1999; Gao et 
al, 1999; Schmitt & Stork, 2000), or inhibit MAPK (Siddhanti et al, 1995; 
Plevin et al, 1997). As for H89, it inhibits PKA efficiently but also inhibits 
S6K1 and MSK1 as efficiently, and can also inhibit AKT and MAPK to a lesser 
extent (Davies et al, 2000).
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Although Fsk inhibits E6-14-3-3 association, this might actually be a useful 
way of looking for other potential phosphorylation-dependent interactions of 
HPV E6. For example, Forkhead-associated (FHA) domains-containing 
proteins (Durocher & Jackson, 2002; Hammet et al, 2003) and MH2 (MAD 
Homology 2) domain containing proteins (Wu et al, 2001), and several others 
(Table 4), are all phosphoserine/threonine binding proteins, and proteomic 
analyses would be one possible approach to study this further.
Table 4: Example of phosphoserine/threonine domain containing proteins.
WW domains, Forkhead associated (FHA) domains, WD40 or Leucine rich 
repeat (LRR) domains, with their respective phospho-binding motifs and 
binding partners. Adapted from Yaffe & Elia (2001).
Protein Consensus motif Binding partner References
WW domain pSP or pTP
Cdc25C, Tau, Weel, 
Plkl, Cdc27
Lu et al., 1999; 
Elia et a l , 2003
a) Pinl
b) NEDD4
FHA domain
a) Rad53
b) KAPP
c) Nippl
d) Chk2
pT
Rad9
Receptor-like
kinases
Cdc5L
(Durocher & 
Jackson, 2002)
WD40/LRR 
domain of F- 
box proteins
a) Cdc4
b) Pop 1/2
c) Grrl
d) Skp2
L-I/L/P-pT-P
DpSGXXpS
Sicl, Farl, Cdc6 
Cdcl8, Ruml 
Clnl/2 
p27
Orlicky et al., 
2003
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In some cases, 14-3-3 can recognise proteins in which phosphorylation is 
replaced by a phospho-mimic mutation, such as Aspartic (D) or Glutamic acid 
(E), and in some cases it does not. In the cases of Bassoon protein (a 
presynaptic anchoring scaffold protein) (Schroder et al, 2013), or IRSp53 
(insulin receptor substrate p53/58) (Cohen et al, 2011), phospho-mimic mutants 
do not bind to 14-3-3, whereas a phosphomimic mutant of YAP (Yes-associated 
protein) showed a reduced ability to interact with 14-3-3 compared with the 
wild type YAP (Zhao et al, 2010). In contrast, a phosphomimic mutant of 
Bruton tyrosine kinase (Btk) interacts strongly with 14-3-3 (Mohammad et al, 
2013). In the case of HPV-18 E6, substituting Thrl56 with an acidic residue 
does not result in a phospho-mimic with respect to interaction with 14-3-3£, 
even though the HPV-18 E6 T156E mutant is weakly recognised by the anti- 
phospho-E6 specific antibody. This indicates that in the case of HPV-18 E6, 14- 
3-3£ recognition is phosphate-dependent, and is not amenable to simple charge 
substitution. This result also has one other very important consequence. Thus, 
simple deletion, or even single point mutational ablation of the Ser/Thr residue 
embedded within the PBMs of the high risk HPV E6 oncoproteins inhibits PDZ 
association, as well as abolishing interaction with 14-3-3. It is therefore 
extremely important that this is taken into consideration when assigning 
biological functions to this particular region of the E6 oncoprotein.
All of the above regulation by phosphorylation is observed only in HR HPV E6 
proteins. Due to the lack of the PBM in LR HPV E6, such regulation by PKA is 
absent, and the same will be expected for AKT. However, this does not exclude
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the possibility that LR HPV E6s can be regulated by kinases such as PKC or 
ATM kinase (Appendix). Having said that, there is a smaller number of kinases 
predicted to phosphorylate LR HPV E6 proteins from the scansite. This may 
serve as a hint that phospho-regulation or other post-translational modifications 
may not be a common feature of the LR HPV types E6 which may be one of the 
reasons for their weaker oncogenic potential, compared with the HR HPV 
types. However, it is possible that if the LR HPV E6s can be phosphorylated at 
a serine/threonine residue, this may confer interaction with a 
phosphoserine/threonine binding protein and these possibilities require further 
investigation.
4.2.2 Phosphorylation stabilises E6
Previous studies had indicated that an intact E6 PBM might have an effect on 
E6 stability (Nicolaides et al, 2011), and I wondered if this might be related to 
the ability of E6 to be phosphorylated. To investigate this, a series of analyses 
were done to assess the stability of the phospho-E6 protein. The results 
demonstrated that phosphorylated HPV-18 E6 has a much longer half life than 
the non-phosphorylated form of the protein. Furthermore, it is also intriguing to 
note that E6* appeared to be more stable under conditions when the full-length 
E6 protein was phosphorylated. Since E6* lacks the PBM/phospho-acceptor 
site, this suggests that its increased half life may be mediated, in part, through 
complex formation with the full length phosphorylated E6 oncoprotein. Further 
studies are obviously required to confirm this.
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Certainly, the increased stability of phosphorylated forms of HPV E6 protein 
might be aided by the association with 14-3-3. It has been reported previously, 
that 14-3-3 association can modulate the stability of its binding protein, such as 
for Bad (Chiang et al, 2001) and tristetrapolin (TTP) (Sun et al, 2007; Kraemer 
& Clement, 2014). In the case of HPV-18, loss of 14-3-3 expression in HeLa 
cells does reduce the steady state levels of E6, suggesting that phosphorylated 
E6 can be stabilised by 14-3-3 interaction. However, it is important to note that 
the extension of E6 half life following Fsk treatment is most likely independent 
of 14-3-3 interaction, since under these conditions, the E6-14-3-3 interaction is 
disrupted. Possible explanations for this include HPV E6 interaction with other 
phosphoserine/threonine proteins, some of which are listed in Table 4. 
Alternatively, Fsk treatment itself is likely to increase protein synthesis 
(Xenophontos et al, 1989), this may include increased level of E6AP and EDD, 
which in turn, associate with E6 and contribute to E6 stability independent of 
E6s phospho-status.
4.2.3 Cell cycle regulation of E6 phosphorylation and E6's activities during S 
and G2/M phases
Analysis of the HPV-16 and -18 E6 phospho-status in vivo also confirmed 
important differences in how the two proteins are phosphorylated. In 
asynchronously growing cells, HPV-16 E6 was consistently phosphorylated at a 
higher level than HPV-18 E6, probably reflecting the high levels of AKT
1 5 9
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activity under these conditions. However, following Fsk treatment, HPV-18 E6 
was most strongly phosphorylated, and this increase was not as apparent for 
HPV-16 E6. This is consistent with the in vitro analyses showing HPV-18 E6 to 
be a better substrate of PKA than HPV-16 E6.
Based on this, I then proceeded to investigate whether E6 would be 
differentially phosphorylated through the cell cycle, since this is a more 
physiologically relevant way of analysing the phospho-regulation of HPV E6. 
Indeed, the differences in phosphorylation are even more apparent in the cell 
cycle analyses, which showed that HPV-18 E6 is phosphorylated most strongly 
during G2/M. Interestingly, the total levels of E6 appear lower during Gl/S and 
S phases and this might be a reflection of lower levels of E6 phosphorylation 
under the influence of Aphidicolin, although this is not apparent when the cells 
were synchronised using a double thymidine block. The mechanism of actions 
of Aphidicolin and the double thymidine block are different. Aphidicolin 
inhibits DNA replication through DNA polymerase and can affect the cell 
growth (Spadari et al, 1982), whilst high concentration of thymidine in the cells 
can synchronise the DNA synthesis in S phase in a more physiological way. 
However, this is perhaps less robust than an Aphidicolin block, as DNA 
synthesis can be continued at a low level (Bostock et al, 1971). Interestingly, 
the highest levels of phosphorylation and E6 stability coincide with G2/M, 
which has also been reported previously to be when PKA activity is at its 
highest (Daub et al, 2008; Chandrasekhar et al, 2013). A recent study showed 
that AKT activity is the highest 4 hrs post-release from a double thymidine
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block when the cells are in S phase (Liu et al, 2014). Consistent with this, HPV- 
16 E6 is most heavily phosphorylated during S phase, and this is also reflected 
in the levels of its expression. Taken together, these analyses reflect very clearly 
the discrete phases of the cell cycle when the HPV-16 E6 and HPV-18 E6 
oncoproteins are most heavily phosphorylated. Although the other HR HPV E6 
proteins were not analysed in vivo, one would predict that HPV-58 E6 would 
probably be heavily phosphorylated throughout the cell cycle, being a very 
good substrate for both AKT and PKA. As for HPV-31 E6, it would have a 
PBM phosphorylation pattern very similar to that of HPV-16 E6, but will 
instead have a S82 phosphorylation in the G2/M phase of the cell cycle.
Cell cycle analyses showed compelling evidence linking in vivo 
phosphorylation of E6 with its increased association with 14-3-3 proteins and 
Cdc25C, potentially as a complex. In the case of HPV-18 E6, these interactions 
were always strongest during G2/M which corresponds to the phase in which 
HPV-18 E6 is most heavily phosphorylated. In the case of HPV-16 E6, 
interaction with 14-3-3 and Cdc25C proteins was highest during S phase, and 
again, this corresponds to the phase of cell cycle when HPV-16 E6 is most 
strongly phosphorylated. These differences may indicate that 14-3-3 may 
contribute to the stability of phospho-E6 during the different stages of the cell 
cycle, with the stability of HPV-16 E6 being maintained throughout the 
epithelial layers and HPV-18 E6 in the upper epithelial layer. This also implies 
that HPV-16 E6 interacts with 14-3-3 more intensively than HPV-18 E6. In 
addition, 14-3-3 functions might also be perturbed differently at the different
1 6 1
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epithelial layers during the viral life cycle. In comparison, interactions with 
E6AP were found to be relatively unchanged throughout the cell cycle. Another 
intriguing feature of these studies was the behavior of the E6 oncoproteins with 
respect to hDlg and Scribble. Based on the in vitro analyses, one would predict 
that E6-Dlg interactions would decrease during G2/M for HPV-18 E6 and S 
phase for HPV-16 E6, when the E6 is most heavily phosphorylated. However, 
this is not the case, and a clear increase in the interaction of both HPV-18 and - 
16 E6 proteins with hDlg occurs during G2/M. The most obvious explanation 
for this is that post-translational modifications to hDlg actually increase its 
ability to interact with a subset of unmodified E6 at this period of the cell cycle. 
Indeed, the result shown in Figure 29(A) and consistent with previous studies, 
suggesting that nuclear forms of phosphorylated hDlg were more readily 
targeted by the E6 oncoprotein (Narayan et al, 2009b; Massimi et al, 2006), and 
these studies go some way to support those observations. Likewise, HPV-18 E6 
also interacts most strongly with Scribble during G2/M, whilst HPV-16 E6 
interaction with Scribble is strongest during S phase and reduces somewhat 
during G2/M phase. The reason for these differences might again partially 
reflect differences in the phospho-status or localisation of the target protein, but 
they are also most likely a direct reflection of changes in the total amount of E6 
present during these different phases of the cell cycle. Obviously, a major 
question for future studies is to determine the percentage of E6 that is 
phosphorylated at any given time and, furthermore, whether there is any 
significant dephosphorylation of E6 at different cell cycle phases.
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Previous studies showed that HPV E6 and E7 are involved in perturbing cell 
cycle checkpoints and this is partly the result of the abrogation of p53 and pRB 
functions by E6 and E7, respectively (Demers et al, 1994; Wazer et al, 1995; 
Stewart et al, 1995; Xiong et al, 1996; Dyson, 1998). The p53 protein 
accumulated at cell cycle checkpoints (Darzynkiewicz et al, 1986), and the 
majority of p53 is degraded by E6 efficiently. However, there is detectable 
levels of p53 in HeLa cells, and the levels of p53 increase from G1 to S phase. 
This could be due to the low levels of E6 during these phases of the cell cycle, 
and hence, the levels of p53 protein does not change significantly, as this 
pattern of p53 protein levels is similarly to that observed in the previous studies 
performed using HPV negative cells (Reich & Levine, 1984; Danova et al, 
1990; Gudas et al, 1994). Intriguingly, I also found that, there is a dramatic loss 
of p53 in G2/M phase of the cell cycle, especially its cytoplasmic pool (Figure 
29). At this phase, p53 is probably phosphorylated, which consequently 
activates the G2/M checkpoint (Dellinger et al, 2003), and this is partly 
overcome by E6 degrading p53. Ablation of HPV-18 E6 using siRNA against 
HPV-18 E6 and E7 restores the levels and correct expression pattern of p53, 
with higher levels of nuclear than cytoplasmic forms of p53. Taken together, the 
results in this study show that HPV-18 E6 appears most active and exerts its 
multiple functions during G2/M, including degrading p53 and PDZ-containing 
proteins, and deregulating cell cycle, partly through 14-3-3 and other 14-3-3 
functions. In the case of HPV-16 E6, these activities are also very apparent 
during S phase and continue into G2/M. The involvement of HPV E6s in
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regulating the cell cycle events, both within an individual cell and more 
globally, are depicted in Figure 34 and 35, respectively.
4.2.4 E6 perturbs the subcellular localisation of 14-3-3 and p53 transcriptional 
transactivation.
As mentioned earlier, most of the 14-3-3 isoforms, with the exception of o, are 
overexpressed and possess oncogenic potential in cancers (Lodygin & 
Hermeking, 2005; Danes et al, 2008; Bai et al, 2014; Zhao et al, 2014). One of 
the major functions of 14-3-3 proteins is to regulate the subcellular distribution 
of their different binding partners, and this is linked very closely to the correct 
spatial distribution of 14-3-3 between the nucleus and cytoplasmic fractions of 
the cell (Brunet et al., 2002;reviewed in Muslin & Xing, 2000; Seimiya et al., 
2000). In most cases, 14-3-3 interacts with phospho-proteins and keeps them in 
an inactive form in the cytoplasm, as for Raf-1 (Wan et al, 2004; Ritt et al, 
2010; Radhakrishnan & Martinez, 2010), Bad (Rommel et al, 1997; Dumaz & 
Marais, 2003) and Cdc25 (Peng et al, 1997; Esmenjaud-Mailhat et al, 2007; 
Chan et al, 2011). Nuclear 14-3-3 was suggested to be either unbound 14-3-3 or 
to be associated with transcriptional co-factors in the nucleus, such as the 
Forkhead transcription factors (Brunet et al, 2002; Obsilova et al, 2005) and 
p53 (Rajagopalan et al, 2010). In addition, 14-3-3 is also found to relocalise in 
the nucleus during mitosis (Su et al, 2001). In cancer cells, 14-3-3 is 
overexpressed and the normal distribution and functions of these proteins
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Figure 35. Involvement of HPV oncoproteins in the different phases of cell 
cycle. During G1 phase, Cdc25A can dephosphorylate and activate the Cyclin 
D/Cdk4/6 complex. This, in turn, allows Cyclin D to phosphorylate pRB which 
bound to E2F. Hyperphosphorylated pRB dissociates from E2F, allowing cells 
to progress to S phase. The presence of HPV E7 targets and degrades 
hypophosphorylated pRB, this also allows cells to progress to S phase. At Gl/S, 
Cdc25A can activate the Cyclin A/E/Cdk2 complex and allow cells to progress 
to S phase. However, during the normal cell cycle checkpoint, or when cells 
sustain DNA damage, Cdc25A is phosphorylated and this creates a 14-3-3 
binding motif. 14-3-3 binds and keeps Cdc25A inactive in the cytosol. When 
cells progress to S phase, the levels of AKT increase and this could also be 
enhanced by the presence of HPV E7. This results in the phosphorylation of 
HPV-16 E6 , allowing association with 14-3-3 and Scribble. In G2/M phase, the 
levels of PKA increase and phosphorylate HPV-18 E6 , also resulting in 
association with 14-3-3 and retention of 14-3-3 in the cytosol. HPV-16 E6 can 
also be phosphorylated at this phase, although this seems to occur at a lower 
level compared with HPV-16 E6 phosphorylation during S phase. Both HPV 
E6s associate with hDlg and Scribble through E6-PBM-PDZ recognition, 
resulting in the degradation of hDlg and Scribble. Meanwhile, p53 plays a 
crucial role in cell cycle checkpoints by activating p21 , which then inhibits 
Cyclin-dependent kinases (Cdkl and Cdk2). However, this is abrogated when 
the majority of p53 is degraded by HPV E6 . The remaining pool of p53, which 
are phosphorylated can bind to 14-3-3 and this keeps p53 away from p21 
transcriptional transactivation in the nucleus. Similarly, 14-3-3 associates with 
phosphorylated Cdc25C and keeps it as an inactive form in the cytosol.
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regulated by 14-3-3 can be perturbed. As a consequence, the cell survival 
signals, such as Ras-Raf-MAPK pathways can be over-activated, and cell cycle 
progression can be dysregulated, for example through abrogation of p53 and 
Cdc25 function. To investigate whether E6 might perturb 14-3-3 distribution, 
cell fractionation analyses were done in G2/M phase cells, where E6 associates 
with 14-3-3 most strongly. In G2/M phase cells, in the presence of E6, 14-3-3 
was localised mainly in the cytosol. However, when E6 is not interacting with 
14-3-3, either through loss of E6 or loss of its PBM, the nuclear localisation of 
14-3-3 was restored. Taken together, these results indicate that the consequence 
of the E6-14-3-3 association is a reduction in the level of nuclear 14-3-3, and 
hence potentially a perturbation of 14-3-3 mediated functions in the nucleus.
As mentioned earlier, 14-3-3 is involved in controlling the shuttling of proteins 
in and out of the nucleus (Brunet et al, 2002). Two prime candidates to be 
affected by E6-induced alteration in the subcellular distribution of 14-3-3 are 
Cdc25 and p53, which are the two important components of G2/M checkpoint 
controls. The results in Figure 29 showed that the majority of Cdc25C remains 
in the cytosol, and the phospho-Cdc25C which also remains in the cytosol 
during G2/M phase. The downregulation of HPV-18 E6 leads to reduced levels 
of Cdc25C. This is due to the upregulation of p53 following ablation of HPV- 
18 E6, which is in agreement with the notion that the downregulation of 
Cdc25C is a means to induce a G2 arrest, which is tightly regulated by p53 (St 
Clair et al, 2004; St. Clair & Manfredi, 2006). However, Cdc25C is 
overexpressed in many cancers, which results in an imbalance in normal cell
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cycle regulation (Boutros et al, 2007). Therefore, the presence of E6, which 
downregulates p53, allows high levels of Cdc25, possibly resulting in genome 
instability in cancer cells (Bugler et al, 2006; Ray et al, 2007; Dalvai et al, 
2013).
Previous studies showed that 14-3-3 interacts with p53 in a phosphorylation- 
dependent manner (Agarwal et al, 1995; Waterman et al, 1998). Binding of 14- 
3-3 at the C-terminal region of p53 increases p53's ability to bind to DNA and 
this enables p53 to activate its downstream transcriptional targets such as p21 
(Hupp et al, 1992; Halazonetis et al, 1993; Agarwal et al, 1995; Waterman et 
al, 1995, 1998; Rajagopalan et al, 2008). I was therefore interested in 
investigating any potential function for residual pools of p53 in HeLa cells, and 
the results showed that 14-3-3 interacts with p53 especially during the G2/M 
phase. Downregulation of HPV-18 E6 is thought to increase the levels of p53 
and this should increase the p53-14-3-3 interaction. However, this does not 
seems to be the case, as can be seen in Figure 3 0B, HeLa cells transfected with 
siRNA against HPV-18 E6/E7, despite showing increased levels p53 do not 
show an increase in the amount bound to 14-3-3. This indicates that E6 does not 
abrogate the 14-3-3 association with p53. Therefore, an alternative possibility 
was that E6 might alter the function of the 14-3-3-p53 complex and I reasoned 
that cytoplasmic retention of 14-3-3 during G2/M might impair p53 
transcriptional transactivation function. Indeed, in a series of transfection 
assays, I found that in the absence of p53 degradation E6 could still effectively 
inhibit p53 transcriptional activation of the p21 promoter. This activity of E6
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was found to require not only an intact PBM, but most importantly also an 
intact phospho-regulation site upstream of T156, suggesting that the ability to 
bind 14-3-3 is important for E6's ability to inhibit p53 transcriptional activity. 
Since the HPV-18 E6 R153A mutant cannot be phosphorylated by AKT or 
PKA even though its PBM remains intact, and hence it does not associate with 
14-3-3, this mutant will also be very useful to address the existence of 14-3-3- 
p53-E6 complex, the role of E6 in perturbing 14-3-3 nuclear localisation and 
the p53 transcriptional transactivation mediated by 14-3-3 during G2/M phase. 
It is expected that this mutant should not have an effect on 14-3-3 localisation, 
similar to the APBM mutant. E6 and p53 potentially fit into the 14-3-3 binding 
pocket in an anti-parallel manner, as illustrated in Figure 36, hence, this may 
not result in p53 degradation by E6. This probably occurs through retention of 
14-3-3 in the cytosol, and obviously future studies will be required to determine 
whether p53 is also present in this complex. This can be done by performing 
sequential co-immunoprecipitation and immunofluorescence. H I299 cells can 
be transiently transfected with HA-tagged HPV-18 E6 and Flag-tagged p53 
expression plasmids. The HA-18 E6 can be immunoprecipitated using anti-HA 
conjugated agarose beads, and the bound complex is further 
immunoprecipitated using anti-Flag conjugated agarose beads. Subsequently, 
western blot analysis can be performed to detect the bound endogenous 14-3-3. 
As controls, HPV-18 E6 APBM or R153A mutants can be included. 
Alternatively, immunofluorescence assays can be performed to detect the 
colocalisation of 14-3-3, p53 and E6 proteins. A particularly exciting aspect to
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this study is that it links p53 to the PBM function of E6. Several recent 
studies have shown that loss of the E6 PBM results in an inability of HPV 
genomes to remain as episomes (Lee & Laimins, 2004; Delury et al, 2013), 
but that this could be rescued in part by ablation of p53 (Lorenz et al, 2013; 
Brimer & Vande Pol, 2014). My results link these sets of observations, and 
suggest that the ability of E6 to interact with 14-3-3, and thereby inhibit p53 
transcriptional transactivation, is a critical step in maintaining episomal 
genomes.
4.3 Overview of the involvement of E6 and E7 proteins in HPV-induced 
carcinogenesis
The above studies have important implications on how E6 function is 
controlled both during the viral life cycle and during the development of 
malignancy. As the epithelial cells differentiate and move upwards from the 
basal cells, numerous changes take place in the cells. For survival, the virus 
has adopted capabilities to manipulate these events in order to allow cells to 
accomodate the virus, complete their life cycle, maintain their stability and 
avoid elimination from the host. In the early stages of viral infection, in the 
basal layers, the expression of HPV E6 and E7 results in the downregulation 
of the p53, pRB, PDZ-containing proteins and other pro-apoptotic proteins. 
This has been known for some time to favour the viral life cycle, enabling 
the virus to establish viral DNA replication and the eventual productive 
infection. As the cells differentiate, it was also shown that the suprabasal 
layer of infected epithelium is thicker than the non-infected epithelium. In
171
CHAPTER 4: DISCUSSION
the cells harbouring HPV genomes, the majority of the cells in the 
suprabasal layers exist in an S-like or G2/M-like phases, where the PKA and 
AKT activity peaks. This means that in the suprabasal layer, the majority of 
HPV-16 and -18 E6 proteins are phosphorylated and stabilised, and they 
interact with 14-3-3. This interaction keeps 14-3-3 in the cytosol and, hence, 
potentially perturbs 14-3-3 nuclear-cytoplasmic shuttling ability. In the 
G2/M phase, HPV-18 E6 also degrades a significant portion of p53, whilst 
the remaining pool of p53 is kept in the cytoplasm by E6 through 14-3-3, 
preventing p5 3-mediated transcriptional transactivation. In addition, HPV- 
16 and -18 E6 target components of the Scribble polarity module (hDlg and 
Scribble) during S and G2/M phases in a slightly different manner. HPV-16 
and -18 E6 target hDlg for degradation during G2/M, whilst HPV-18 E6 
seems to target Scribble in G2/M, whilst HPV-16 E6 targets Scribble in both 
S and G2/M phases. In the long run, accumulation of chromosomal 
instability, lack of DNA repair mechanisms and improper cell cycle 
checkpoints induced by E6 and E7 may favour viral integration. However, it 
is important to note that viral DNA integration is not the ultimate goal of the 
virus. In cases where infection persists and the host immune response is 
suppressed, this can result in cervical carcinoma where the HPV E6 and E7 
oncoproteins are highly expressed and the other viral proteins are lost. The 
phospho-status of E6 in this case is still unclear. However, it is tempting to 
speculate that changes in the E6 phosphorylation status, along with an 
increased population of cells in S-like and G2/M-like phases, might play an 
important role during the development of HPV-induced disease. All the 
above mentioned cellular events are expected to be enhanced, including
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enhanced survival kinases which can phosphorylate E6, resulting in 
increased association with 14-3-3 and further retention of 14-3-3 in the 
cytosol, as well as increased degradation of hDlg, Scribble and p53. All 
these cellular changes in the infected epithelial cells, from low grade lesions 
to carcinoma are depicted in Figure 37. These events, in cooperation with 
E7, all together abrogate apoptosis and cell cycle checkpoints, inducing 
chromosomal abnomalities and instability, as well as increased survival 
signalling. Studies have shown that estrogen treatment can enhance HPV- 
induced carcinogenesis (Chung et al, 2008b; Chung & Lambert, 2009; 
Chung et al, 2013). Therefore, future studies should investigate whether or 
not estrogen has an effect on phospho-status of E6 in pre-cancerous lesions 
and carcinomas. This is of clinical relevance as it might be useful to predict 
the behaviour of the different types HP Vs in cancer progression, and 
possibly in their life cycle.
4.4 Future directions
These studies address the differential regulation of HR HPV E6s by PKA 
and AKT, which have an effect on E6 stability and its preferences in cellular 
protein targeting during different stages of the cell cycle. They also indicate 
that E6 phosphorylation has important implications for the viral life cycle 
and cause perturbation of p53 transcriptional transactivation mediated by 
14-3-3 through E6-PBM. These results suggest future studies to investigate 
the following:
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i. To determine the ratio of phosphorylated HPV E6 to non- 
phosphorylated HPV E6. This can be done by performing stable isotope 
labelling by amino acids and cell culture (SILAC) or enzyme-linked 
immunosorbent assays (ELISA).
ii. Identify in which epithelial layer HPV E6 is phosphorylated. This can be 
done by performing immunohistochemistry using organotypic culture, 
by comparing the phospho-status of wild type E6 and E6 R153A or 
APBM, mutants that are not phosphorylated by PKA or AKT. It would 
then be important to investigate if phospho-E6 colocalises with 14-3-3 
and p53 or 14-3-3 and Cdc25 complex in the cytosol.
iii. Since the ubiquitously expressed 14-3-3 proteins are involved in 
multiple cellular events, it would also be interesting to identify other 14- 
3-3 functions that can be perturbed by E6.
iv. Identify other kinases that could potentially phosphorylate HR HPV E6s 
besides PKA and AKT.
v. As HPV E6 is involved in manipulating signalling pathways and 
estrogen has been reported to be one of the co-factors that enhances 
HPV-induced carcinogenesis, it would be very interesting to study 
whether E6 is involved directly in targeting signalling components and 
whether estrogen has an effect on the phospho-status of HPV E6.
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